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 ABSTRACT 
 
Cancer progression is driven by cumulative changes that promote and maintain 
the malignant phenotype. Epigenetic alterations are central to malignant transformation 
and to the development of therapy resistance. Changes in DNA methylation, histone 
acetylation and methylation, noncoding RNA expression and higher-order chromatin 
structures are epigenetic features of cancer, which are independent of changes in the 
DNA sequence. Despite the knowledge that these epigenetic alterations disrupt essential 
pathways that protect cells from uncontrolled growth, how these modifications 
collectively coordinate cancer gene expression programs remains poorly understood. In 
this dissertation, I utilize molecular and informatic approaches to define and characterize 
the genome-wide epigenetic patterns of two important human cancer cell models. I 
further explore the dynamic alterations of chromatin structure and its interplay with gene 
regulation in response to therapeutic agents. 
 
In the first part of this dissertation, pancreatic ductal adenocarcinoma (PDAC) cell 
models were used to characterize genome-wide patterns of chromatin structure. The 
effects of histone acetyltransferase (HAT) inhibitors on chromatin structure patterns were 
investigated to understand how these potential therapeutics influence the epigenome and 
gene regulation. Accordingly, HAT inhibitors globally target histone modifications and 
also impacted specific gene pathways and regulatory domains such as super-enhancers. 
Overall, the results from this study uncover potential roles for specific epigenomic 
domains in PDAC cells and demonstrate epigenomic plasticity to HAT inhibitors. 
 
In the second part of this dissertation, I investigate the dynamic changes of 
chromatin structure in response to estrogen signaling over a time-course using Estrogen 
Receptor (ER) positive breast cancer cell models. Accordingly, I generated genome-wide 
chromatin contact maps, ER, CTCF and regulatory histone modification profiles and 
compared and integrated these profiles to determine the temporal patterns of regulatory 
chromatin compartments. The results reveal that the majority of alterations occur in 
regions that correspond to active chromatin states, and that dynamic chromatin is linked 
to genes associated with specific cancer growth and metabolic signaling pathways. To 
distinguish ER-regulated processes in tamoxifen-sensitive and in tamoxifen-resistant 
(TAMR) cell models, we determined the corresponding chromatin and gene expression 
profiles using ER-positive TAMR cancer cell derivatives. Comparison of the patterns 
revealed characteristic features of estrogen responsiveness and show a global 
reprogramming of chromatin structure in breast cancer cells with acquired tamoxifen 
resistance.  
 
Taken together, this dissertation reveals novel insight into dynamic epigenomic 
alterations that occur with extrinsic stimuli and provides insight into mechanisms 
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1.1: Basic principles underlying genome organization  
Research over many decades has enhanced our knowledge concerning eukaryotic 
genome organization. Genome organization refers to the structural orientation of 
deoxyribonucleic acid (DNA) and is highly controlled. The discovery of the structure of 
DNA in the 1950s [1] provided the platform for later investigations regarding its 
mechanisms within genetic inheritance, determination of cellular fates and contributions 
to disease phenotypes. Other studies in the 1950s-1960s elucidated significant aspects of 
DNA structure including the ratio of bases [2] and the determination of DNA as the 
‘backbone’ of chromatin structure [1, 3]. After the discovery of its involvement in 
inheritance during the 19th century, its rediscovery inspired researchers to expand on this 
fundamental knowledge and to further investigate DNA’s regulation and influences on 
cellular mechanisms. This became possible as new revelations discovered the genome to 
be densely organized inside of the approximate 10 μm nucleus  [4].  In this section, I 
provide an overview of key concepts governing genome organization including DNA 
structure, epigenetics and gene expression.   
 
1.1.1: The nucleosome as the fundamental subunit of DNA   
Scientific investigations in the 1970s paved the way for succeeding chromatin 
research. In the early 1970s, chromatin fibers were discovered to be approximately 100 
angstroms thick [5, 6] and in 1975 the structure of this fiber was confirmed after earlier 
propositions acknowledging that DNA was wrapped around eight histone proteins in 
repeating units, comprising chromatin  [7]. These units, called nucleosomes, were first 
visualized by Oudet et al. with an electron microscope. They achieved these after 
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depleting lysine-rich histones, which allowed them to observe chromatin structure as a 
replicating unit of spherical particles [7]. The molecular structure of the nucleosome was 
subsequently solved [8, 9] and research began to reveal its significance in biological 
outcomes including transcription, DNA repair and cell cycle processes [10-12]. 
Elucidating the organization of the tightly packed chromatin within the nucleus provided 
the foundation needed to explore chromatin regulation in cellular mechanisms.  
 
1.1.2: Gene expression  
 As the central dogma of molecular biology highlights, underlying information 
contained within DNA has the potential to be transferred to RNA followed by protein 
through successive steps (transcription and translation, respectively) [13]. The 
complexity of how these processes are achieved and the particular outcomes as a result, 
extends far beyond this basic fundamental principle. Underlying this complexity is 
temporal and spatial control of genes relative to the rest of the genome. This determines 
the accessibility of genes and the ability of regulatory protein complexes to bind those 
regions in order to undergo transcription. RNA polymerase proteins are the core of 
transcriptional machinery. There are many different types of RNA polymerases with 
distinct roles regarding the types of genes they are able to transcribe [14]. While RNA 
polymerases I and III transcribe ribosomal RNAs and transfer RNAs/small RNAs 
respectively [15-17], RNA polymerase II regulates protein coding genes and long non-
coding RNA via sophisticated control steps assuring correct structure at the site of 
transcription and allows for correction of mismatched bases [18-20]. Additionally, RNA 
polymerase II coordinates with core general transcription factors, which acts to help RNA 
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polymerase II localize to transcriptional initiation regions known as promoters to carry 
out these activities  [21].  
 A different type of transcription factor class contains proteins that are sequence 
specific and have the ability to bind to DNA binding domains such as the High Mobility 
Group-box (HMG) domain [22, 23].  This ubiquitous protein domain is found in many 
transcription factors including the Sry-type HMG box (SOX) family of transcription 
factors, which play transcriptional roles in development and differentiation [24]. 
Additionally, transcription factors have other effector domains allowing for various other 
functions; for example, the recruitment of other regulatory complexes [25]. The spatial 
and temporal control of the genome also contributes to the ability of these factors to 
recognize their DNA binding sites and carry out their given roles. To this end, there are 
far less transcription factors within the human genome than there are genes and so they 
function via combinatorial mechanisms and make up transcriptional regulatory networks 
[22]. The effector function of transcription factors can vary and dictate the regulatory 
outcome. For instance, they have the capability of activating or repressing gene 
expression programs through the recruitment of chromatin-modifying enzymes and other 
cofactors that influence DNA accessibility directly impacting transcription [26].  
 
1.1.3: Foundational principles of epigenetics  
 Epigenetic mechanisms play key roles in chromatin accessibility. In regard to the 
term itself, ‘epigenetics’ was coined by C.H. Waddington around 1940-1950 [27]. While 
the field of genetics encompasses research elucidating gene-based mechanisms regarding 
heritability, epigenetics extends beyond this notion to not only include heritable changes 
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but rather concerns modifications occurring along the genome that do not include 
alterations to DNA sequences themselves. Consequences of research efforts over many 
years has revealed modifications influencing transcriptional control including DNA 
methylation, post translational histone modifications, chromatin architecture and non-
coding RNAs to be among these epigenetic aspects [28-32].  DNA methylation was 
identified in the 1940s and refers to the transfer of methyl groups to CpG dinucleotides 
by DNA methyltransferase enzymes [33]. Mechanistically, this modification can result in 
gene silencing by blocking the binding of transcriptional regulators or by recruiting gene 
repressive complexes [34-37]. Histone modifications incorporate different edits to amino 
acid tails of histone proteins some of which include acetylation, methylation, 
ubiquitination and phosphorylation. These modifications can either be transferred on or 
removed and can further act as docking sites for chromatin regulatory proteins and 
transcriptional complexes modulating chromatin accessibility and gene regulation [38]. 
Importantly, epigenetic regulation contributes to the heterogeneity of cellular functions as 
a result of gene expression alterations, in part, due to these modifications.  
 
1.2: Higher order chromatin organization  
 Aspects underlying chromatin architecture within the nucleus and its 
contributions to cellular phenotypes are still largely unknown. After the identification of 
3-dimensional chromatin structure within the nucleus, researchers over the last several 
decades have desired to elucidate fundamental principles regarding the nuclear 
organization of chromatin. Moreover, questions within these explorations have included: 
(1) In the small nuclear environment, how is chromatin organized and why does it take on 
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this organization?; (2) What molecular consequences does chromatin organization play in 
driving differentiation and development?; (3) Where are the genome-wide chromosome 
contacts in different cell types and what implications do these have on gene expression 
programs?; and (4) What are the implications of chromatin organization on diseased 
outcomes? In this section, I highlight principles of chromatin architecture and its 
importance in normal cellular phenotypes as well as cancer.  
 
1.2.1: Fundamental principles of chromatin architecture  
Chromatin regulation is a dynamic process by which fluctuations between 
condensed and relaxed chromatin states have been recognized to impact various cellular 
processes. Among these mechanisms are DNA repair [39], transcription [40] and cell 
division [41]. Cells must maintain genomic structural integrity and functional identity 
throughout successive generations to prevent transformations into an aberrant phenotype 
[42, 43]. Unveiling 3-D chromosome organization within the nucleus is crucial for 
understanding direct structural mechanisms underlying gene regulation and other cell-
type specification processes.  
It was first proposed in 1885 by Carl Rabl that chromosomes exist in distinct 
chromosome territories, which was later supported with experimental findings conducted 
by Cremer et al. [44, 45]. How the chromosomes are oriented during interphase is 
important for transcriptional regulatory targets and therefore directly influences cellular 
phenotypic outcome.  The radial positioning of chromosomes in the nucleus and the 
relationship between these territories and gene density have been determined in the 
interphase nucleus [46]. To this end, it is well accepted that these chromosome territories 
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are organized such that gene-dense chromosomes are positioned interiorly [45], allowing 
for long-range interactions between genomic regions and can help dictate the phenotypic 
outcome of the cell [47]. For example, a long range single nucleotide polymorphism 
region was shown to interact with the oncogenic gene c-MYC through long-range 
chromatin interaction in colorectal cancer cells, ultimately playing a role in the 
upregulation of this cancer driver [48].  
Further elucidation of structures contributing to chromosome architecture and 
organization within the nucleus revealed additional components including: the nucleolus, 
transcriptional complexes, histone locus bodies, heterochromatin and euchromatin [49]. 
These discoveries were products of combinatorial efforts involving traditional 
microscopic techniques as well as newly developed molecular tools (discussed in Chapter 
1.5). From here, the interest arose in focusing efforts to identify specific domains 
associated with distinct territories in the nucleus.  
Among the different types of associating contacts identified were lamina 
associated domains, nucleolar associated domains and topologically associated domains 
[50]. While nucleolar and lamina associated domains involve the interaction of 
chromosomes with nuclear components, topological associated domains refer to DNA-
DNA contacts. In addition to the identification of different interacting regions, genomic 
compartments were discovered. These spatially segregated compartments along the 
genome were defined at a 1 Mb resolution and are categorized into either compartment 
types A or B [47]. These compartments were coordinated with epigenetic and gene 
expression programs, allowing for further characterization of these regions. Type A 
compartments were found to be enriched in genes and associated with open chromatin 
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regions; therefore, compartment A is commonly referred to as an open compartment. In 
contrast, compartment B was determined to be more densely packed and is referred to as 
a closed compartment. Understanding these compartments have revealed functional 
relationships between chromatin structure and gene activity. The topologically associated 
domains mentioned previously were identified within these compartments [51]. 
Moreover, topologically associated domains are genomic regions with self-interacting 
chromatin regions. The frequency of interactions within 100 kb along the genome 
revealed dense regions of self-interactions. Observations of these topological associated 
domains also revealed regions along the chromatin where interaction density abruptly 
ends. These regions, termed boundary regions, separate topologically associated domains 
and contain high levels of the transcription factor CCCTC-binding factors (CTCF) [52] in 
addition to other chromatin remodeling proteins, condensin and cohesin [53].  
Long-range chromatin interactions are involved in cis gene regulatory programs 
by facilitating enhancer-promoter interactions [54]. After the discovery of enhancer 
regions, it was postulated that enhancer regions interact with promoter regions to regulate 
gene expression. Their interaction is achieved through chromatin looping as these 
regulatory regions are far apart from each other on a one-dimensional level [55, 56]. For 
example, with the goal of defining mechanisms underlying a gene relevant to kidney 
cancer, Moisan et al., identified enhancer elements that were localized to the promoter 
region of the PKD2 gene via CTCF stabilization mediated by chromatin looping in renal 
cancer cells [57].   
Together the identification of compartments and topological associated domains 
have laid the groundwork needed for understanding spatial organization of chromosomes 
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and its regulatory link to functional biological outcomes. The architecture of 
chromosomes during interphase is important for mediating maintenance of cellular 
genomes and gene expression regulation. Current efforts seek to further elucidate 
mechanisms that these architectural elements play in normal and diseased processes.  
 
1.2.2: Gene regulation mediated by higher order chromatin organization in development 
 While chromosome territories have been determined to display differences in cell 
types through repositioning [57, 58], topologically associated domains are largely 
conserved between species and have shown little variance during differentiation [59]. 
However, the interactions occurring with the topologically associated domains 
themselves can vary. Therefore, the separation of chromosomes into topologically 
associated domains provides a framework for distinct developmental-specific nuclear 
positioning.  As cells differentiate, they respond to many different signals and rely on 
their underlying transcriptional machinery including protein complexes to respond to 
these cues. Among these responses are that of transcriptional regulatory control [60, 61]. 
The gene expression programs are controlled by many different proteins including 
transcription factors, co-regulatory proteins and chromatin regulators that bind to DNA at 
regulatory regions. As chromosomes are arranged in their territories during interphase, 
and within these territories, chromosomes contain regulatory interacting regions as 
discussed earlier. It is evident that organization of the genome is directly important for 
gene expression and therefore research has aimed to uncover their role in development 
through differentiation and cell-type specificity.  
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Among the hallmark studies investigating the role of chromatin organization and 
gene expression in regard to development include studies investigating the inactivation of 
the X chromosome [62-64]. A study seeking to characterize cis-regulatory mechanisms 
involved in X inactivation using female mouse embryonic fibroblasts found that while 
topologically associated domain organization remains largely the same for the X 
inactivated chromosome compared to the activated, there were differences in internal-
topological associated domain interactions [63]. Additionally, when interrogating gene 
expression differences within these regions, they found a correlation between intra-
topologically associated domain alterations and differential gene expression throughout 
differentiation. Lastly, they revealed that alterations of boundary regions resulted in the 
mis-regulation of long-range gene-networks.  A more recent study by Dixon et al. 
mapped genome-wide chromatin interactions in H1 human embryonic stem cells and 
human embryonic stem cell-derived lineages and ultimately uncovered reorganization of 
chromatin architecture during stem cell differentiation [65]. This reorganization during 
lineage specification was observed through switches between chromosome compartment 
types (A and B) and changes in the frequency of local interactions within the topological 
associated domains. They associated these regions with gene expression and identified 
subsets of genes displaying alterations in gene expression patterns. Together these studies 
serve as examples to the groundbreaking efforts implicating differential 3D-genomic 
architecture within chromosome compartments and topologically associated domains, 
their influence on gene regulation and moreover the implications of this molecular 
network on cellular development.  
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1.2.3: Chromosome architecture in cancer programs  
Some of the first hypotheses regarding chromosomal abnormalities within cancer 
were conceived in the late 1800s and early 1900s by the German scientists David Paul 
von Hansemann and Theodore Boveri who proposed that cancer is a result of aberrant 
chromosome regulation during the cell cycle [66,67].  For many years pathologists have 
used changes in nuclear structure as a diagnostic framework to detect cancer [68]. 
Expanding from fundamental observations of abnormal nuclear morphology in addition 
to the quantity of nuclei in cancer cells comes later observations, which have revealed 
changes in higher-order chromatin organization. Despite the advancements in our 
knowledge regarding abnormal gene expression programs within various cancers, the 
specific roles these changes in 3D-chromatin structure plays in cancer phenotypes 
remains to be further elucidated.  
 Changes in chromosome territories have been linked to differential gene 
expression programs in cancer [69, 70]. Marella et al. investigated chromatin territory 
organization in normal epithelial and breast cancer cell lines and observed alterations in 
chromosome territories through an increase in associations between chromosome 4 and 
chromosome 16 [71]. Another study investigating alterations in topologically associated 
domains in cancer revealed changes within interacting regions where they also identified 
differences in chromatin architecture surrounding genes that were differentially expressed 
within these altered long-range chromatin interactions [72]. While there are other similar 
observations in different cancers [73] and recent studies have produced large datasets for 
studying 3-D chromatin alterations in cancer, much still remains to be elucidated.   
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1.3: Post translational histone modifications 
The structure of chromatin and gene expression has emerged as a key area of 
research for uncovering mechanisms underlying cellular phenotypes. Modifications of the 
core histone proteins influence gene expression programs in the way that some 
modifications can dynamically alter how open or closed the chromatin is, thereby 
affecting regulatory protein accessibility to genes during transcription. Research has 
identified modifications that can occur to the free amino acid tails of the core histone 
proteins at specific residues that are directly linked to a biological outcome; this is 
referred to as the histone code hypothesis [74]. Histone tail acetylation and methylation 
are the modifications that have been identified to primarily play the role in switching the 
dynamics of chromatin accessibility. To this end, therapeutic agents targeting epigenetic 
histone modifications have been developed to mitigate oncogenic development in the 
cancer phenotype.  
 
1.3.1: The core histone proteins 
Post translational histone modifications have emerged as important regulatory 
components of cellular processes influencing gene regulation. Histone proteins wrapped 
in DNA assemble into nucleosomes and are the foundational building blocks of 
eukaryotic chromatin. Early reports in the late 1880’s suggest the discovery of histone 
proteins and work in the 1960s was the first to report a potential function for these 
proteins in controlling gene regulation [75]. Evolutionary processes have resulted in the 
four core histone proteins that make up the nucleosome and pack the DNA tightly. These 
four core proteins that make up the octamer are H2A, H2B, H3 and H4 [76]. Each histone 
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protein contains globular domains that modulate the interactions between the core histone 
proteins. Additionally, each protein contains amino tails that contain approximately 30 
amino acids that extend away from the nucleosome structure and are subject to different 
modifications [77].  
 
1.3.2: Modifications of the core histone proteins 
Histone proteins have the potential to gain post translational covalent 
modifications on their extended free amino acid tails. While on an individual level, these 
modifications largely do not affect the structure of the nucleosomes themselves, higher 
order chromatin structure containing many nucleosomes can be impacted by these 
changes [78]. Modifications to the N-terminal tails of H2A, H2B, H3 and H4 were first 
reported in the 1963 by Phillips et al. [79]. The variety of modifications that can occur to 
the amino acid tails include methylation, acetylation, ubiquitylation, phosphorylation, 
ribosylation and sumolyation and each modification has the ability to translate into 
distinct biological outcomes [78]. The histone protein H3 is the most extensively 
modified histone protein and has been studied to examine epigenetic post translational 
histone modifications during normal cellular development as well as the progression and 
maintenance of diseased states [80]. In this review, I highlight histone acetylation and 
methylation of the core histone protein, H3.  
 
1.3.3: Overview of histone acetylation and methylation 
Histone acetylation and methylation was first described in 1964, when Allfrey et 
al. suggested its potential role in the regulation of RNA synthesis [81]. Notably, these 
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modifications have been extensively studied in regard to their contribution to closed and 
permissive chromatin states ultimately impacting nucleosome positioning and orientation 
of key regulatory sequences [82]. 
Histone acetylation is mediated by histone acetyltransferase (HAT) enzymes. 
There are different HATs containing specific subunits that dictate the distinct acetylation 
pattern it writes on the histone tail [83]. Human HATs can be grouped into five families, 
comprising of approximately thirty different HATs and while the sequences in HAT 
domains differ between families, they have high structural similarities within family 
members [84]. These enzymes rely on accessory proteins along the chromatin for 
localization to specific sites allowing the exchange for the acetyl group provided by 
Acetyl-CoA to modify the lysine [77].  This results in a more permissive, open chromatin 
state and allows the recruitment of proteins to these now accessible regions as the 
nucleosomes typically act as a barrier for RNA polymerase during this process [26].  
The HAT ability of CBP/p300, one of the five HAT family members, was 
discovered in 1996 [85, 86]. These enzymes are the only HATs that are able to acetylate 
all of the core histone proteins [86]. In terms of a functional example of this HAT, 
CBP/p300 are recruited by the transcription factor DUX4 in myoblasts to globally mark 
the underlying genome with the H3K27ac modification [87]. This transcription factor is 
known to be involved in a form of muscular dystrophy; however, the mechanisms of 
action remain poorly defined. In this study, Choi et al., highlights a new epigenetic 
mechanism by which a HAT, recruited to the genome via a transcription factor, modifies 
histones resulting in open chromatin surrounding genes relevant to muscular dystrophy.  
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The dynamic exchange between HAT and histone deacetylase (HDAC) enzymes 
results in changes between chromatin states as HDACs remove acetyl groups typically 
resulting in a more closed chromatin arrangement [74]. In principle, the acetylation to the 
lysine group serves two overall purposes: (1) it neutralizes some of the positive charge of 
the histone protein and thus results in a weaker interaction of the DNA with the histone, 
thereby resulting in a euchromatin state [81] and (2) it acts as a docking site for the 
recruitment of other regulatory proteins that can come in and direct transcriptional 
changes.  
In contrast to histone acetylation, histone methylation results in condensed 
chromatin. This modification to the histone tails can be acquired at the amino acids 
arginine or lysine; however, the role of arginine in chromatin dynamics and 
transcriptional regulation is not as well defined compared to those of lysine alterations 
[88]. Lysine has the ability to gain either one, two or three methyl groups which are 
mediated by the enzymes, histone methyltransferases (HMT), that recognize specific 
lysine residues. HMTs that mediate the acquisition of methyl groups of lysine residues 
are of two different broad classes, SET domain containing or non-SET domain 
containing, each with different catalytic mechanisms [89].  
Histone methylation does not change the charge of the histone and so it has the 
ability to correlate with either transcriptional activation or transcriptional repression 
depending on the location of the methylation [77]. These methylation patterns are also 
dynamically regulated by demethylase enzymes and for the case of lysine demethylation, 
these are referred to as lysine demethylases. The methyl groups replace the hydrogen 
groups by exchanging with methyl groups provided by S-Adenosyl methionine to result 
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in either mono, di or tri methylation [90]. Similar to that of acetylation, regulatory 
proteins can recognize these methyl groups. Different chromodomains of HMTs prefer to 
bind to specific methylated lysine residues and go on to perform their specific effector 
function; this results in the outcome of either a more heterochromatin or euchromatin 
state [91].  
Foundational studies characterized the fundamental core histone proteins and 
revealed their N-terminal tails are subject to different covalent post-translational histone 
modifications. Later research identified factors writing and removing these modifications 
from the tails, which was followed with advancements in our knowledge surrounding 
regulatory proteins reading these modifications and carrying out the gene regulatory 
programs influencing cellular phenotypes. The dynamic relationship within histone 
acetylation and histone methylation programs allows for the switch between open and 
closed chromatin states.   
 
1.3.4: Histone acetylation and methylation in cancer 
Cancer is a heterogeneous disease with underlying abnormalities in genomic and 
epigenomic profiles [92]. Aberrant regulation of posttranslational histone modifications is 
among these abnormalities, which has been shown to contribute to the cancer phenotype 
by altering accessibility of key target genes [93]. In fact, histone modifications have 
emerged as key regulators in this disease [94, 95]. This finding expanded on the prior 
determination of DNA methylation in cancer that revealed the interaction of HDACs with 
a chromatin-modifying factor that aids in methylating DNA within promoter regions of 
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tumor suppressor genes [96, 97]. Furthermore, the association of DNA 
methyltransferases (DNMTs) with HDACs was revealed [94, 95].  
The dynamic mechanisms within histone acetylation and histone methylation 
have since been discovered to regulate known oncogenes and tumor suppressors 
ultimately influencing the progression and metastasis of cancers [98, 99]. These finding 
have inspired the expansion of the histone code hypothesis to include the regulatory roles 
of epigenetics in cancer transcriptional programs. Histone acetylation and methylation 
patterns are controlled by the interchange of their enzyme activities, which ultimately 
provide balance in a dynamic relationship between a euchromatin and heterochromatin 
state. Since these processes impact active and inactive gene states, continuing to elucidate 
these mechanisms in the development and maintenance in cancer cell models holds 
relevant purpose in better understanding the mechanisms underlying the disease and has 
also shown promise in therapeutic targets.  
Histone acetylation landscapes that are altered in cancers can be attributed to the 
recruitment of HDACs to tumor suppressor genes that are important for silencing 
epigenetic programs. In contrast, increased HAT activity at oncogenes can contribute to 
growth and proliferation of cancer cells. For example, abnormal HDAC regulation has 
been identified in pancreatic cancer where HDAC1-3 and HDAC7 have been identified to 
be overexpressed [100-103]. The cellular consequence of these alterations is dependent 
on the specific enzyme involved. Notably, the aberrant expression of HDAC7 results in 
the ability to distinguish between advanced pancreatic cancer from earlier neoplasms 
[101] and HDAC1-3 enzymes have been shown to impact processes of p53, NFkB and 
p65 programs, which have been correlated with cancer progression including pancreatic 
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cancer [104, 105]. The HAT p300 has been shown to be influenced by the activity of 
nuclear factor of activated T cells (NFAT) and glioma-associated oncogene family zinc 
finger 3 (GLI3) in that these transcription factors recruit this active HAT and thereby 
mechanistically results in loosening of the chromatin and allows for the transcription of 
the c-MYC oncogene [106], a known regulator of many cancer phenotypes [107, 108].  
 
1.4: Next generation sequencing methods for studying chromatin-based mechanisms  
Early methods in determining DNA structure and the organization relied primarily 
on microscopic and biochemical techniques. These techniques have led us to 
groundbreaking findings that have since served as the foundation of normal and aberrant 
cell phenotypes. Modern technologies have allowed us to study the epigenome and 
transcriptome on a genome-wide scale. These technologies termed ‘Next Generation 
Sequencing’ technologies have revolutionized the way we study genomic based 
mechanisms and have notably provided great insight into cancer phenotypes. Here I 
describe methodologies used to study the various layers of genomic regulation described 
above including: (1) 3-dimensional chromosome architecture, (2) post translational 
histone modifications and (3) gene expression.  
 
1.4.1: Methods for studying 3D chromosome organization  
 Research investigating nuclear organization initially relied on microscopic 
techniques. While on the fundamental level, light microscopy has allowed for the basic 
observation of nuclear morphology, advancements in microscopic methods have allowed 
for interrogation of nucleic acid sequences within the nucleus. Fluorescence in situ 
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hybridization is a microscopic technique developed in the 1980’s that uses fluorescent 
probes designed to bind to a complementary sequence along the genome. This technique 
identified co-localization of distal genes during active transcription [109]. Fluorescence 
in situ hybridization and its derivatives holds power when investigating single cells or 
smaller cell populations. However, when inquiring about cell populations on a genome-
wide level, this and other microscopic techniques fall short.  
 While microscopy still holds importance and value in genomic and molecular 
biology research, advancements in genome-wide methods have allowed for the 
investigation of entire genomes within single or whole cell populations. Modern methods 
for defining genome-wide landscapes of histone modifications uses Next Generation 
Sequencing technologies to expand characterization past single loci. A groundbreaking 
study in 2002 by Dekker et al. described the first chromosome conformation capture (3C) 
based assay, which allows for the association of genome-wide contacts [110]. Some of 
the derivatives of 3C technologies include 4C and 5C. While there are differences in the 
number of targeted genomic regions, the fundamental principle of 3C is shared across the 
other derivatives. In short, the chromatin is fixed using a fixative such as formaldehyde 
which results in covalent linkage between DNA and protein interactions [111]. The 
crosslinked chromatin is then digested typically using a 6 bp restriction endonuclease and 
is followed by chromatin dilution and ligation, resulting in the ligation of intramolecular 
fragments. The advancements of 3C into 4C (circularized chromosome conformation 
capture) and 5C (chromosome conformation capture carbon copy) builds on the 
limitations from the given predecessor. Whereas 3C interactions represent a ‘one vs. one’ 
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interaction, 4C allows for the detection of ‘one vs. all’ interactions and 5C expands to 
‘many vs. many’.  
 The innovation of Next Generation Sequencing technologies permitted the 
development of methods determining all genome-wide interactions for any given loci. In 
2009, Lieberman et al. developed the first among these methods named Hi-C [47]. This 
methodology does not require the identification of target loci and rather identifies all 
chromosome interactions. The principles of Hi-C are shared with that of 3C and its 
derivatives; however, modifications include filling the digested ends with a biotin and 
generation of a Next Generation Sequencing library following ligation and isolation of 
biotinylated fragments post dilution, ligation and linearization. Paired-end massive 
parallel sequencing is then performed on the fragments to amplify and identify the 
junctions. This method was modified in 2011 by Kalhor et al. with the aim of improving 
the signal to noise ratio [112]. This method biotinylates the proteins after crosslinking 
and solubilization of the chromatin. After enzyme digestion, the fragments are tethered to 
magnetic streptavidin beads and selected through magnetization allowing for reduction of 
inappropriate intermolecular interactions. The ends of the DNA are then filled in, 
biotinylated, purified, exonuclease treated, sheared into smaller fragments and pulled 
down by magnetic streptavidin beads. Lastly, the Next Generation Sequencing libraries 
are prepared and sequenced as described for Hi-C. This technique is referred to as 
Tethered Chromatin Conformation Capture. These technologies have advanced our 
understanding of chromosome contacts due to the high resolution they provide at any 
given interaction loci across the genome.  
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1.4.2: Methods for post translational histone modifications 
           Next Generation Sequencing has also led to the development of novel methods for 
identifying the genome-wide landscape of histone modifications. These technologies 
have afforded an advantage for genome-wide analyses compared to prior methods that 
limited investigations to specific loci. This method pairs the traditional chromatin 
immunoprecipitation (ChIP) technique with massive parallel sequencing and is termed 
ChIP-seq. ChIP allows for the investigation of protein-DNA interactions within the 
nucleus [113, 114] and when paired with NGS, results in genome-wide binding sites of 
the protein of interest [115]. To perform the ChIP, proteins are first crosslinked with 
formaldehyde and the cells are lysed to release the DNA from the nuclei [116]. 
Sonication is then used to fragment the DNA into approximately 500 bp fragments, 
which can then be used to isolate protein-DNA complexes. The complexes are 
immunoprecipitated with an antibody against the protein target of interest and isolated 
using protein A/G magnetic bead selection with a series of washes. The chromatin bound 
to the protein is then eluted, the cross-links are reversed and the proteins are proteinase 
digested. After the DNA is purified, enrichment can be detected using quantitative 
polymerase chain reaction (qPCR) with primers designed against known target regions 
for the protein of interest. For some studies this is the endpoint of the investigation; 
however, when inquiring about whole genome targets either microarrays or high-
throughput sequencing can be used. Microarrays utilize a hybridization technique that 
allows for fluorescently labeled DNA fragments to hybridize to an array of genomic 
targets, when paired with ChIP this is referred to as ChIP-on-chip. In contrast, Next 
Generation Sequencing libraries can be built from the fragments and used in massive 
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parallel sequencing by synthesis to yield high throughput results of the proteins’ targets 
along the entire genome. The enrichment of these targets are determined when comparing 
the ChIP-seq data for the protein of interest relative to an input control.  
 
1.4.3: Evaluating gene expression  
 Many methods have been designed to quantify gene expression over the years. 
Quantitative reverse transcriptase PCR (qRT-PCR) can be used to determine expression 
of individual gene targets along the genome [117]. The development of two technologies, 
the microarray and RNA-sequencing, have advanced our capability of studying gene 
expression by allowing the investigation of thousands of genes. As mentioned above, 
microarray is a hybridization technique that utilizes a fluorescent dye for later 
quantification. The array is designed with fixed DNA probes against the RNAs of 
interest. The prepared cDNAs from the given experiment are passed over the microarray 
slide and any complementary sequences between the probes and cDNAs will have an 
affinity for hybridization. The fluorescent dyes are ultimately used for optimal 
measurements where relative amounts from each probe can be calculated, thereby 
correlating with expression quantification [118]. Next Generation Sequencing, described 
earlier, resulted in the development of RNA-sequencing. This technique was developed 
to investigate the quantity and presence of RNA at a given time. This method utilizes 
massive parallel sequencing to investigate the entire transcriptome.  
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1.5: Dynamics of chromatin structure 
 Chromatin accessibility is a dynamic process mediated by external stimuli and 
affects the capability of transcriptional regulators to bind their regulatory elements along 
the genome. The switch between open and closed chromatin states is referred to as 
chromatin-remodeling and is influenced by a variety of epigenetic mechanism. In 
addition to DNA methylation [29], posttranslational histone modifications [30] and non-
coding RNAs [31], environmental stimuli can also influence chromatin organization and 
accessibility. For example, cigarette smoke has been shown to remodel chromatin by 
altering histone acetylation patterns resulting in increased gene expression of pro-
inflammatory genes [119] and has recently been implicated in lung cancer phenotypes 
[120]. Moreover, chromatin-remodeling is a well-known facet underlying cancer 
phenotypes [121] and because of the reversibility of chromatin-remodeling, efforts have 
been made to target regulatory factors with the potential for therapeutic intervention. 
Therefore, elucidating chromatin-remodeling mechanisms underlying disease phenotypes 
is important for identifying agents capable of disease mitigation.  
 
1.5.1: Chromatin-remodeling in response to hormone signaling 
 Nuclear receptors have been shown to mediate chromatin-remodeling by 
recruiting regulatory proteins that alter downstream transcriptional programs [122]. These 
nuclear receptors are transcription factors that are activated by their coordinated ligand 
and contribute to epigenetic and gene expression changes in normal and disease 
phenotypes.  
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A clear example of this relationship is that of hormones and their corresponding 
receptors. St. John et al. studied the hormone Vitamin D3 in the transition between 
osteoblasts and osteocytes [123]. Through the integration of genome-wide histone 
modifications and gene expression datasets in response to hormone-stimulation, they 
identified temporal changes in chromatin-remodeling around osteocyte-relevant genes. 
Since Vitamin D3 hormone is involved in bone remodeling, this provided mechanistic 
context for this hormone in chromatin-remodeling during osteoblast differentiation. 
Another study in mammary epithelium during different cellular states investigated 
genome-wide H3K27me3 changes in response to two hormones, prolactin and progestin 
[124]. Ultimately, they determined hormone-regulated histone methylation patterns to be 
mediated by the chromatin remodeling complex EZH2 in mammary cell lineage 
specification.   
Aberrant nuclear hormone receptors are underlying phenotypes of several cancers 
and furthermore can be used to further classify cancer subtypes of breast cancers [125]. 
Among these prevalent cancers is the estrogen receptor (ER) positive subtype [126]. 
Other receptors linked to breast cancer are the progesterone (PR), androgen, thyroid and 
glucocorticoid receptors [127-129]. A study investigating chromatin-remodeling 
signatures in ER/PR positive breast cancer in response to temporal stimulation revealed 
structural transitions in topologically associated domains that coordinated with the 
hormones estrogen and progestin [130]. Furthermore, changes in genome-wide histone 
modification signatures were also observed that coordinated with hormone response and 
suggested unique and concordant hormone chromatin reorganization. Furthermore, 
changes in genome-wide compartments and histone modifications resulted in gene 
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expression differences in response to either hormone. In another study, alterations in 
long-range chromatin interactions and DNaseI hypersensitivity coordinated with changes 
in gene expression in response to glucocorticoid steroid hormone pulsations in a murine 
breast cancer model [131]. 
As nuclear receptors play a role in transcriptional processes and aberrant 
expression of nuclear receptors has been associated with disease phenotypes, elucidating 
mechanisms underlying their alterations in response to their given ligands is important. 
While there are many nuclear receptors whose downstream mechanisms result in distinct 
cellular phenotypes, among these are hormone nuclear receptors. Understanding the 
dynamic mechanisms within chromatin remodeling in regard to genome-wide chromatin 
architecture and histone modification alterations in cancer phenotypes will allow for 
elucidation of chromatin-mediated etiology of cancer and may provide insight into 
therapeutic targets. In Chapter 4 of this dissertation, I present high resolution chromatin 
dynamics in response to temporal stimulation of an estrogen derivative in ER positive 
breast cancer cell models.   
 
1.5.2: Chromatin-remodeling in response to small molecules 
 Changes in chromatin structure are often mediated by enzymes that communicate 
toward downstream transcriptional programs as discussed earlier. As research has 
continuously supported epigenetic mechanisms governing chromatin-remodeling to be 
reversible, there has been increased interest in modulating these processes in human 
disease. To this end, small molecule inhibitors have emerged as promising for altering 
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mechanisms involving chromatin-remodeling and a subset of the selective inhibitors have 
advanced to clinical trials.  
Some of the major overall classes of inhibitors that have been developed include: 
histone acetyltransferase inhibitors and histone deacetylase modulators [132], 
bromodomain inhibitors, DNA methyltransferase modulators and protein 
methyltransferase inhibitors [133]. HDAC inhibitors have been widely developed for 
cancer therapies [134]. Recently, an HDAC inhibitor was shown to increase expression of 
a tumor antigen and resulted in a decrease in immune suppressive cell types in non-small 
cell lung cancer cells [135]. 
 
1.6: Scope of Dissertation: 
            As discussed in the literature review portion of this chapter, aberrant chromatin 
based processes including higher order chromatin organization and post translational 
histone modifications are widely appreciated as contributing constituents to cancer 
development and maintenance. Elucidating these processes is important not only for 
gaining understanding regarding the molecular heterogeneity underlying this disease but 
targeting these mechanisms has also shown therapeutic promise. Here, I describe our 
work applying Next Generation Sequencing technologies to study functional genomics 
within the 3-dimensional and epigenetic landscape of two prevalent cancers.  
            Chapter 2 of this thesis embodies integrative genomic analyses revealing 
epigenetic plasticity in a pancreatic ductal adenocarcinoma cell-line model. The overall 
goal of this chapter was to reveal chromatin-based mechanisms in pancreatic ductal 
adenocarcinoma and to determine the effects of clinically relevant histone 
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acetyltransferase inhibitors on the cancer epigenome. This chapter builds on our study 
identifying the impact of ICG-001 and C646 on gene expression in pancreatic ductal 
adenocarcinoma and colorectal cancer cell-lines (highlighted in Appendix A). I define the 
3-dimensional chromatin landscape of pancreatic ductal adenocarcinoma and 
characterizes the distribution of post translational histone modifications within these 
interacting regions and correlate these regions with gene regulatory programs. I then 
determine the effects of histone acetyltransferase inhibitors on chromatin loops and gene 
expression in the widely used pancreatic ductal adenocarcinoma cell-line, PANC1. 
In Chapter 3, I characterize grade-specific broad H3K4me3 and H3K27ac regions 
in pancreatic ductal adenocarcinoma cell-lines and furthermore determine the influence 
of these histone acetyltransferase inhibitors on these broad epigenomic domains. Lastly, I 
propose genome-wide mechanisms mediated by these inhibitors within these regulatory 
regions.  
            In Chapter 4, I identified the dynamic reorganization of chromatin domains in 
estrogen receptor positive breast cancer cell models. The overall goal of this chapter was 
to elucidate chromatin-based mechanisms in response to temporal stimulation of the 
estrogen derivative, 17-β estradiol, in an estrogen receptor positive breast cancer cell-line 
and the tamoxifen resistant derivative of these cells. Furthermore, we aimed to establish 
the role of estrogen receptor alpha in mediating these dynamics and further linked these 
processes to gene expression. 
            This body of work focuses on the characterization of higher-order chromatin 
organization and histone-modification mechanisms of two deadly cancers. Furthermore, 
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we investigate the plasticity of these mechanisms in response to external stimuli to 
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Three-dimensional analysis reveals altered chromatin interaction by enhancer 

















Distal regulatory elements influence the activity of gene promoters through 
chromatin looping. Chromosome conformation capture (3C) methods permit 
identification of chromatin contacts across different regions of the genome. However, due 
to limitations in the resolution of these methods, the detection of functional chromatin 
interactions remains a challenge. In the current study, we employ an integrated approach 
to define and characterize the functional chromatin contacts of human pancreatic cancer 
cells. We applied Tethered Chromatin Capture (TCC) to define classes of chromatin 
domains on a genome-wide scale. We identified three types of structural domains (TAD, 
boundary and gap) and investigated the functional relationships of these domains with 
respect to chromatin state and gene expression. We uncovered six distinct sub-domains 
associated with epigenetic states. Interestingly, specific epigenetically active domains are 
sensitive to treatment with histone acetyltransferase (HAT) inhibitors and decrease in 
H3K27 acetylation levels. To examine whether the subdomains that change upon drug 
treatment are functionally linked to transcription factor regulation, we compared TCF7L2 
chromatin binding and gene regulation to HAT inhibition. We identified a subset of 
coding RNA genes that together can stratify pancreatic cancer patients into distinct 
survival groups. Overall, this study describes a process to evaluate the functional features 
of chromosome architecture and reveals the impact of epigenetic inhibitors on 





The compartmentalization of the eukaryotic genome into highly organized 
chromatin domains is central to the regulation of gene expression and to cellular 
homeostasis (Dekker & Mirny, 2016). Until recently, the genome and its structural 
organization has largely been studied as a unidimensional entity where local chromatin 
structure is regulated by epigenetic mechanisms such as post-translational histone 
modifications, DNA methylation and chromatin-binding proteins. However, advances in 
genome-wide chromatin conformation capture (3C) methods have enabled the study of 
the three-dimensional (3D) organization of the genome. Studies employing various 3C-
based methods, including 4C, 5C, ChIA-PET and Hi-C, have been developed to map 
long-range chromatin interactions, and have provided experimental evidence to explore 
the principles of 3D genomic architecture (Ramani, Shendure, & Duan, 2016). 
Collectively, these approaches support a model that interphase chromosomes occupy 
distinct chromosome territories and provide insight into how chromosomes fold within 
these territories (Duan et al., 2010; Heidari et al., 2014; Lieberman-Aiden et al., 2009; 
Sexton et al., 2012). However, the mechanisms that underlie the partitioning of the 
genome into these domains and their functional importance remains poorly defined. 
Analysis of Hi-C data has revealed characteristic structural features of the 
genome, including chromatin compartments, topologically associated domains (TADs), 
and chromatin loops (Dixon et al., 2012; Lieberman-Aiden et al., 2009; Rao et al., 2014; 
van Steensel & Dekker, 2010). These distinctive higher order chromatin structures are 
believed to frame long-range enhancer-promoter interactions for epigenetic gene 
regulation (de Laat & Duboule, 2013; Dekker, Marti-Renom, & Mirny, 2013; G. Li et al., 
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2012; Sanyal, Lajoie, Jain, & Dekker, 2012). However, large-scale structural studies 
generally provide little mechanistic detail regarding the functional relationships between 
higher order chromatin structure and cell-specific gene regulation. Recent computational 
and statistical approaches demonstrate that Hi-C data can be used to identify interacting 
genomic loci at a resolution of 8-20 kb (Ay, Bailey, & Noble, 2014; Jin et al., 2013; Lan 
et al., 2012), providing sufficient resolution to integrate higher order chromatin 
organization and gene expression data.  
In cancer, altered regulation of epigenetic networks plays a central role in 
tumorigenesis and metastasis. While DNA methylation and histone modification patterns 
are frequently associated with both solid and hematological malignancies, it remains to 
be determined if 3D chromatin states are characteristic to specific cancer types and their 
gene expression programs (de Laat & Duboule, 2013; Dowen et al., 2014; Gondor & 
Ohlsson, 2009). The reversibility of histone modifications makes them an attractive target 
for cancer therapy and thus defining the epigenetic landscape of specific cancer types 
may provide important insight into the development of new therapeutic targets. Small 
molecule inhibitors that target histone modifying enzymes to disrupt the cancer cell 
epigenome are being developed for the treatment of cancer (Perri et al., 2017). In 
particular, histone acetyltransferases (HATs) are emerging targets in drug discovery with 
potential applications in cancer and other disease models (Wapenaar & Dekker, 2016). 
HATs catalyze the acetylation of lysine residues on histones during the epigenetic 
regulation of gene transcription (Grunstein, 1997). In addition to histones, HATs mediate 
the lysine acetylation of transcription factors, which is important for their function 
(Farnham, 2009; Singh et al., 2010; Vaquerizas et al., 2009). However, currently the role 
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that HATs, histone acetylation and HDACs play in regulating higher order chromatin 
structure remains unknown.  
In this study, we investigate the relationship of higher order chromatin structure, 
histone modification and gene expression using the human pancreatic cancer cell line 
PANC1. We conducted Tethered Chromatin Capture (TCC), a modified Hi-C protocol 
(Kalhor et al., 2011), to identify and characterize chromosome interactions and domains 
in PANC1 cells. We integrated the interacting regions with chromatin state information 
(histone modifications, DNase hypersensitivity, and RNA Polymerase II binding) to 
uncover distinct types of subdomains associated with specific epigenetic states. We then 
determined the impact of two epigenetic inhibitors that target the histone 
acetyltransferases CBP (ICG-001) and EP300 (C646) on chromatin architecture (Bowers 
et al., 2010; Eguchi, Nguyen, Lee, & Kahn, 2005).  Finally, we incorporated chromatin 
binding and gene expression data for the transcription factor TCF7L2 to examine the 
association of chromosome architecture and TF-mediated gene regulation. Overall, our 
analysis highlights (1) a process for evaluating chromosome architecture and epigenetic 
states (2) the impact of two histone acetyltransferase inhibitors on chromosome 









Identification of chromosomal interacting regions in PANC1  
We conducted our studies of higher order chromatin structure in the human 
pancreatic ductal adenocarcinoma (PDAC) cell-line PANC1, which is a model used for a 
variety of mechanistic and functional studies of pancreatic cancer. We identified the 
interacting regions of chromatin via tethered conformation capture (TCC) using 2 
biological replicates (Kalhor et al., 2011). The TCC protocol decreases random 
intermolecular ligations between DNA fragments, particularly from interchromosomal 
interactions. We assessed the TCC data quality by comparison to available Encyclopedia 
of DNA Elements (ENCODE) HiC datasets for PANC1. Figure 2.1-A compares the 
genome-wide and chromosome 17 contacts for the TCC and HiC datasets binned at 1 Mb 
resolution, respectively, where the heatmap color indicates the contact frequency. Both 
interaction maps exhibit comparable patterns of the regional enrichment of long-range 
interactions. However, the TCC dataset has a notable depletion of interchromosomal 
interactions compared to the HiC dataset with a similar percentage of cis interactions 
greater than 20 kb (cis and trans interactions, respectively; Fig. 2.1-B). Pairwise 
comparison of TCC and Hi-C interaction matrices binned at 1 Mb have Pearson 
correlation coefficients greater than 0.9 (Fig. 2.1-C). The correlation of the TCC 
replicates for each chromosome binned at different resolutions (200 kb, 500 kb and 1 
Mb) also correlate well, except for chromosome 9. Poor correlation for chromosome 9 
has been found in other cell types (Rao et al., 2014). Further, the PANC1 TCC and HiC 
datasets have a comparable number of corresponding topological associated domains 
(TADs) and TAD boundaries (Appendix B-1). Overall, these results indicate a high 
 28 
degree of similarity between the TCC and HiC datasets. Thus, TCC replicates were 
combined for downstream analyses of PANC1 chromatin structure. 
Using the merged TCC replicates, we defined a total of 1,371 TADs, 709 
boundary and 71 gap domains. Boundaries are interaction-sparse regions that lack inter-
domain chromosomal interactions with neighboring TAD regions, whereas gaps are 
regions that lack interactions and are located between two identified domains. Gaps 
occurred in gene deserts or centromeres and few boundaries or gaps were found between 
two adjacent TADs. This is consistent with other studies showing that the genome is 
partitioned into Mb-sized local chromatin interaction domains (Dekker et al., 2013; 
Dixon et al., 2012; Rao et al., 2014). 60% of genes are contained within TADs whereas 
boundaries and gaps contain 38% and 2% of genes, respectively.  
 
Classification of epigenetic marks 
We next characterized the epigenetic states associated with the different types of 
PANC1 structural domains (TADs, boundaries, and gaps). We applied a Hidden Markov 
Model (HMM) to segment the genome based on combinatorial epigenetic states using 
histone ChIP-seq data (Bonneville & Jin, 2013). A12-state HMM with a 1 kb bin size and 
an optimized emission probability matrix using the best Bayesian Information Criterion 
(BIC) scores was used (Fig. 2.2-A). The resulting 12 epigenetic states are referred to as 
S1-S12, and can be categorized by regulatory potential by the emission probability 
values. In particular, values greater than 0.1 are considered valid marks for that state and 
values larger than 0.5 represent dominant marks. S1 and S7 are one-mark states enriched 
with the repressive mark H3K27me3, whereas S9 is a two-mark state having both 
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H3K27me3 and H3K9me3. Both S2 and S11 represent regions that are depleted of any 
epigenetic marks (emission probabilities less than 0.015), thus are termed depleted states.  
We determined the proximity of the epigenetic states by evaluating their transition 
probabilities (Fig. 2.2-B). Three states (S1, S7, and S9) also have relatively high 
transition probabilities to each other, indicating a strong neighborhood of interspersed 
H3K36me3 and H3K9me3 repressive marks. The S6 state is a one-mark state enriched 
only with the repressive H3K9me3 and the S8 state enriched with both H3K36me3 and 
POLR2A. S3 and S4 are enriched with H3K27ac/H3K9ac/H3K4me1 and 
DNase/POLR2A. S10 is an intermediate active state, with a pattern similar to S3 and S4, 
but only enriched with H3K4me1. S5 and S12 are two mixture states showing enrichment 
of both active and repressed marks, as well as high POLR2A. 
 We categorized genomic regions into 8 different categories and determined the 
distribution of epigenetic states within each region (Fig. 2.2-C). Non-promoter regions, 
including 5’ and 3’ distal and gene body (intragenic) categories are enriched in repressive 
states (S1, S7 and S9). Active states are enriched in 5’ TSS and 3’ Proximal regions 
(states S4 and S5).  Figure 2.2-D shows a region that contains a gap, boundary and TAD, 
with the corresponding epigenetic state. The bulk of gaps are S2 domains and are 
depleted of any epigenetic mark (Fig. 2.2-E). Interestingly, there are subgroups of 
boundaries and TADs that have varied patterns of histone modifications. We therefore 
further divided these into different categories; S1/S7 dominant (repressive marks), 
S4/S5/S10 dominant (active marks, near a TSS), or a mixture (mixed percentage of active 
and repressive states). This characterization indicates distinct epigenetic states are 
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physically connected and certain domains contain interspersed repressive epigenetic 
patterns (Appendix B-2).  
Based on the association of epigenetic states, we classified adjacent or intra-
domain states by defining subdomains. These combinations of states resulted in six 
subdomains referred to as SD1 to SD6 (Fig. 2.2-F). The subdomains are on average 60 
kb. SD1 is a depleted subdomain (comprised of S2 and S11) and lacks marks, SD2 and 
SD3 are repressed subdomains (S6/S7 and S1/S7/S9, respectively) and SD4 is a gene 
body subdomain (S5/S8/S12). SD5 is an active enhancer subdomain (S4/S5/S10/S11 or 
only S10/S11), and SD6 is an active promoter subdomain (S3/S4/S5 states), which are 
centered by a promoter (S4) and extend up/downstream of the 5’ TSS (S3).  
 
Correlation of sub-domains and interacting peaks 
To explore the relationships between chromosomal loops epigenetic states and 
domains, the loci of interacting chromatin regions were determined at a 10 kb resolution 
in 40 kb overlapping windows (interaction peaks (IPs). We identified 30,297 significant 
IPs (FDR <0.1 with a peak pair distance >20 kb). 90% of IPs are intra-domain 
interactions, whereby the two different loci are located within the same domain. Nearly 
80% of the IPs are within a TAD, 19% of the IPs are in a boundary, and very few IPs are 
in gap regions. Since cancer cell-lines typically harbor chromosomal abnormalities, 
including chromosomal amplification, we investigated whether amplified regions 
contribute to the set of IPs. Only 0.72% of the IPs for PANC1 are in amplified regions of 
PANC1 cells, confirming that amplified regions are not enriched in the set of identified 
long-range interactions (Lan, Farnham, & Jin, 2012). Since the small number of IPs in the 
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amplified regions of PANC1 cells may play important roles in gene regulation, we 
included them in downstream analyses, which has been done previously (Fullwood et al., 
2009).  
The heatmap in Figure 2.3-A demonstrates that the specific subdomains of 
interacting loci tend to be the same on either end. For instance, an IP having SD4 at one 
end usually has a matched SD4 at the other end. This result is consistent with the 
hypothesis that the two ends of an IP are indeed physically close to or interacting with 
each other and thus have similar epigenetic states. We also found that many IPs have at 
least one locus in a depleted or repressed subdomain (SD1, SD2, or SD3) (summarized in 
Fig. 2.3-A, right panel).  
We annotated the IPs according to gene regions and defined six promoter-
centered and one non-promoter interaction groups (Fig. 2.3-B); Promoter (P; -5 to +1 kb 
of a TSS), Distal (D; 100 kb upstream or downstream of a TSS), and Far (F) regions 
(greater than 100 kb from a TSS). We defined promoters that interact with each other. 
Because the distance between two loci was calculated using the center of each locus (as 
opposed to the boundary), in certain cases, the two loci of one IP could actually overlap 
with each other. If this occurs, then it is possible that the same promoter is identified by 
both loci; these are designated PP1. There are also promoter-promoter (PP) IPs, where 
different promoters are at each loci (PP2). If one end of an IP is in the promoter region of 
one gene and the other end in the distal region of the same gene, this IP is categorized as 
PD1. PD2 is an IP that has one end in promoter region of Gene1 and the other end in 
distal region of Gene2. Similarly, if one end is in the promoter region of one gene and the 
other end in the far region of the same gene, this IP is categorized as PF1. PF2 is an IP 
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that has one end in the promoter region of Gene1 and the other end in far region of 
Gene2. If neither end is in the promoter region of any gene, that IP is classified as non-
promoter-related and given the designation O-O (total number is 19,035). 
In total, we obtained 11,262 IPs associated with at least one promoter, and thus 
referred them as P-centered IPs or looping. We found that approximately 26% of looping 
events represent promoter-promoter interactions with 951 PP1 and 2,059 PP2 
(interactions between the promoters of different genes), respectively. Further, 24% 
promoter IPs (2,724) occur with distal regions of the same gene (PD1; 2,898 genes), 
whereas 27% of IPs (3,045) are between the promoter and distal regions of different 
genes (PD2). The expression level of genes in PANC1 cells linked to each IP categories 
was determined (Fig. 2.3-C) (Gaddis et al., 2015). Interestingly, promoter-centered loops 
either contain genes that are in the repressed states (low expression and in SD1-3) or 
genes that are in the active states (higher expression and in SD4-6). Genes in IPs 
corresponding to SD5 and SD6 are more highly expressed as compared to any other types 
of subdomains. Overall, these results indicate that connecting epigenetic states to 
topological structure can identify epigenetic subdomains that have distinct patterns of 
gene expression. 
 
HAT inhibitors affect chromosomal organization in PANC1 cells 
We previously reported the impact of the histone acetyltransferase (HAT) 
inhibitors ICG-001 and C646 on global gene expression in PANC1 cells (Gaddis et al., 
2015). To examine whether PANC1 sub-domains are functionally linked to changes in 
gene expression, we treated cells with ICG-001 and C646 for 24 hours and performed 
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TCC on control and treated cells. The total number of TADs within each chromosome is 
equivalent between drug-treated and control-treated PANC1 cells (Appendix B-3). While 
a large proportion of the TADs, boundaries and gaps do not change with treatment (50%, 
40%, and 80%), we identified some of the chromatin domains to be sensitive to HAT 
inhibitor treatment. We therefore classified the domain changes (Fig. 2.4-A). The most 
frequent type of change occurred within TADs, whereby treatment increases the TAD 
length by a maximum of 300 kb (Fig. 2.4-B; conserved-expand category, yellow bar). In 
contrast, a TAD in treated cells that overlaps with a TAD in untreated cells but the 
position shifts by more than 300 kb occurs much less frequently (Fig. 2.4-B; the shift 
category, blue bar). The boundaries were most sensitive to treatment and were more 
prone to change than either gap or TADs (Fig. 2.4-B, purple bar). Pearson correlation 
showed that domain type changes are associated with boundaries and represent the active 
subdomains (SD4-6; Appendix B-4). This suggests that changes of a domain type, 
especially the transition of boundary to TADs are linked to epigenetically active regions. 
To examine how the HAT inhibition impacts histone acetylation within chromatin 
domains, we conducted ChIP-seq for H3K27ac in ICG001- and C646-treated PANC1 
cells. We calculated the log2 Fold Change (log2FC) of normalized and averaged 
H3K27ac read signals in 100 bp bins in drug-treated versus untreated PANC1 cells for 
each domain and sub-domain. We observed a minor decrease of H3K27ac at altered 
categorical domains (Shift/Split/Type-Change) and a slight increase of H3K27ac in the 
No Change category (Fig. 2.4-C, left panel). While we did not observe major alterations 
in these domain categories, there were significant differences in the sub-domains. 
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Specifically, all of the active subdomains (SD4-6) showed loss of H3K27ac signal 
in the treated cells (Fig. 2.4-C, right panel). H3K27ac is enriched at promoter and at 
distal regions. We found that the loss of H3K27ac is more profound at the promoter 
active subdomain SD6 than at the enhancer active subdomain SD5, suggesting that these 
inhibitors may affect HAT activity at promoters more than at enhancers. To assess how 
IPs are altered in drug-treated cells, we performed an Interaction Peak (IP) analysis 
(described above) and identified 10,787 IPs in ICG001-treated and 13,773 IPs in C646-
treated PANC1 cells. This represents an approximate 50% reduction in total IPs in treated 
PANC1 cells compared to the untreated control. Additionally, we identified that only 
approximately 50% of IPs in drug-treated cells were concordant with the control. Thus, 
treatment with ICG001 and C646 results in a decline in total IPs and also generation of 
new IPs (Fig. 2.4-D).  
We previously identified 2,029 differentially expressed genes (DEGs) in ICG001-
treated and 1,740 DEGs in C646-treated cells compared to control cells treated with 
DMSO (using a log2FC cutoff of 0.5 and a detection p-value < 0.05), with an overlap of 
754 DEGs common to both drugs (Gaddis et al., 2015). We integrated expression data 
with domains and found that approximately 70% of the genes that respond to drug 
treatment are located in conserved domains. Strikingly, the subdomains SD5 and SD6 
contain a large number of DEGs, regardless of the type of domain or domain change they 
are associated with (Fig. 2.4-E). After further associating DEGs with regions of 
differential H3K27ac enrichment and with looping events, we derived a list of 784 genes 
for ICG001-treated cells and 380 genes for C646-treated cells, for a combined total of 
992 DEGs that have altered chromatin domains. 
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TCF7L2-regulated genes are involved in altered chromatin interactions 
ICG001 and C646 inhibit the activity of CBP and P300 HATs and likely alter key 
signaling pathways. ICG001 was developed to be a specific inhibitor of the Wnt signaling 
pathway, which is important for developmental and disease processes (Eguchi et al., 
2005; Emami et al., 2004). A key transcription factor involved in this pathway is 
TCF7L2, which recruits CBP/P300 to its target gene regulatory elements. Our previous 
study assessed the impact of TCF7L2 and HAT inhibitors in PANC1 cells; however, the 
relationship between these processes and chromatin interactions and their epigenetic 
states remains unknown. TCF7L2 has been linked to a variety of human diseases such as 
type II diabetes and cancer (Blahnik et al., 2010; Cauchi & Froguel, 2008). In a previous 
study exploring cell type-specific binding patterns of TCF7L2, we showed that the 
majority of TCF7L2 sites co-localize with H3K4me1 and H3K27ac (Frietze et al., 2012). 
Given the relationship between TCF7L2 and H3K27ac marked distal regulatory 
elements, we hypothesized that drug treatment would affect TCF7L2-associated 
chromatin loops in PANC1 cells. We therefore identified promoter-distal (PD) IPs that 
were bound by TCF7L2 in PANC1 cells that are no longer classified as IPs in the drug-
treated cells. We isolated the genes associated with these IPs and compared them to genes 
differentially expressed upon drug treatment or upon TCF7L2 knockdown in PANC1 
cells, which we identified in a previous study (Fig. 2.5-A) (Gaddis et al., 2015). We 
found that the highest fraction of these IPs were those containing interactions between 
promoter and distal regions of different genes (PD2-D). We derived a list of 39 genes that 
are differentially expressed in drug-treated PANC1 cells and are also regulated by 
TCF7L2.  Pathway analysis using Gene Set Enrichment Analysis (GSEA) (Fig. 2.5-B) 
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(Subramanian et al., 2005) reveals enrichment in several cancer-related pathways, 
including Wnt signaling. We used SurvExpress (Aguirre-Gamboa et al., 2013) to 
determine if these genes can stratify survival risk of pancreatic cancer patients and found 
that this geneset predicts a significant survival correlation (Fig. 2.5-C, left panel, p-value 
2.5e-07), with high-risk patients displaying a probability of an overall worse survival rate 
(Aguirre-Gamboa et al., 2013). Specifically, 25 of the candidate genes showed 
differential gene expression between the high- versus low-risk patient groups (Fig. 2.5-C, 
right panel). Thus, our results demonstrate that the HAT inhibitors not only alter 
chromatin interactions but also distinguish TCF7L2-regulated genes for potentially useful 
clinical signatures.      
 
Discussion 
Despite advances in 3C-based chromatin interaction mapping (Dekker, Rippe, 
Dekker, & Kleckner, 2002; Libbrecht et al., 2015), there is a lack of understanding of 
how nuclear architecture affects gene expression and cellular function. In particular, our 
knowledge of how the 3D chromatin architecture of cancer cells contributes to cancer 
cell-specific gene expression programs is limited. Due to the limitation of sequencing 
depth and the use of 6-mer cut sites of restriction enzymes, most studies of 3D chromatin 
architecture thus far have focused on characterizing very large 0.7-2Mb TADs. Although 
such studies provide important insights into chromosomal architecture (Deng et al., 2014; 
Lan, Farnham, et al., 2012), studies of large domains do not address the challenge of 
associating chromosomal interactions with transcriptional control at the individual gene 
level. Recent advances in both the experimental and computational aspects of 
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chromosomal interaction analyses now enable the exploration of the 3D chromatin 
architecture of the human genome at a much higher resolution than previously possible, 
allowing for the construction of a detailed genome-wide interaction map (Ay et al., 2014; 
Jin et al., 2013; Lan, Farnham, et al., 2012). A recent study used an in situ Hi-C protocol 
to achieve 1-5 kb resolution of interacting genomic segments and linked chromatin loops 
with promoters, enhancers, and CTCF sites (Rao et al., 2014); however, it did not address 
the relationship between gene loops and gene regulation.  
 In this study, we demonstrated that the method of TCC can partition the PANC1 
genome into three types of structural domains termed gap, boundary and TAD. Our 
results are similar to previous studies of other cell types that used different experimental 
chromatin interaction methods (Dixon et al., 2012; Nora et al., 2012). Interestingly, we 
observed that both TAD and boundary domains (which are 1-5 Mb in length) were 
embedded with approximately 170,000 intra-domain chromatin interactions or interaction 
peaks. We found that these domains could be further categorized into six types of sub-
domains, each with distinct epigenetic characteristics. We note that similar types of sub-
compartments were defined in a previous study (Rao et al., 2014). However, there are 
notable differences between the method we present here and that of which was described 
in the previous study. The previous method divided each of two compartments with 
histone marks based on underlying interaction intensity and patterns. In contrast, we first 
used an unbiased training process in which we trained epigenetic states on the whole 
genome. We then associated the states with gene structure, expression, and other features 
resulting in the derivation of the six sub-domains. Using this approach, we found that 
promoter-centered looping genes within the three active subdomains (SD4-6) showed 
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much higher expression than those in the two repressed subdomains (SD2-3) (Fig. 2.3-
C), suggesting these newly defined subdomains have functional distinctions.   
 We further examined the relationship of histone acetylation in chromatin 
architecture. Although two histone acetyltransferase inhibitors, ICG001 and C646, have 
been previously shown to alter gene expression in cancer cells (Emami et al., 2004; 
Gaddis et al., 2015; Oike et al., 2014), their impact on the 3D genome and epigenome 
structure has not been studied. Therefore, we conducted TCC and ChIP-seq of H3K27ac 
in ICG001- and C646-treated PANC1 cells. Interestingly, we uncovered five major types 
of domain changes that occur upon treatment of PANC1 cells with ICG001 or C646 (Fig. 
2.4-A). In regards to Type-Change domains, we found that TADs are largely conserved 
and stable with drug treatment whereas boundary domains tend to switch to TADs. We 
also found that the drugs altered chromatin structures associated with positive regulatory 
elements. The H3K27ac enrichment is reduced predominantly within the active enhancer 
subdomains (SD6; Fig. 2.4-C) and the most significant gene expression changes occurred 
in the active-promoter subdomains (SD6; Fig. 2.4-E). We were able to link loops that are 
lost upon drug treatment with a list of 39 coding genes regulated by TCF7L2, a 
transcription factor important for developmental processes and implicated in human 
disease. This subset of genes is associated with cancer-related pathways and could 
separate pancreatic cancer patients into distinct survival groups. 
 In summary, we have developed a computational analytical approach for analysis 
of HiC/TCC data that can identify domains and subdomains and can classify chromatin 
looping events. Through the use of epigenetic inhibitors, our work also provides insights 
into the interdependence of 3D chromatin looping and transcriptional control. We 
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recognize that our current studies cannot determine if the enhancers that are affected by 
the epigenetic drugs are the same enhancers as identified by the chromosomal looping 
method. Future work using CRISPR/Cas9 to delete the TCF7L2-associated enhancers 
within the identified promoter-enhancer loops is needed to fully elucidate the mechanistic 
involvement of enhancer-mediated looping events in the regulation of drug-responsive 
genes. Nevertheless, our work provides genome-wide evidence that a strong association 
exists between a subset of enhancer-associated loops and enhancer-regulated genes. 
 
Methods 
Tethered Chromatin Capture (TCC)  
TCC was performed as described (Kalhor et al., 2011). Briefly, approximately 
5x107 PANC1 cells were crosslinked with 1% formaldehyde for 10 minutes at room 
temperature, crosslinking was quenched with 0.125M glycine for 5 minutes at room 
temperature and cell pellets were collected and stored at -80C. Nuclei were digested 
with 2000U HindIII prior to dilute solid-surface ligation reactions and TCC library 
preparation as described (Kalhor et al., 2011). For drug treatments, PANC1 cells were 
grown to 60% confluency before a 48-hour treatment with 10 μM ICG-001 (Tocris), 10 
μM C646 (Sigma-Aldrich) or DMSO and fixed and harvested as described above. 
 
Frequency contact matrix of TCC data 
Paired raw reads of TCC data for the PANC1 cell line were aligned to the human 
reference genome (hg19) by BWA (H. Li & Durbin, 2009) with default parameters. 
Reads were trimmed by 5 bp until 25 bp and aligned iteratively. Multiple aligned reads 
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and reads with a MAPQ less than 30 were removed. After performing fragment filtering 
(such as removing self-circles, error-pairs, and PCR duplicate reads), the reads were 
binned into either 500 kb or 1 Mb size bins, where the sum of interaction pairs within the 
bins was used for all bin-bin interactions. The construction of a frequency contact matrix 
was done as described previously (Bau et al., 2011; Wang et al., 2013). Briefly, binned 
data was first subjected to normalization and transformation into Z-scores, the 
distribution of chromosomal interaction frequencies of both cell lines was then examined 
using a 500 kb or 1 Mb resolution for intra-chromosomal and a 1 Mb resolution for 
whole-genome contact matrices. More specifically, for every 500 kb or 1 Mb bin of 
chromosome regions, the number of interactions (i.e., Z-scores not equal to zero) between 
each chromosome region and the rest of the chromosome regions was counted. The 
chromosomal interaction frequency of the region was then calculated as the counted 
number of interactions in the region divided by the total number of chromosome regions 
(e.g. with a 1 Mb resolution there are 3,029 chromosome regions in the human genome, 
and with a 500 kb resolution there are 498 chromosome regions in chr1). Z-scores of 
intra- or inter-chromosomal interaction matrices were then constructed as either a 
genome-wide contact heat map or a chromosome-specific intra-chromosomal contact 
heat map.  
 
Topological domains of TCC data 
A raw interaction contact matrix of each chromosome at 100 kb resolution was 
normalized using Hi-Corrector (W. Li, Gong, Li, Alber, & Zhou, 2015), which 
implements a set of scalable algorithms adapted from the original IC algorithm (Imakaev 
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et al., 2012)  for parallel computing. Domains were detected using TopDom (Shin et al., 
2016) based on the local minima of normalized contact matrix. For two consecutive local 
minima, if any bin does not show a significant difference between the contact frequencies 
of within interactions and between interactions, they are defined as being within a 
topological domain (TAD); otherwise, they are either a boundary or a gap. The boundary 
and gap regions represent TAD-free chromatin at the given sequencing resolution and 
current parameter settings. We note that a boundary does not refer to the left or right side 
of a TAD, but is a specific region that has low interactions within itself and also between 
neighboring regions. Thus, based on this definition, there is not always a boundary 
between two TADs. A Gap is a region depleted of interactions. 
 
HMM epigenetic states and subdomains 
Histone modification marks (H3K27ac, H3K4me1, H3K4me3, H3K36me3, 
H3K27me3, H3K9me3), RNA Polymerase II, DNase-seq and TCF7L2 datasets in 
PANC1 cell lines were obtained from the ENCODE Project (Consortium, 2012; Frietze 
et al., 2012).  
The data was trained by a univariate first-order Hidden Markov Model (HMM) 
(Heinz et al., 2010) to identify combinatorial epigenetic states. For each bin on the 
genome, the reads of each epigenetic mark were evaluated to determine if that mark is 
enriched in that bin (1) or not (0). We then used this binarized information of all 
epigenetic marks to train the HMM model for the default 300 iterations. For each 
combination of bin size (1 kb) and number of states (8, 10, 12, and 20), 5 trainings of the 
HMM model were performed and the best model was selected based on the Bayesian 
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information criterion (BIC). The outputs of emission and transition matrices or states 
were visualized using the commercial MATLAB program. Consecutive bins of the same 
HMM states were merged into a single region, given that the bins were within the same 
domain defined by TopDom. 
The emission probability of the HMM represents the distribution of the epigenetic 
marks in that particular bin, whereas the transition probability represents the possibility 
that a certain state should be assigned to a specific bin given the known state of the 
previous bin. If in a given state there were marks with an emission probability greater 
than 0.5, only these marks are considered as dominant marks for that state. For states 
without dominant marks, we used an emission probability cutoff of 0.1 for a mark to be 
considered as valid to identify a corresponding state. 
The transition matrix indicates which states are frequently neighbors. In addition, 
states that have very low values in the emission matrix, such as S2 and S11 in Figure 
2.2-A, may represent epigenetic mark-depleted states. Therefore, based on the transition 
and emission matrix, as well as the other genomic features, certain epigenetic states were 
merged together to a single region and biologically defined as a subdomain.  These 
subdomains reflect the epigenetic modification context over a chromatin structural 
domain. 
 
TCC data modeling using HOMER 
We use HOMER (Heinz et al., 2010) to find significant interactions or interaction 
peaks (IPs) in our TCC data. HOMER can search for pairs of loci that have a greater 
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number of reads in interaction data than would be expected by chance using a 







where f is the expected frequency of reads, N* is estimated total number of reads, and n* 
is the estimated total number of interaction reads at each region. HOMER uses the actual 
number of interaction reads at each region as the initial value and then iteratively 
calculates the expected number of reads using the above model until the error between 
expected and observed reads totals per region is near zero. We examined genomic regions 
at 40 kb resolution to find significant interactions, using a minimum distance of 10 kb to 
consider an interaction between regions. The peaks were then further filtered using an 
FDR cutoff of 0.1 and distance cutoff of 20 kb between loci centers. 
In addition to the genomic location of the two interacting regions, HOMER also 
outputs a binomial p-value and FDR based on Benjamini correction. We further filtered 
the peaks using FDR<=0.1 and loci distance greater than 20 kb to isolate a more stringent 
set of IPs. 
 
Associating chromatin interactions with epigenetic subdomains 
For each IP, the subdomain overlaps (1 bp) with the two loci of the peaks were 
extracted. The average sizes of interaction peaks are longer than that of subdomains, so 
one peak locus may cover multiple subdomains. Changes in histone modifications in 
treated PANC1 cells were calculated by first extracting and averaging reads in the 
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subdomains in 100 bp bin, then dividing the averaged reads in drug-treated PANC1 cells 
by control PANC1 cells. 
 
Associating chromatin interactions with annotated genes  
For all annotated human RefSeq genes, we defined 5 genomic regions (Fig. 2.3-
B) relevant to transcription start sites (TSS), which are Promoter (-5 kb to +1 kb), Distal 
(±100 kb), and Far (beyond 100 kb). Then, we defined the following seven categories of 
IPs: 1) PP1—any IPs with both ends within the same Promoter; 2) PP2-- any IPs having 
two ends located in two different Promoters; 3) PD1-- any IPs between a Promoter and a 
Distal region, with the closest TSS to the Distal region being the same gene as for the 
Promoter end; 4) PD2-- any IPs between a Promoter and a Distal region, with the closest 
TSS to the Distal region NOT being the same gene as for the Promoter end; 5). PF1-- any 
IPs between a Promoter and a Far region, with the closest TSS to the Far region being the 
same gene as for the Promoter end; 6) PF2-- any IPs between a Promoter and a Far 
region, with the closest TSS to the Far region NOT being the same gene as for the 
Promoter end; and 7) Other-- any IPs that do not involve a Promoter.  
 
Integrating gene expression datasets 
All of our expression datasets were obtained from our previous study (Gaddis et 
al., 2015). Further details for each component of our analysis are described. For assessing 
the differential expression analysis for IP alterations within untreated and HAT-inhibitor 
treated PANC1 cells, total RNA was collected for untreated PANC1 cells and cells 
treated with either epigenetic inhibitor for 96 hours.  Total RNA was collected using 
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Trizol (Life Technologies). Ultimately, these RNAs were labeled, hybridized and 
analyzed with Illumina HT-12 v4 Expression BeadChips (catalog#: BD-103-0204) with 
the Direct Hybridization Assay and then scanned on an Illumina HiScan (catalog#: BD-
103-0604). We analyzed the data as described. For this analysis we used a log2FC cutoff 
of 0.5 and p-value <0.05 for further analyses.  
To incorporate TCF7L2 regulation we utilized our knockdown RNA-seq data. 
Total RNA after knockdown with 40nM siRNA targeting TCF7L2 or an siControl. We 
then performed RNA-sequencing on the polyA+ RNA selected True-Seq libraries using 
the Illumina HiSeq2000 platform and differential expression was determined as described 
(Gaddis et al., 2015). For this analysis we used a log2FC cutoff of 0.5 and p-value <0.05 
for further analyses. Lastly, for determining the expression levels of PANC1 genes within 
promoter-centeric IPs we used our control dataset from the RNAseq experiment.  
Ontology analyses were performed using GSEA (Subramanian et al., 2005) with 













Figure 2.1: Characteristics of interacting chromatin regions in PANC1 cells. A, 
Genome-wide and chromosome 17 interaction matrices for PANC1 HiC (top) and TCC 
(bottom) datasets. The color intensity represents the normalized number of contacts 
between a pair of loci and the chromosome numbers are indicated on the outside of the 
matrix. B, The observed proportions of intra- and interchromosomal interactions in the 
valid HiC pairs using HiC or TCC (cis and trans, respectively). C, Histogram displaying 
the size distribution of TADs within each individual chromosome. TCC, tethered 































Figure 2.2. Classification of PANC1 domains with epigenetic marks. A, Emission 
probabilities of 12 epigenetic states trained by an HMM model on seven histone 
modifications, DNase and POLR2A. Marks containing emission probability values 
greater than 0.1 for a given state are considered to be valid and values greater than 0.5 are 
considered valid marks for that state and values larger than 0.5 represent dominant marks. 
B, Transition probabilities of the 12 epigenetic states mentioned in (A) with a high 
transition indicating a higher probability that a state is assigned to a given bin due to the 
state of the previous bin. C, Genome‐wide location analysis of the 12 epigenetic states 
defined in (A). D, Illustration of one genomic region along chromosome 7 displaying a 
TAD, boundary and gap domain with the corresponding IGV snapshots of 7 histone 
modifications, DNase and POLR2A. E, Heatmap displaying clustering of the 12 
epigenetic states within the corresponding domains. Each row corresponds to one domain 
and each column represents the percentage of each epigenetic state in each domain. 
Columns are clustered based on the TAD domains. F, We then categorized the 
12 epigenetic states based on their regulatory potential, these new categorizations are 
referred to as “sub‐domains.” We identified six sub‐domains (SD1‐6). The epigenetic 
mark‐depleted states S2 and S11 are merged into SD1, the interspersed S6‐S7 transition 
regions are merged into a repressed SD2, the interspersed S1‐S7‐S9 regions are merged 
into a repressed SD3, and the regions having active states are merged into a genebody 
SD4 and two active enhancer/active promoter SD5 and SD6. TADs, topological 
associated domains; HMM, Hidden Markov Model. 
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Figure 2.3: The relationship between interaction peaks and sub‐domains. A, 
Subdomains at each locus of interaction peaks (IPs) (left). ‘Peak Loci 1′ and ‘Peak 
Loci 2′ represent the two ends of an IP. The table on the right summarizes the sub‐
domains identified in (Figure 2). B, Classification of promoter‐centric IPs based on 
nearest genes. We defined a promoter region (P) to include 5 kb upstream to 1 kb 
downstream of a TSS, a distal region (D) as 100 kb upstream or downstream of a TSS, 
and any region beyond 100 kb from a TSS as a far (F) region. IPs for which the same 
gene is the nearest gene to both ends are defined as PP1, PD1, and PF1 whereas loops in 
which the nearest gene is different for each end are denoted as PP2, PD2, and PF2. C, 
Boxplots of expression for genes associated with promoter‐centric IPs in PANC1 cells. 
For PD1 genes, only one gene is involved and that data is plotted in the PD1 panel, for 
PD2 genes, the expression of the gene at the promoter end is plotted in the PD2‐P panel 
and the expression of the gene at the other end is plotted in the PD2‐D panel. P‐P is PP1 
and PP2 combined. The expression of all other genes that are not involved in IPs in 
PANC1 cells are plotted in the Non‐IP panel. The genes are grouped by the type of 







Figure 2.4: Effects of histone acetyltransferase inhibitors on chromatin loops and gene 

















Figure 2.4: Effects of histone acetyltransferase inhibitors on chromatin loops and 
gene expression in PANC1 cells. A, Diagram of observed types of domain alterations 
after HAT inhibitor treatment. (1) No change – regions which match exactly between 
control and treated cells, (2) conserve‐expand – regions identified as a TAD in both 
control and treated cells, with the length of the TAD increasing by at most 300 kb in 
treated cells, (3) conserve‐shrink – regions identified as a TAD in both control and treated 
cells, with the length of the TAD decreasing by at most 300 kb in treated cells, (4) shift – 
a region identified as a TAD in treated cells that overlaps with a TAD in control cells, 
with the position shifting by more than 300 kb, (5) split – a region identified as one TAD 
in control cells but covers multiple TADs in treated cells, and (6) type‐change – a region 
identified as a TAD in control cells but has switched to a gap or boundary in treated cells. 
B, Percentage of domain changes after treatment for 96 hours with ICG001 (left) and 
C646 (right). C, Log2 fold change of H3K27ac levels after treatment, separated by type 
of domain changes described in (A) (left panels) and type of sub‐domains (right panels). 
D, Overlap between IPs identified in untreated and ICG001 treated (left) or C646 treated 
(right) PANC1. E, Number of differentially expressed genes after ICG001 (left) or C646 
(right) treatment, separated by type of domain change or sub‐domain. HAT, histone 







Figure 2.5: Effects of histone acetyltransferase inhibitors on TCF7L2‐mediated looping 













Figure 2.5: Effects of histone acetyltransferase inhibitors on TCF7L2‐mediated 
looping in PANC1 cells. A, Number of differentially expressed genes within promoter‐
centric IPs that were bound by TCF7L2 in untreated PANC1 cells that are no longer 
classified as IPs in the drug treated cells. These differentially expressed genes were 
altered in siTCF7L2 knockdown cells as well as drug treated cells. PP2‐P1 and PP2‐P2 
are genes of which the promoters are associated with a PP2 IP, PP1 is the gene of which 
the promoter is associated with a PP1 IP, PP2‐D is the distal gene, while PP2‐P is the 
promoter gene that are associated with a PD2 IP and PD1 is the gene that is associated 
with PD1 IP. B, KEGG pathway analysis of the genes (n = 39) that are associated with 
promoter‐distal interactions and that are differentially expressed in drug treated PANC1 
cells that are regulated by TCF7L2. C, Survival analysis of 176 TCGA pancreatic 
adenocarcinoma patients of the 39 genes identified in (A). The red line is the survival of 
the High Risk group, and green line is the survival of the low risk group patients. “+” in 
the legend stands for the censored patients in each risk group (left). Boxplots displaying 
the expression of the 39 genes in the two risk groups (right). CI, confidence interval; HR, 
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The spreading of epigenetic domains has emerged as a distinguishing epigenomic 
phenotype for diverse cell types. In particular, clusters of H3K27ac- and H3K4me3-
marked elements, referred to as super-enhancers and broad H3K4me3 domains, 
respectively, have been linked to cell identity and disease states. Here, we characterized 
the broad domains from different pancreatic ductal adenocarcinoma (PDAC) cell lines 
that represent distinct histological grades. We find that distinct PDAC grades exhibit 
characteristic broad epigenetic features that are predictive of patient prognosis and 
provide insight into pancreatic cancer cell identity. In particular, we find that genes 
marked by overlapping Low-Grade broad domains correspond to epithelial phenotype 
and hold potential as a marker for patient stratification. We further used ChIP-seq to 
compare the effects of histone acetyltransferase (HAT) inhibitors to detect global changes 
in histone acetylation and methylation levels at broad domains. HAT inhibitors treatment 
influence subclasses of broad domains in pancreatic cancer cells, which are potentially 
reflective of therapeutic responses. Thus revealing imperative insight into nuclear signals. 
The results reveal potential roles for broad domains in cells from distinct PDAC grades 






Cancer is a complex disease arising from both genetic and epigenetic alterations 
that impact changes in gene expression to drive and maintain the malignant phenotype. In 
recent years, epigenomic profiling has revealed that cancer progression involves a global 
reprogramming of networks of functional DNA regulatory elements including enhancers 
[1]. Enhancers are cis-acting elements that positively control the transcription of target 
genes and play central roles in regulating cell-type or tissue-type specific genes during 
development and differentiation [2]. Enhancer sequences are comprised of DNA 
sequence motifs that allow transcription factors to bind in a sequence-specific manner, 
and to recruit various histone writers to regulate transcriptional regulation. Recently, 
clusters of enhancer elements, referred to as super-enhancers have been linked to cell 
identity and disease states [3-7]. In addition, regions with widespread H3K4me3 
modification called broad H3K4me3 domains have also emerged as important domains 
linked to the expression of tumor suppressor and cell identity genes [8, 9]. Understanding 
the functional roles of these epigenomic domains in different cancer types has the 
potential to uncover new strategies for the development of new cancer therapies [10]. 
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of 
pancreatic cancer and ranks as one of the deadliest diseases with a five-year survival rate 
of less than 5% [11, 12]. PDAC is associated with a number of genetic and epigenetic 
alterations, leading to the activation of growth promoting and cell survival pathways and 
the inactivation of apoptotic and tumor suppressor pathways [13]. Recent reports have 
demonstrated the PDAC enhancer landscape and have classified enhancers associated 
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with PDAC progression [14-16]. However, the genes regulated by broad epigenomic 
domains in PDAC cells remains unanswered.  
To increase our understanding of broad epigenomic domains and their association 
with PDAC gene regulation in cancer progression, we classified super-enhancer and broad 
H3K4me3 domains in human PDAC cell lines. We specifically defined groups of 
epigenomic domains that correspond to distinct histological grades and compared their 
enriched pathways and linked gene expression levels. We show that broad domains 
correlate with clinical features and hold potential as markers for patient stratification. As 
epigenetic inhibitors are promising avenues for cancer treatment, we also explored the 
ability of these compounds to target PDAC epigenomic domains.  
 
Results 
Classifying the broad domains of different PDAC cell lines 
We analyzed ChIP-seq data from different human PDAC cell lines to identify 
super-enhancer and broad H3K4me3 domains, respectively [14]. This data was derived 
from a panel of human PDAC cell lines that are representative of both Low and High PDAC 
tumor grades, based on genotypic and phenotypic characteristics [17-19]. For example, the 
‘High-Grade’ PANC1, MiaPaCa2 and PT45P1 cell lines all express mesenchymal genes 
[14, 19], show mesenchymal spindle-shaped cell morphology [20], and are considered to 
be poorly differentiated [17, 21, 22]. In contrast, the ‘Low-Grade’ PDAC cell lines 
CAPAN1, CAPAN2, CFPAC1 and HFPAC1 display epithelial-like features and are 
considered to be well-differentiated [23-26]. To determine the super-enhancer domains 
using these different PDAC datasets, we essentially followed the same procedures used in 
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Hnisz et al. [3] with some slight modifications. Briefly, H3K27ac peaks were called from 
ChIP-seq data against input and enriched peaks that clustered within 5 kb were stitched 
together. These stitched regions were then ranked to determine super-enhancers. Broad 
H3K4me3 domains were determined from enriched peaks identified from ChIP-seq, where 
the top 5% of peaks based on domain size were used to call broad H3K4me3 domains [27]. 
In total, we identified between 457 to 1,346 super-enhancers and 1,214 to 2,559 broad 
H3K4me3 domains in seven different PDAC cell lines that correspond to Low- and High-
Grade groups, respectively (Figure 3.1-A). We observed that many genes were 
differentially marked by broad domains according to the assigned PDAC Grade group. As 
an example, the VIM gene encoding VIMENTIN, which is central to metastasis and is 
highly expressed in poorly differentiated High-Grade cells, is bound by both types of broad 
epigenetic domains only in High-Grade cells (Figure 3.1-B). We inspected the profiles of 
other regulatory histone modifications within the broad epigenetic domains using 
ENCODE data from PANC1 cells [28, 29]. The PANC1 super-enhancers exhibit higher 
H3K4me3 and H3K4me1 signal compared to typical enhancers (Appendix C-1). Both 
typical and broad H3K4me3 domains display low H3K4me1 enrichment, whereas broad 
H3K4me3 domains display higher H3K27ac than typical H3K4me3 regions (Appendix C-
2). Comparison of the ChIP-seq signal of the different domains between cell lines reveals 
that the majority of super-enhancers and broad H3K4me3 domains are uniquely enriched 
in a given cell line (Figure 3.1-C and D).  
We hypothesized that cells in separate differentiation states exhibit characteristic 
broad epigenetic patterns. We therefore compared the regions between different PDAC cell 
lines to define Grade-specific broad domains. Altogether, 38 super-enhancers were 
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common to all PDAC cell lines, and 61 and 224 super-enhancers were unique to High-
Grade and unique to Low-Grade groups (HGU and LGU, respectively) (Figure 3.2-A). 
Similarly, we identified 228 common and 177 HGU and 302 LGU broad H3K4me3 
domains (Figure 3.2-B). We further compared the overlap of both types of broad domains 
for the different PDAC groups by clustering these regions. There were 87 overlapping 
super-enhancer and broad H3K4me3 domains for LGU, compared to the 34 overlapping 
HGU (Figure 3.2-C). In general, Low-Grade PDAC cells had an increased number of 
super-enhancer domains compared to High-Grade PDAC cells, whereas both groups have 
a similar number of broad H3K4me3 domains. Overall, this analysis revealed that 
distinctive PDAC Grades exhibit characteristic broad epigenomic domains. 
 
Broad epigenomic domains mark distinctive PDAC pathways 
Prior studies have demonstrated that broad domains are associated with 
developmental and cell identity genes and broad H3K4me3 domains in particular have 
been shown to mark tumor suppressor genes [8, 9, 30]. To explore the gene pathways 
associated with super-enhancers and broad H3K4me3 domains, we annotated genes 
marked by each type of domain and determined their functional classifications (Appendix 
C-3 and Figure 3.2-D). Interestingly, pathway enrichment analysis showed that the genes 
marked by overlapping domains are involved with a variety of signaling pathways that 
were either specific to LGU, HGU, or common to all PDAC cells. For example, pathways 
that enriched common to all PDAC cells included TGFB, microRNAs in cancer and cell 
cycle. Pathways specific to HGU included VEGF and Ras signaling pathways, whereas 
pathways specific to LGU were tight junction and Hippo signaling (Figure 3.2-D).  
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Broad regions predict poorer survival in PDAC patients 
Super-enhancers and broad H3K4me3 domains have been linked to increased gene 
expression in a variety of tissue types [31, 32]. We therefore inspected the relative 
expression levels of genes marked by  different broad domains across PDAC Grades using 
available RNA-seq data from the corresponding cell lines [14]. As expected, both super-
enhancer and broad H3K4me3 domains unique to each Grade group (LGU and HGU) 
showed appreciably elevated expression in the corresponding group compared to the 
contrasting group (Figure 3.2-E, Appendix C-4). For example, genes marked by HGU 
super-enhancers had significantly higher expression levels in High-Grade cells compared 
to Low-Grade cells.   
We next explored the clinical association of the gene expression for genes uniquely 
marked by different broad domains relative to patients’ overall survival using the TCGA 
PDAC dataset [33]. Kaplan-Meier survival analysis showed that gene expression marked 
by HGU super-enhancers as well as HGU broad H3K4me3 domains are strong predictors 
of poor survival (Figure 3.2-F). In contrast, gene expression linked to LGU domains do 
not predict a poorer survival rate. However, the expression levels of genes bound by both 
LGU super-enhancers and broad H3K4me3 domains are significantly associated with a 
worse overall survival in PDAC patients (Figure 3.2-F). Overall, these results reveal that 






Histone acetyltransferase inhibitors alter global H3K27ac and H3K4me3 levels 
Epigenetic modulation via small molecule inhibitors has been proposed as an 
approach for treating various malignancies, including pancreatic cancer [34, 35]. We have 
previously shown that the two HAT inhibitors ICG-001 and C646 differentially impair the 
global gene expression levels in human pancreatic and colorectal cancer cell lines [36]. 
However, the impact of HAT inhibitor treatment on histone acetylation remains unknown. 
To determine the effect of HAT inhibitors on genome-wide H3K27ac enrichment, we 
treated PANC1 cells with ICG-001, C646 or a vehicle control and performed H3K27ac 
ChIP-seq, each with biological replicates. As expected, HAT inhibitor treatment caused 
significant changes in genome-wide H3K27ac patterns compared to vehicle treatment 
(Figure 3.3-A). Differential H3K27ac analysis showed that 4,675 and 5,362 regions with 
reduced H3K27ac levels in ICG-001 and C646 treated cells, respectively (FDR <0.1). 
There were also 2,391 and 4,383 sites with elevated H3K27ac levels in ICG-001 or C646 
treated cells, respectively (Figure 3.3-B). Interestingly, for either treatment the majority of 
higher H3K27ac enrichment clustered within the gene body (intragenic regions), whereas 
the bulk of reduced H3K27ac enrichment corresponded to distal intergenic regions (Figure 
3.3-C). Examples of genes that display altered H3K27ac patterns for each treatment are 
shown in Figure 3.3-D. Pathway enrichment analysis indicated that HAT inhibitor 
treatments influence H3K27ac enrichment at genes that map to a variety of pathways 
(Figure 3.3-E). For example, both treatments decreased H3K27ac levels at genes that 
belong to pancreatic, glioma, breast and gastric cancers, whereas C646 decreased the 
H3K27ac at HIF-1 and phosphatidylinositol signaling gene pathways.   
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We further investigated the impact of ICG-001 treatment on global H3K4me3 
levels in PANC1 cells. ChIP-seq for H3K4me3 showed global H3K4me3 enrichment 
alterations in ICG-001 treated PANC1 cells. In total there were 6,847 increased and 3,219 
decreased regions (Appendix C-5). PPP2R2C, a tumor suppressor gene [37], exhibited 
elevated H3K4me3 signal with ICG-001 treatment compared to control. In contrast 
NKIRAS1, encoding a RAS-like protein exhibited decreased H3K4me3 signal with ICG-
001 treatment (Appendix C-5).  
 
HAT inhibitors alter PDAC broad epigenomic domains 
We next determined the impact of HAT inhibitor treatment on H3K27ac signal at 
super-enhancers and found that both treatments specifically impact H3K27ac enrichment 
levels at many super-enhancers (Figure 3.4-A). In total, there were 136 and 128 super-
enhancers with reduced H3K27ac levels, whereas 121 and 117 super-enhancers showed 
significant gains in H3K27ac levels after ICG-001 and C646 treatments, respectively (FDR 
< 0.1). Notably, the majority of super-enhancers with decreased H3K27ac are the same 
between either treatment (~90%), whereas only ~50% of the domains with increased 
H3K27ac are the same between either treatment (Figure 3.4-B). Increases in H3K27ac 
signal at super-enhancers was associated with elevated gene expression levels and similarly 
decreased enrichment at super-enhancers corresponded to a reduced gene expression 
levels, but only with ICG-001 treatment (Figure 3.4-C). Pathway enrichment analysis 
showed that different pathways are linked to the super-enhancers targeted by HAT 
inhibitors (Figure 3.4-D). ICG-001 treatment targets super-enhancers that correspond to 
genes involved with AGE-RAGE signaling complications in diabetes. In addition to super-
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enhancers, ICG-001 treatment resulted in 4 decreased and 113 increased broad H3K4me3 
domains. A comparison of both domains targeted by ICG-001 treatment reveals an increase 
of H3K27ac and H3K4me3 enrichment at 24 distinct genomic regions (Appendix C-5). 
Overall, these results delineate the broad epigenomic domains that are sensitive to HAT 
inhibitor treatment in PANC1 cells.  
 
HAT inhibitor treatment targets broad domains that are enriched at TAD boundary regions  
Recently, super-enhancer domains that overlap with broad H3K4me3 domains 
were shown to be linked to higher-order chromatin interactions, signifying a unique spatial 
organization of chromatin around cell-specific epigenetic domains [8, 38]. We therefore 
examined the relationship between higher-order chromatin organization and broad 
epigenetic domains in PANC1 cells. Genome-wide chromatin contacts were determined 
by analyzing tethered-chromatin conformation capture (TCC) data in PANC1 [39]. 
Chromatin contacts were partitioned into topologically associated domains (TADs) and 
TAD boundary regions using a resolution of 40 kb (Figure 3.5-A and Appendix C-6). We 
examined TADs in relation to CTCF and PANC1 broad domains. As expected, CTCF was 
significantly enriched at TAD boundaries (Figure 3.5-B). Similarly, broad H3K4me3 
domains were significantly linked to TAD boundaries, however super-enhancers were not 
found to be enriched at TAD boundaries (Figures 3.5-C and 3.5-D). To study if HAT 
inhibitor-sensitive domains are linked to higher-order chromatin structures, we 
investigated the significance of association of both types of broad domains that are 
impacted by ICG-001 treatment with TAD boundaries. We found that the domains with 
increased H3K4me3 and H3K27ac enrichment were significantly associated with TAD 
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boundaries, whereas domains with decreased enrichment were not associated with TAD 
boundaries (Appendix C-7). Thus, these results show that broad domains that gain 
enrichment of either active histone modification are linked to TAD boundaries. Overall, 
this analysis demonstrates a global impact of drug treatment on the epigenome and shows 




An improved understanding of PDAC tumor biology and tumor grading should 
leverage available therapies and data. Here we extend prior data that indicated HAT 
inhibitors elicit distinctive effects on cancer cell transcriptomes by exploring the 
susceptibility of broad domains to HAT inhibitor treatment [36]. While drugs that target 
epigenetic mediators are currently in development [40, 41], the downstream effects on the 
epigenome of existing drugs has not yet been thoroughly examined. In particular, 
epigenome-wide studies of their effects remains largely undetermined. In this study, we 
utilize ChIP-seq to compare the effects of treatment with C646, which is a competitive 
inhibitor of both p300 and CBP [42] to the effects of ICG-001, which prevents CBP 
interaction with the co-activator β-catenin [43, 44]. Indeed, following treatment with either 
drug we detect global changes in histone acetylation levels. Our results suggest that, in 
general, these two drugs have similar effects on the epigenome of PDAC cells; however, 
we were able to identify cell-specific and drug-specific responses after treatment.  
We observed dramatic effects on the epigenome upon treatment with either ICG-
001 or C646, with hundreds of regions showing differential enrichment of H3K27ac or 
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H3K4me3. Interestingly, both drugs targeted similar super-enhancers, causing a reduction 
in histone acetylation levels near genes involved in pancreatic cancer and other solid 
cancers (Figure 3.4). Since it is of current interest to target super-enhancers, we find that 
both super-enhancers and broad H3K4me3 domains are sensitive to epigenetic modulation. 
Thus, our results provide insight into the plasticity of these domains in response to 
epigenetic modulation. Future work could tailor these therapeutics to target such domains; 
thereby impacting specific cellular pathways involved with PDAC tumorigenesis. 
The extension of epigenetic regulatory domains has emerged as a diagnostic marker 
that can serve to distinguish cancer cell identity and disease state. Accordingly, we 
characterized the broad domains in several different cell lines that represent distinct PDAC 
histological grades. By clustering the domains from 7 different PDAC cell lines into High- 
and Low-Grade groups, we find that different PDAC grades exhibit characteristic 
epigenetic features that are predictive of PDAC prognosis and provide insight into 
pancreatic cancer cell identity. Of particular interest are the genes marked by both super-
enhancer and broad H3K4me3 domains in Low-Grade groups. Low-Grade groups 
demonstrate an enrichment for a greater number of unique gene pathways, which include 
several pathways significant to PDAC progression. Such pathways include tight junction, 
glycerophospholipid and Rap1 signaling pathways. We also provide evidence that genes 
marked by overlapping Low-Grade broad domains correspond to epithelial phenotype and 
hold potential as a marker for patient stratification (Figure 3.2). Thus, different PDAC 
grades exhibit characteristic pathways marked by broad epigenomic domains that provide 
insight into pancreatic cancer cell identity in the context of PDAC progression. 
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Pancreatic Ductal Adenocarcinoma (PDAC) broad domains span numerous 
distinctive loci including the HOX, SMAD, and FOX family of genes, proteins that have 
known roles in cell-type specific functions and are known factors in PDAC tumor cell 
biology [45-47]. After annotating the genes marked by different broad domains, we 
identified known PDAC signaling pathways including the TGFβ and MAPK pathways, 
which are downstream effectors of oncogenic KRAS. Oncogenic KRAS is an established 
driver of pancreatic cancer and several pathways that are known downstream effectors of 
KRAS signaling and play central roles in PDAC cancer cell growth and survival [48-50], 
were found to be marked by broad domains in domains common to all PDAC cells. Super-
enhancers common to all PDAC cell lines were significantly enriched with a variety of 
cancer signaling pathways including focal adhesion, PI3K-AKT, microRNAs and Hippo 
signaling. LGU super-enhancers were uniquely associated with several pathways that 
include tight junction, Rap1 signaling and glycerophospholipid metabolism. Aberrant lipid 
synthesis and the reprogramming of lipid metabolism has been associated with the 
development and progression of pancreatic cancer [51] and several phospholipids have 
been identified as potential biomarkers in different types of pancreatic cancers [52, 53]. 
MAPK signaling was the singular KEGG pathway enriched in HGU super-enhancers 
(Appendix C-3). Similarly, the broad H3K4me3 domains common to all PDAC groups 
were associated with distinctive pathways including transcription corepressor, protein 
kinase, cadherin binding and RNA binding pathways (Appendix C-3). Several enriched 
pathways linked to LGU broad H3K4me3 domains include SMAD, protein kinase C, TGF 
beta, and beta-catenin pathways, whereas the HGU broad H3K4me3 domains solely mark 
genes enriched in transcriptional corepressor pathways. Examples of broad PDAC 
 77 
epigenomic domains encompassing disease-associated genes include SMADs and FOXC2 
for super-enhancer regions and MYC and CCND1 for broad H3K4me3 domains (Appendix 
C-1 and 2). 
Interestingly, our analysis indicates that Low-Grade unique broad H3K4me3 
domains are enriched for TGFβ signaling pathways. TGFβ acts as a tumor suppressor with 
growth-inhibitory activity in epithelial cells during early pancreatic tumorigenesis. 
However, TGFβ appears to promote tumor progression in advanced disease [54]. We also 
found broad epigenomic domains mark several others pathways with less well-
characterized roles in PDAC tumor biology, including microRNAs and proteoglycans in 
cancer.  
The histone modifications H3K4me3 has been widely recognized as a mark of 
active promoter regions [55]. Recent studies have correlated broad H3K4me3 domains 
with enhancer activity at tumor suppressor genes in normal and cancer cells to provide 
mutation-independent insight into tumor suppressor pathways of disease states [9]. Here, 
we found broad H3K4me3 domains span a number of genes including HOX, MYC and 
CCND1 genes. As super-enhancers and broad H3K4me3 domains have been shown to 
function coordinately through chromatin interactions [8, 38], we identified regions 
containing both domains in both High- and Low-Grade cells. As mentioned previously, the 
expression of genes marked by both domains is significantly associated with poor 
prognosis in pancreatic cancer patients.   
In summary, our data provides new perspective on the effect of HAT inhibitors on 
the epigenome and provides knowledge of the broad domains unique to different 
histological grades of pancreatic cancer. Our data show that epigenomic domains that 
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Cell culture and epigenetic inhibitor experiments 
The human cell line PANC1 (ATCC #CRL-1469) was obtained from the American 
Type Culture Collection. The cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. We obtained 
ICG-001 from Michael Kahn (University of Southern California) and C646 from VWR 
(catalog# 102516-240). Cells were grown to 70% confluency followed by treatment with 
10μM ICG-001 or 10μM C646 and were collected after 12hrs.  
 
ChIP-sequencing  
After 12-hour incubation with either ICG-001 or C646, cells were crosslinked with 
1% formaldehyde (Thermo Scientific #28908) for 10 minutes and quenched with 0.125M 
Glycine. The ChIP-seq experiments were further performed as described by O’Geen et al. 
[56] and the antibodies used for the given targets were as follows: H3K27ac (Abcam, 
Cambridge, MA, USA; Ab4729 lot#GR16377-1) and H3K4me3 (Abcam, Cambridge, MA, 
USA; Ab8580). We performed duplicate ChIP-seq experiments for each histone. For each 
histone ChIP-seq assay, 10μg of chromatin was incubated with (2.5-5μg) of antibody. To 
confirm enrichment of target sequences, we performed qPCR in ChIP versus input samples. 
DNA was quantified using Qubit (Invitrogen) and libraries were prepared using the 
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NEBNext ChIP-seq Illumina Sequencing library preparation kit (New England Biolabs, 
Ipswich, MA, USA). 
 
Tethered Chromatin Capture (TCC) 
Tethered chromatin capture (TCC) was performed as detailed by Kalhor et al. [57]. 
Briefly, approximately 5 x 107 PANC1 cells were crosslinked as described above for ChIP-
seq experiments and cell pellets were collected and stored at -80C. Nuclei were digested 
with 2000U HindIII prior to dilute solid-surface ligation reactions and TCC library 
preparation was performed as described [57].  
 
ChIP-sequencing analysis   
For all datasets raw sequencing reads were aligned to the human reference genome 
hg19 using bowtie2 with default parameters [58]. ENCODE ChIP-seq datasets were 
obtained from GSE31755. We determined binding sites of each ChIP-seq experiment using 
MACS2 with default parameters with the exception of using the flag ‘-broad’ for 
determining broad H3K4me3 binding sites [59]. Super-enhancer regions were identified 
over typical-enhancer regions using the Ranked Ordering of Super Enhancer (ROSE) tool 
[5, 60]. Briefly, peaks were called from the H3K27ac ChIP-seq data and stitched together 
in 12.5 kb windows, which were further used to identify super-enhancers (ranked cutoff 
score of 19701.68). Broad H3K4me3 regions were obtained via filtering for the top 5% of 
peaks (largest by domain size). Enrichment of signal within regions was plotted with the 
functions ‘plotProfile’ and ‘plotHeatmap’ within deepTools [61]. Overlapping binding 
regions were determined using peak interesectR. To determine peak locations relative to 
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gene regions, we utilized the ‘annotatePeaks.pl’ function within HOMER 
[62].  Visualization snapshots of ChIP-seq regions were obtained by building a signal track 
via the ‘bdgcompare’ utility in MACS [59]. Bigwigs were obtained by 
‘bedGraphToBigWig’ via UCSC tools [63] and further visualized using Integrated 
Genomic Viewer [64, 65].  
 
Coordination of Grade-Specific Broad Domains  
H3K4me3, H3K27ac and control ChIP-seq datasets for PDAC cell lines were 
obtained from GSE64557 and processed as described above. We utilized the Bioconductor 
package ‘seqsetvis’ [66] to visualize the distribution and overlap of genomic regions. 
 
Differential Binding Analysis of ChIP-seq datasets 
To determine differential typical and broad H3K27ac and H3K4me3 regions we 
used the DIffBind R package [67, 68] with an FDR cutoff of <0.1.  
 
Pathway Enrichment Analysis 
Annotation of enriched gene pathways was performed using either ClusterProfiler 
or the Stanford GREAT tool [69, 70].   
 
Integration of Gene Expression Datasets 
For integrating High- and Low-Grade gene expression for the different cell lines, 
we retrieved the corresponding RNA-sequencing expression datasets (GSE64558). We 
mapped these datasets to the human genome reference, hg19 and gene counts were 
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nomalized using DESeq2 [71]. The mean of the normalized counts between replicates of 
each cell line was used to generate expression heatmaps. ICG-001 and C646 Illumina 
beadchip expression datasets were obtained from our previous study (GSE64038). We 
overlapped these differentially expressed genes within treatments with our genes annotated 
within drug altered broad regions to demonstrate expression changes at these genes.  
 
Topological domains from TCC data  
Paired raw reads of TCC data for the PANC1 cell line was processed using the HiC-
Pro pipeline [72]. Briefly, these reads were aligned to the human reference genome hg19 
using bowtie2 with default parameters [58]. 25bp of the reads were trimmed and the reads 
were then aligned iteratively. Reads with a MAPQ score less than 30 were removed and 
the fragments were filtered for self-ligated fragments, duplicated reads from PCR and 
error-pairs. Domains were detected using TopDom based on the local minima of 
normalized contact matrix [73, 74]. To visualize the relationship between broad domains 
and TADs, we used HiCPlotter [75]. 
 
Feature Enrichment Analysis within TAD Boundary Regions 
To determine enrichment of broad domains within +/- 20 kb of the Boundary 
regions, we iteratively determined the expected distribution either CTCF, broad H3K4me3 
or super-enhancer regions within our TAD boundary domains within 8,354 randomly 
selected bins and iteratively repeated this 1,000 times. We then calculated our observed 
estimation of the given regions (either for CTCF, broad H3K4me3 or super-enhancers) 
within TAD Boundaries. 
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Figures 
Figure 3.1: Determination of super-enhancers and broad H3K4me3 domains in PDAC 


































Figure 3.1. Determination of super-enhancers and broad H3K4me3 domains in 
PDAC cell lines that correspond to different histological grades. A. The total number 
of super-enhancers and broad H3K4me3 domains found in different human PDAC cell 
lines that represent either High-Grade (purple) or Low-Grade (green) PDAC groups. B. 
Genome browser representation of the H3K27ac and H3K4me3 ChIP-seq signal, as well 
as the RNA-seq signal over an approximate 14 kb region surrounding the VIM locus. C. 
Heatmap displaying the classification of super-enhancer domains across 7 human PDAC 
cell lines. The color scale reflects the density of H3K27ac signal at super-enhancer regions. 
D. Heatmap displaying the classification of broad H3K4me3 domains across 7 human 








































Figure 3.2: Broad domains mark distinctive pathways and are predictive of poorer 
PDAC patient survival. A. Clustering of genomic regions encompassing super-enhancers 
across seven human PDAC cell lines to define common, High- and Low-Grade unique 
super-enhancers. B. A similar analysis was performed on broad H3K4me3 domains to 
define common, High- and Low-Grade unique (HGU and LGU, respectively) broad 
H3K4me3 domains. C. A similar analysis was performed to look at overlapping domains, 
where ‘B’ represents Broad H3K4me3 domains and ‘S’ represents super-enhancers. D. 
Gene Ontology pathway enrichment profiles of genes marked by both domains that are 
common, HGU or LGU domains. E. Comparison of expression levels of genes marked by 
the indicated domains in High-Grade and Low-Grade PDAC cells. Data is derived from 
mean normalized expression counts of genes. F. Kaplan-Meier survival analysis of high- 
and low-risk groups (red and black, respectively) for genes marked High-Grade unique 























































Figure 3.3: Inhibitors of histone acetyltransferases impact global H3K27ac levels. A. 
Differential H3K27ac enrichment analysis reveals significantly altered genome-wide 
H3K27ac sites in response to ICG-001 (Top) or C646 (bottom) treatment (FDR <0.1), 
signal is represented as log2 normalized read count for the indicated condition. B. Signal 
heatmaps representing the H3K27ac within altered regions after ICG-001 or C646 
treatment identified from the differential analysis. C. Location analysis of increased or 
decreased H3K27ac signal after treatment relative to gene regions. D. Example of genes 
with increased or decreased H3K27ac signal after ICG-001 treatment, signal is represented 
as fold enrichment over input. E. KEGG pathway enrichment analysis of genes within 






























Figure 3.4. HAT inhibitors influence the acetylation levels at super-enhancers.  
A. Scatterplot displaying the differential enrichment of H3K27ac (log2 ChIP-seq read 
count) for ICG-001 (left) and C646 (right) compared to control, the blue diagonal line 
separates those of increasing or decreasing signal with the colored dots corresponding to 
regions with significant changes in treatment compared to control (FDR <0.1). B. Overlap 
analysis of regions comparing the increased or decreased H3K27ac regions after ICG-001 
and C646 treatment. C. Boxplots displaying log2 fold change of genes (treatment vs 
control) within the given differential domains identified in A. D. Pathway enrichment 



















Figure 3.5. Broad domains are linked to topological associated domain boundaries. 
A. Chromatin interaction matrix at 40 kb resolution showing broad domains contained 
within TAD regions. Statistical associations of TAD boundaries were performed for B. 
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Temporal dynamic reorganization of 3D chromatin architecture in hormone-






















Recent studies have demonstrated that chromatin architecture is linked to the 
progression of cancers. However, the roles of 3D structure and its dynamics in hormone-
dependent breast cancer and endocrine resistance are largely unknown. Here we report 
the dynamics of 3D chromatin structure across a time course of estradiol (E2) stimulation 
in human estrogen receptor α (ERα) positive breast cancer cells. We identified subsets of 
temporally highly dynamic compartments predominantly associated with active open 
chromatin and found that these highly dynamic compartments showed higher alteration in 
tamoxifen resistant breast cancer cells. Remarkably, these compartments are 
characterized by active chromatin states, and enhanced ERα binding but decreased 
transcription factor CCCTC-binding factor (CTCF) binding. Lastly, we identified a set of 
ERα-bound promoter-enhancer looping genes enclosed within altered domains that are 
enriched with cancer invasion, aggressiveness or metabolism signaling pathways. This 
large-scale analysis expands our understanding of higher order temporal chromatin 




Numerous efforts have been devoted to revealing the basic principle of three 
dimensional (3D) chromatin architecture and genome organization inside the cell nucleus 
of various mammalian genomes1-8. One prominent structural feature of genome 
organization is the formation of various types of chromosomal domains9 defined as 
spatial compartments1,10, topologically association domains (TAD)3 or lamina-associated 
domains (LAD)11. The discrete TADs ranging from several hundreds of kilobases (kb) to 
several megabases (Mb) are usually stable in diverse cell types and are highly conserved 
across different mammalian species, suggesting that they are inherent and important 
functional units of mammalian genomes12,13. By contrast, spatial compartments 
comprised of two types, compartment A or B, form an alternating pattern of active and 
inactive domains along chromosomes. Their sizes usually range around 5 Mb and are 
characterized by genomic features associated with transcriptional activity, such as 
chromatin accessibility, active or repressive histone marks, gene density, GC content and 
repetitive regions14,15. Furthermore, A and B compartments show tissue- or cell-type 
specificity that are correlated with cell-type specific gene expression patterns16,17. 
However, a recent study found A or B compartments may be much smaller in size at a 
couple of hundred kb when using improved Hi-C protocols in higher resolution maps18. 
These maps are similar in size to the topologically constrained domains19. It is also 
increasingly recognized that spatial compartments and TADs are fundamentally two 
independent chromosomal organization modes20,21, thus disputing the common notion of 
a hierarchical folding principle that TADs are the building blocks of larger compartment 
domains. 
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Recent efforts have focused on understanding the relationship between higher-
order structures and human development and disease.22-24. For instance, new studies 
demonstrated that the reprogramming of high-order structures of both the paternal and 
maternal genomes gradually occurs during early mammalian development23,24. Another 
study showed that disorganization of prostate cancer 3D genome architecture occurs 
coincident with long-range epigenetically activated or silenced regions, which 
coordinated with gene transcription25. Despite the advances in our knowledge of 3D 
genome regulation, several critical questions remain to be answered in the field. For 
example: (1) how stable or dynamic are chromosome domains upon signaling stimuli as 
cells respond to external cues? (2) To what extent do these changes affect establishing or 
re-establishing the compartmentalized architecture? (3) What degree of impact do the 
master or key transcription factors in a particular cell system have on chromatin 
reorganization? (4) What are the roles of chromatin architecture in governing the 
progression of human diseases, such as cancers?  
Estrogen (E2) signaling plays a crucial role in driving estrogen receptor α positive 
(ERα+) breast cancer cell growth and proliferation26,27. The cellular response to E2 
induction is characterized by timed and coordinated transcriptional regulation primarily 
mediated by ERα. Thus, it has been frequently used as a model system to illustrate the 
mechanisms underlying transcriptional controls in cancer development and progression 
as well as in fundamental biological process28-32. Using genome-wide approaches, we and 
others demonstrated very little coincidence between ERα targeted genes in breast cancer 
cells versus acquired endocrine resistant breast cancer cells indicating distinct 
transcriptional regulatory mechanisms underlying endocrine resistance33-37. In a recent 
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study, we used a 3C-based high throughput protocol to identify two densely mapped 
distant estrogen response element (DERE) regions which were frequently amplified in 
ERα+ breast cancer38,39. Interestingly, these aberrantly amplified DEREs deregulated 
target gene expression linked to cancer development and tamoxifen resistance. However, 
the roles of 3D structure and its dynamics in hormone-dependent breast cancer and 
endocrine resistance are largely unknown. 
To establish a basis for data-driven learning and modeling of the temporal 
dynamics and 3D chromatin reorganization, we applied tethered chromatin conformation 
(TCC), a modified Hi-C protocol40 for high depth sequencing. We performed TCC in a 
time-series of E2-induction in the ERα+ breast cancer cell line, MCF7 as well as the 
tamoxifen resistant MCF7 (TamR) cell line. Here, we present a time-series of genome-
wide maps of chromatin contacts, identify the temporal dynamic patterns of chromatin 
compartments, compare the patterns between MCF7 and TamR cells and examine the 
enrichment of ERα and CTCF binding as well as five active and repressive histone marks 
in the patterns. We further identify ERα-bound promoter-enhancer (ERα-PE) looping 
genes enclosed within TamR altered dynamic compartments. This large 3D-scale of 
chromatin data provides a rich resource for studying the basic characteristics of hormone-







Re-compartmentalization of chromatin at early E2 treatment 
Despite many studies demonstrating that E2 induces the highest levels of ERα 
binding and gene activity around 45min to 1hr28,30, little has been done to 
comprehensively characterize the changes of chromatin architecture in MCF7 cells in a 
genome-wide manner. In this study, we conducted TCC analysis in hormone-starved 
MCF7 cells (T0) and compared this to MCF7 cells treated with 1hr of E2 (T1). The 
Pearson correlation of chromatin interactions showed that biological replicates are largely 
correlated for each treatment at different resolutions (Figure 4.1-A), illustrating good 
quality TCC data. We thus combined two replicates at either time point to identify 
chromosome compartments with HiCLib10 (Figure 4.1-B). With a sequencing depth of 
around 200 million (75 million uniquely mapped) paired-end reads for each data set, we 
expect the resolution of compartments around 40-50kb41. Surprisingly, the genomic size 
of a majority of compartments is either smaller than 1Mb or between 1-2Mb, and very 
few are larger than 5Mb (Figure 4.1-C and D). Our data seems to contradict earlier 
studies that determine compartment sizes to be larger than 2Mb1,10; however, it is 
consistent with newly reported studies using improved Hi-C protocols in conjuction with 
a higher sequencing depth18. We found a similar number of compartments, 2,067 and 
2,039, in the untreated and E2-treated cells respectively, where approximately half 
consisted of compartment A (active chromosome domains) and half were compartment B 
(inactive chromosome domains) at each time point (Figure 4.1-E). We then compared 
the compartments between untreated and E2-treated cells, and found that the type of 
compartments drastically changes following E2 treatment. The number of common or 
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conserved compartments between treatments increases from 28%, 55%, 74% to 78% 
using different bin sizes of 100kb, 250kb, 500kb and 1Mb, respectively (Figure 4.1-F). 
Our results at lower resolution (500kb or 1Mb) are in-line with many other studies that 
report approximately 80% conserved domains among different conditions or cell 
types3,12. However, at a higher resolution of 100kb, we identified 576 Common 
compartments between untreated and E2-treated cells and 1,463 Transit compartments 
sensitive to E2 treatment that shifted in size or flipped between A/B compartments. Of 
Transit compartments, 743 (51%) of them shift only 100kb and 247 (17%) shift more 
than 400kb while 116 (8%) flipped between A/B compartments (Figure 4.1-G). These 
data demonstrate a re-compartmentalization of higher-order chromatin domains following 
1 hour of E2 treatment. 
 
Temporal dynamic chromatin along prolonged E2 treatments 
Several studies found that transcriptional responses to longer E2 treatments were 
dramatically different than responses to shorter treatments30,31. In order to understand the 
dynamics of chromatin structure in longer E2 treatment periods in MCF7 cells, we further 
conducted TCC analysis in three more time points, 4hr (T4), 16hr (T16) and 24hr (T24), 
each with biological replicates. In order to capture the dynamic patterns following a 
prolonged E2 treatment, we determined compartments at 100kb and compared the 
compartments among the five time points. As expected, the number of compartments was 
very similar among the five time points. We used the Common and Transit compartments 
obtained from the comparison of T1 vs. T0 and compared them to T4, T16 and T24 
respectively. We also separated the comparison of active open chromatin compartment A 
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(Figure 4.2-A, upper panel) from inactive closed chromatin compartment B (Figure 4.2-
A, lower panel). When re-examining these sets of Common or Transit compartments, we 
identified 15 patterns of changed compartments from 16 sets (Appendix D-1) and 9 
additional patterns from the last set (labeled X in Appendix D-1) based on the converted 
bins. We were able to categorize these 24 patterns of chromatin into six types of 
temporally dynamic re-compartmentalization (TDRC): Highly Common Compartments 
(HCC, patterns 1-4 with a FDR of 0.268), Early Transit Compartments (ETC, patterns 5-
8 with a FDR of 0.230), Late Transit Compartments (LTC, patterns 9-12 with a FDR of 
0.192), Lowly Dynamic Compartments (LDC, patterns 13-16 with a FDR of 0.178), 
Moderately Dynamic Compartments (MDC, patterns 17-20 with a FDR of 0.161), and 
Highly Dynamic Compartments (HDC, patterns 21-24 with a FDR of 0.201) (Figure 4.2-
B). There is also a statistically significant difference (p=7.6x10-11, Wilcoxon rank-sum 
test) between highly dynamic compartments (MDC and HDC) and lowly dynamic 
compartments (HCC, ETC, LTC and LDC) (Figure 4.2-C). Interestingly, the MDC and 
HDC are predominantly composed of compartment A mainly from Transit to Transit 
compartments along the time courses of E2 treatment (Figure 4.2-D and E), while the 
LDC has the most changed compartment B. This data suggests that active chromatin 
domains are more susceptible to change in response to E2 stimulation over time.  
 
Altered chromatin compartmentalization in resistant cells 
Increasing evidence suggests that ERα-mediated gene deregulation or epigenetic 
alterations may be key mechanisms underlying acquired tamoxifen resistant breast 
cancer42,43. However, the knowledge of endocrine resistant associated 3D regulation is 
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still limited. To delineate the altered 3D architectures, we further conducted TCC analysis 
in a tamoxifen resistant MCF7 cell line, MCF7-TamR44. At a resolution of 100kb, we 
identified 2,103 compartments including both A and B (Figure 4.3-A). We further 
defined a compartment to be a tamoxifen resistant altered compartment (TRAC) if it was 
a Transit compartment and if there was at least one converted bin between TDRC and a 
TamR compartment. As such, we obtained six corresponding types of TRACs: TA-HCC 
(FDR of 0.154), TA-ETC (FDR of 0.250), TA-LTC (FDR of 0.154), TA-LDC (FDR of 
0.165), TA-MDC (FDR of 0.139) and TA-HDC (FDR of 0.226). Patterns 17, 19, 21, 23, 
and 24 in TA-MDC and TA-HDC types showed higher alteration than other patterns, 
suggesting that the higher dynamics of the compartments in E2-induced MCF7 cells, the 
stronger alterations of the compartments in TamR cells (Figure 4.3-B). Further, we 
observed that the average size of TA-HDC and TA-ETC types were longer than those in 
unaltered compartments, while the size of TamR unaltered compartments (TRUCs) were 
longer than TA-HCC (Figure 4.3-C). Att a bird’s-eye-view, we identified three 
interesting types of TRACs: Shrunk, Expanded and Flipped (Figure 4.3-D-F). Our data 
suggest that a group of genes within the same domain may be concordantly regulated 
during acquired tamoxifen resistance.  
 
Epigenetic states in dynamic re-compartmentalization 
Epigenetic marks have been shown to classify genomic compartments and 
chromosomal domains into subcompartments or subdomains in diverse cell types18. 
There is little known about the structural roles of one-dimensional (1D) epigenetic states 
in E2-induced 3D chromatin structure. We performed ChIP-seq of three active marks, 
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H3K27ac, H3K4me1, and H3K4me3, and two repressive marks, H3K9me3 and 
H3K27me3 in a time course of E2 treatment in MCF7 cells as well as in asynchronous 
TamR cells, each with biological replicates. We first trained a total of 30 histone 
modification data by ChromHMM at various parameters45, and obtained ten HMM states 
(Figure 4.4-A and B). Through interpreting both HMM emission and transition 
probabilities, we inferred seven biologically meaningful epigenetic states, including two 
active states (S9 and S10), two bivalent states (S3 and S8) and three repressive states (S1, 
S4 and S6) (Figure 4.4-C). We were also able to map these states back into each of six 
types of E2-induced dynamic compartments and TamR altered compartments. Overall, 
we observed that more active states were distributed in compartment A and more 
repressive states in compartment B, while three types of dynamic changed compartments, 
i.e., LDC, MDC and HDC, have a higher percentage of active states than HCC does 
(Figure 4.4-D-G). Surprisingly, S1 showed a high percentage of distribution in 
compartment A despite that it is a repressive state.  
 
ERα and CTCF binding in dynamic re-compartmentalization  
Since ERα is a master transcription factor mainly in response to E2 stimulation in 
MCF7 cells and CTCF is a chromatin organizer known to regulate the 3D architecture, 
we wanted to understand their regulatory roles in mediating these 3D structural 
dynamics. We performed ChIP-seq of ERα and CTCF at five time points of E2-
stimulated MCF7 cells and in TamR cells, each with biological replicates. We used 
MACS46 to call ERα binding sites (peaks) in each of the 12 data sets and obtained 7,553 
peaks in untreated MCF7 cells (T0), and between 13,000-20,000 ERα peaks in E2-treated 
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MCF7 cells at four time points and untreated TamR cells respectively (Figure 4.5-A). 
Interestingly, we found Patterns 18 and 20 of MDC and Pattern 24 of HDC had the 
highest number of ERα binding sites in compartment A but not in compartment B in E2-
induced MCF7 cells as well as in TamR cells (Figure 4.5-B), illustrating that there are 
more ERα binding sites in higher dynamic active chromatin.  
Furthermore, we identified approximately 50,000 CTCF peaks in each of the five 
time points of E2-induced MCF7 cells and in TamR cells (Figure 4.5-C). On the 
switched domain boundary between two compartments, we observed generally lower 
averages of CTCF binding sites in three types of TDRCs (LDC, MDC, HDC), and three 
types of TRACs (TA-LDC, TA-MDC, TA-HDC) than other three types (Figure 4.5-D). 
When testing the correlation of ERα binding within the compartments vs CTCF binding 
on the boundary regions, Pattern 24 of HDC or TA-HDC was the only pattern having 
more than 80% ERα peaks and less than 0.4 CTCF peaks per compartment in E2-induced 
MCF7 cells (Figure 4.5-E—left panel) or in TamR cells (Figure 4.5-E—right panel). 
Collectively, our results indicate a reciprocal relationship to ERα binding and CTCF 
binding at highly dynamic changed compartments during the temporal response to E2 
stimulation which is also observed in cells with acquired tamoxifen resistance. 
 
Differentially expressed genes and putative loops 
We next examined the gene expression and loops within these TDRCs and 
TRACs. We utilized a publicly available time-series RNA-seq dataset47, profiled at 10 
time points of E2-treated MCF7 cells, to identify differentially expressed genes. By 
picking 5 time points close to this study (T0 = 0 min, T1 = 40 min, T4 = 160 min, T16 = 
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640 min, T24 = 1280 min), we identified 4,106 dynamic differentially expressed genes 
(DDEGs) across all time points. As expected, a majority of such genes were located in 
dynamically changed compartment A with most in the MDC and HDC types (Figure 4.6-
A). There seems to be minimal difference in the average of gene expression levels within 
each of the six types of TDRCs. However, the variance of DDEGs in LDC, MDC and 
HDC is higher than HCC, ETC and LTC (Figure 4.6-B). GSEA analysis48 showed 
ribosome, tight junction, endocytosis, lysosome, cell cycle, WNT signaling pathway, 
insulin signaling pathway, focal adhesion, and MAPK signaling pathway were among the 
top functional categories for the 1,396 DDEGs in MDC and HDC types (Figure 4.6-C). 
We further performed RNA-seq in parental MCF7 and TamR cells, each with three 
biological replicates and identified a total of 2,097 TamR-specific differentially 
expressed genes (TDEGs). More than half of them (1,188) were in the combined TA-
M&HDC types (Figure 4.6-D). We then identified 42,390 TamR-specific significant 
interaction pairs or putative loops from TamR TCC data by HOMER49 and using our T0 
TCC dataset as the contrast. 3C-qPCR validations further confirmed the differential 
looping intensity of seven randomly selected pairs between parental MCF7 and TamR 
cells (Appendix D-2). Of the 42,390 identified loops, 16,807 were overlapped with a 
promoter (-5kb/+1kb around the 5’TSS), 9,638 of them had either H3K27ac or H3K4me1 
peaks in the distal loci, 4,122 of them had at least one ERα binding site at either loci of 
the loop and were thus considered as ERα regulated promoter-enhancer (ERα-PE) loops 
(Figure 4.6-E). Finally, 396 TDEGs within 599 ERα-PE loops in the combined TA-
M&HDC types were identified as ERα dysregulated dynamic looping genes in resistant 
cells. Functional annotation and gene pathway analysis with GSEA showed these genes 
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were mapped to nine KEGG signaling pathways related to cancer invasion and 
aggressiveness, as well as glycolysis and metabolism (Figure 4.6-F). Taken together, our 
results demonstrate that these ERα-associated dynamically reorganized active domains 
regulating gene looping events may result in higher susceptibility to alterations in 
tamoxifen resistant cells. This prompts us to speculate that these genome domains and 
looping genes may be responsible for driving the acquired tamoxifen resistance. 
 
Discussion 
Despite the increasing developments of various 3C-derived high throughput 
sequencing techniques in which it advances our understanding of the principles of 3D 
genome architecture, several important questions remain to be answered in the field. One 
of the many aspects is to elucidate how stable or dynamic chromosome domains are in 
response to signaling stimuli and to what extent these changes affect establishing or re-
establishing the compartmentalized architecture. Our main goal of this study is to 
establish a basis for data-driven modeling of temporal dynamics and 3D chromatin 
reorganization given that such studies are very limited. While mega-sized TADs are 
conserved among different cell types and mammalian species3,5,12, 100-500kb size of 
subTADs or compartments are considered to be dynamic where the boundaries are non-
conserved18,50. Though our data showed the total number of compartment domains are 
quite similar among different time points, the changes in size (of at least 100kb) of 
compartments are very pronounced, particularly in these E2-induced highly dynamic 
compartments. With a very loose definition of dynamic changes requiring a minimum of 
100kb, we were able to unveil 24 temporal dynamic patterns upon E2-induction which 
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were further categorized into six major types. Indeed, the MDCs and HDCs were not only 
predominately of active compartment A but also contained dynamic differentially 
expressed genes enriched with biological process terms ribosome, tight junction, cell 
cycle and others (Figure 4.6-C). Many of them characterize known effects of estrogen on 
the MCF7 cell phenotype51. In contrast, there were no significant differences between E2-
induced early and late changed compartments in which both types were comprised of 
very few compartments. Our data implied that these moderate to high dynamic 
compartments may play an essential role in governing hormone-mediated luminal breast 
cancer development. 
Many studies including ours have demonstrated that E2 instructed dynamic 
transcriptional programs rewired or altered transcription regulatory networks in 
tamoxifen resistant breast cancer cells36,52,53; however, very few focused on examining 
3D regulatory roles in tamoxifen resistance. Our previous studies utilized a 3C-seq 
technique to identify two densely mapped DERE regions located on chromosomes 17q23 
and 20q13 frequently amplified in MCF7 cells and found their aberrantly amplified 
DEREs deregulated target genes were potentially linked to cancer development and 
tamoxifen resistance38. However, this study containd many limitations including the 
technique itself, smaller data volumes and fewer computational tools available for a 
thorough analysis. Our current work has significantly improved in the following aspects: 
1) we generated high quality TCC datasets with increased sequencing depth allowing for 
the detection at 40kb resolution; 2) we produced TCC datasets in an E2-induced time 
series in MCF7 cells and then compared it to TamR cells; and 3) we utilized many state-
of-art computational tools to process TCC and ChIP-seq datasets. Remarkably, our 
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integrative analyses uncovered many temporal dynamic patterns characterizing the 3D 
chromatin reorganization upon E2-induction. Interestingly, two types of temporal 
dynamic re-compartmentalization (TDRC), i.e., moderately and highly dynamic 
compartments (MDCs and HDCs), showed higher alteration in TamR cells (Figure 4.3-
B). Furthermore, the looping gene signatures enclosed in these two altered dynamic 
domains were highly enriched with GO terms cancer invasion and aggressiveness or 
metabolism. All of these biological processes captured the nature of acquired resistant 
breast cancer cells54. 
Our definition of 24 patterns or six types of dynamic changed compartments were 
based upon how re-compartmentalization in MCF7 cells respond to E2 induction. 
Interestingly, the resulted six types are identical to the analysis based on a mathematical 
calculation resulting in a total of 256 combinations of E2-induced time-dependent 
compartments (Appendix D-3) when using T0 as a contrast. Furthermore, we observed 
the same trends of E2-induced time-dependent compartments in both MCF7 and T47D 
cell lines, where the major trend are miscellaneous dynamic compartments in both MCF7 
and T47D cell lines. Moreover, the altered compartments of both MCF7-TamR and 
T47D-TamR have higher percentage of miscellaneous compartments. Our results suggest 
that our analytical strategy and observations are generalizable in various cell lines. 
Our findings further illustrated an anti-correlative trend of binding enrichments 
between intradomain ERα sites and boundary CTCF sites (Figure 4.4-D and E). 
Interestingly, the average of CTCF sites is generally lower regardless of its distance from 
the boundary in these highly dynamic changed domains. Although our result is not so 
surprising, it nevertheless implicates an underlying molecular event that ERα regulated 
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high re-compartmentalization may be required to loosen CTCF insulator at the domain 
boundary4,55. Furthermore, our data may support the higher-order chromatin architectural 
role of ERα signaling in mediating hormonal activity, expanding our current 
understanding of the molecular mechanism underlying the E2-induced breast 
carcinogenesis through ERα regulation.  
Collectively, our observations suggest a possible molecular mechanistic model 
(Figure 4.7-A-D). A constitutive estrogen stimulation in breast cancer cells enhances 
stronger ERα activity and further recruits its distal regulatory machinery including 
different co-regulators, mediators, cohesions and chromatin remodelers, and then 
mobilizes highly dynamic gene looping events which essentially expand to render a 3D 
genome re-compartmentalization accompanying with lower CTCF binding at the 
compartment boundary. In contrast, in breast cancer cells with the acquired resistance, 
increased crosstalk between ERα and other signal transduction pathways such as 
EGFR/HER256, IGF-IR53, and AKT/PTEN57 or altered expression of some key co-
regulators particularly reshuffle these highly dynamic gene looping resulting in altered 
chromatin reorganization. To substantiate this model, we propose further functional or 
mechanistic experiments in our follow up studies: 1) establishing genome-edited TamR 
sublines by editing out a handful ERα sites selected from 599 gene loops using the 
CRISPR/Cas9 technique58; in these sublines, examining the changes of ERα regulated 
looping using ChIP-3C-qPCR and determining if resistant cells are re-sensitized; and 2) 
establishing an in vivo model of TamR xenografts44; in this model, examining selected 
ERα regulated loops using ChIP-3C-qPCR by comparing untreated vs. treated Gefitinib, 
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an inhibitor to EGFR/HER2. With these results, we might expect to elucidate the detailed 
3D ERα regulatory role in mediating tamoxifen resistance.  
In summary, the high quality and large 3D chromatin data along with many ChIP-
seq and RNA-seq data provided a comprehensive resource for understanding how 
estrogen exposure drives genome-wide 3D chromatin reorganization in ERα positive 
breast cancer cells as well as how their alterations occur in hormone resistant cells. Our 
integrative analysis reveals temporal dynamic patterning and 3D chromatin 
reorganization of the breast cancer genome that occurs in response to E2 stimulation over 
time. Our work may give further insight into the effective treatment strategies to 
overcome tamoxifen resistance and discovery of novel epigenetic therapeutic targets. 
 
Methods 
Cell lines and reagents 
The human parental MCF7, T47D and Tamoxifen Resistant (TamR) cell lines 
were derived from Osborne et al. 199444. MCF7 cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 
2mM L-glutamine and 1% penicillin/streptomycin (pen/strep) until 90% confluent. For 
temporal estrogen responsiveness, MCF7 cells were hormone-starved for 72hrs followed 
by the addition of 100nM β-Estradiol (MP Biomedicals, Inc.) at 1hr, 4hr, 16hr and 24hr. 
To hormone starve MCF7 or T47D cells, these cells were grown to 80% confluency as 
described above. Once the desired confluency was reached, the cells were washed one 
time with Phosphate Buffered Saline and the media was replaced with phenol-red free 
DMEM supplemented with 5% charcoal-stripped FBS, 2mM (L-glutamine) and 1% 
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(pen/strep). For the 0hr time point, cells were immediately crosslinked following 72hrs of 
hormone starvation.  
TamR cells were cultured in phenol red free DMEM supplemented with 10% 
charcoal-stripped FBS, 2mM L-glutamine, 1% pen/strep, and 100nM Tamoxifen (Sigma-
Aldrich). Tamoxifen was replenished every 48hrs and cells were crosslinked at 90% 
confluency. 
 
Tethered chromatin capture (TCC) 
TCC was performed as Kalhor et al. described40. Approximately 50 million 
MCF7 or T47D cells (either parental hormone starved with temporal addition of β-
Estradiol (E2) or TamR cells as described above) were crosslinked with 1% 
formaldehyde for 10 minutes at room temperature, crosslinking was quenched with 0.125 
M glycine for 5 minutes at room temperature and cell pellets were collected and stored at 
-80oC. The crosslinked cells were lysed with 550μL of Cell Lysis Buffer (10mM HEPES 
pH 8.0, 10mM NaCl, 0.2% Igepal CA-630, containing 1X protease inhibitor cocktail 
(Thermo Scientific #88665) and 1X PMSF (Acros Organics #215740050). The cells were 
homogenized with a dounce homogenizer for 20 strokes with pestle A after incubation on 
ice for 15 minutes. The lysate was then centrifuged at 2,500 rcf for 5 minutes at room 
temperature. The supernatant was discarded and the remaining pellet containing the 
nuclei was washed twice with ice-cold wash buffer #1 (50mM Tris-HCl pH8, 50mM 
NaCl, 1mM EDTA) and resuspended in 250μL of wash buffer #1. The chromatin was 
then solubilized by the addition of 95μL of 2% SDS followed by an incubation at 65oC 
for 10 minutes. The cysteine residues were biotinylated by the addition of 105μL of 
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25mM EZlink Iodoacetyl-PEG2-Biotin (IPB) (Thermo Scientific #21334) and incubated 
at room temperature for 1 hour while rocking. The SDS was neutralized with 1300μL of 
1X NEBuffer 2 (NEB #B7002S) on ice for 5 minutes, followed by the addition of 225μL 
of 10% Triton X-100, which was then incubated on ice for 10 minutes followed by a final 
incubation at 37oC for 10 minutes. DNA was digested overnight at 37oC with the 
following reagents: 100μL of 10X NEBuffer 2, 5μL of 1M DTT, 430μL of water, and 
2000U of HindIII (100U μL-1; NEB #R0104M). To remove remaining IPB, the samples 
were then dialyzed for 4 hours at room temperature using a Slide-A-Lyzer Dialysis 
Cassette with a 20kD cutoff (Thermo Scientific #87735) in 1L of dialysis buffer (10mM 
Tris-HCl, pH 8.0 and 1mM EDTA). The biotinylated chromatin was then tethered using 
400μL of MyOne Streptavidin T1 beads (Invitrogen #65601) after washing the beads 
three times with PBST (1X PBS containing 0.01% Tween20) and re-suspending in 2mL 
of PBST. 400μL of washed Streptavidin T1 beads was then added into each of five equal 
aliquots of dialyzed sample. Binding occurred at room temperature for 30 minutes 
followed by the addition of 150μL of 25mM IPB neutralized with 25mM 2-
mercaptoethanol, which was then incubated at room temperature for 15 minutes. Non-
crosslinked DNA and non-biotinylated chromatin was removed by washing the beads 
once with 600μL PBST followed by one wash with 600μL wash buffer #2 (10mM Tris-
HCl, pH 8.0, 50mM NaCl, 0.4% Triton X-100). To wash the beads, we utilized a 
magnetic rack and ensured beads bound to the magnet before aspirating the buffer out. 
The beads were then resuspended in 100μL of wash buffer #2. The 5’ overhangs were 
filled with 63μL water, 1μL 1M MgCl2, 10μL 10X NEBuffer 2, 0.7μL 10mM dATP 
(NEB #N0440S), 0.7μL 10mM dTTP (NEB #N0443S), 0.7μL 10mM 2’-
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Deoxyguanosine-5’-O(1-thiotriphosphate) sodium salt (dGTPαS) (Biolog Life Science 
Institute #D031-05), 15μL of 0.4mM Biotin-14-dCTP (Invitrogen #19518-018), 4μL of 
10% Triton X-100, and 25U Klenow-large fragment (NEB #M0210L) and rocked at 
room temperature for 40 minutes. 5μL of 0.5M EDTA was added to stop the reaction and 
the beads were washed twice with wash buffer #3 (50mM Tris-HCl pH7.4, 0.4% Triton 
X-100, 0.1mM EDTA) and resuspended in 500μL of wash buffer #3. The crosslinks were 
reversed with 400μL of extraction buffer (50mM Tris-HCl pH8, 0.2% SDS, 1mM EDTA, 
100mM NaCl) followed by the addition of 400μg of proteinase K (NEB #P8107S) and 
incubation for two hours at 65oC. The initial conformation capture library (the 
supernatant) was extracted twice with an equal volume of phenol:chloroform:isoamyl 
alcohol (25:24:1 v/v) and once with an equal volume of chloroform. NaCl was then 
added to a final concentration of 20mM and glycogen to 2ug μL-1 followed by 
precipitation of the DNA with the addition of 900μL of ethanol (200 proof) and 
incubation at -20oC overnight. The DNA was pelleted via centrifugation at 20,000 rcf at 
4oC for 20 minutes. The pellet was then immersed in 500μL of 80% ethanol and 
centrifuged at 20,000 rcf for 10 minutes. The ethanol was removed and the pellet was air 
dried until approximately 90% dry and resuspended in 20μL of 10mM Tris-HCl pH8. 
The five aliquots were combined and the RNA was removed via RNAseA digestion 
(10μg RNAseA) for 30 minutes at 37oC. The DNA was purified using the Invitrogen 
Purelink Quick PCR purification kit (Invitrogen #K310001). Biotin from non-ligated 
DNA was removed from 5μg of purified DNA using 300U EXOIII (NEB #M0206S), 
adjusting the total volume to 90μL with 10X NEBuffer 1 (NEB #B7001S). This reaction 
was incubated at 37oC for 1 hour. The reaction was stopped with 2μL of 0.5M EDTA and 
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2μL of 5M NaCl followed by incubation at 70oC for 20 minutes. A Covaris Focused-
ultrasonicator (Covaris S220) was used to shear the DNA, with a duty factor of 5%, peak 
power of 175W, and 200 cycles per burst. Each sample was sonicated for 180 seconds 
and purified using the Purelink Quick PCR purification kit and eluted in 50μL of elution 
buffer. Libraries were generated with the NEBNext Ultra II DNA Library Prep Kit for 
Illumina (NEB #E7645L). First, end-repair was performed after sonication. 1μg of DNA 
was used and the total volume of sample was brought up to 50μL with 0.1X TE. The end 
repair was carried out as outlined in the manufacturer’s protocol. After end repair, the 
biotinylated DNA was pulled down using 10μL of MyOne Streptavidin C1 beads 
(Invitrogen #65001). The beads were first washed twice with 500μL of 1X Binding and 
Wash buffer (for 2X Binding and Wash buffer: 10mM Tris-HCl pH7.5, 1mM EDTA, and 
2M NaCl) and resuspended in 2X Binding and Wash buffer, which was then added to the 
end-repaired DNA. Lo-bind tubes (Eppendorf #022431021) were used to prevent sticking 
of beads to the sides of the tubes. The samples were rocked for 30 minutes at room 
temperature. The beads were washed one time with 1X Binding and Wash buffer 
containing 0.1% Triton-X100 followed by one wash with 10mM Tris-HCl, pH8 and the 
beads were collected in 60μL of 10mM Tris-HCl, pH8. Next, adaptor ligation was 
performed as described in the NEBNext Ultra II DNA Library Prep protocol, following 
the instructions for 1μg of input DNA. After ligation of Illumina adaptors on the beads, 
the beads were washed twice with 1X Binding and Wash buffer and twice with 0.1X TE. 
The beads were resuspended in 30μL of 10mM Tris-HCl pH8. 15μL of the beads 
containing adaptor-ligated DNA was transferred to a new tube and we continued on to 
PCR enrichment of adaptor-ligated DNA on the beads. The remaining 15µL was saved 
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and stored it at 4oC. The PCR was carried out as outlined in the NEBNext Ultra II 
protocol, NEBNext Multiplex oligos for Illumina (NEB #E7335S and #E7500S) were 
used for the individual barcodes and the enrichment was performed using 10 cycles. 
45μL of the supernatant containing the PCR products was transferred to a new tube and 
were cleaned using a 0.8X bead cleanup of the PCR reaction with Agencourt AMPure XP 
beads (Beckman Coulter #A63881). The AMPure XP beads were brought to room 
temperature and resuspended. 36μL of the resuspended beads were added to the libraries 
and mixed by pipetting. The beads were incubated at room temperature for 5 minutes and 
the supernatant was discarded. The beads were washed twice while on the magnet with 
200μL of 80% 200 proof ethanol. After air-drying the beads, the library was eluted off 
the beads with 23μL of 0.1X TE and transferred to a new tube. The final library was 
quantified using a Qubit fluorometer (Applied Biosystems) and analyzed using a 
Bioanalyzer (Agilent Technologies). 
 
Chromatin immunoprecipitation sequencing (ChIP-seq) 
The antibodies used for ChIP-seq were: H3K27ac (Abcam, Cambridge, MA, 
USA; Ab4729 lot #GR238071-1), H3K27me3 (Abcam, Cambridge, MA, USA; Ab6002 
lot #GR137554-5), H3K4me3 (Abcam, Cambridge, MA, USA; Ab8580 lot #GR240214-
1), H3K4me1 (Abcam, Cambridge, MA, USA; Ab8895 lot #GR114265-2), H3K9me3 
(Abcam, Cambridge, MA, USA; Ab8898 lot #GR216368-1), ERα (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA; sc-543X lot #J0313) and CTCF (Cell Signaling 
Technology, Danvers, MA, USA; D31H2 lot#1). We performed duplicate ChIP-seq 
experiments for each histone or factor using chromatin collected on different cell culture 
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dates. For each histone ChIP-seq assay, 10μg of chromatin was incubated with (2.5-5μg) 
of antibody. 150μg of chromatin was used for CTCF ChIP-seq (with 20μL of antibody) 
and 250μg of chromatin was used for ERα ChIP-seq (with 12 μg of antibody).  ChIP-seq 
samples were prepared as O’Geen et al. described59 with minor adjustments. The cells 
were crosslinked as described above for TCC experiments. The crosslinked cell pellets 
were washed twice with ice-cold 1X PBS and stored at -80oC until sonication. 
Crosslinked cell pellets were thawed on ice and resuspended in 1mL ice-cold cell lysis 
buffer (5mM PIPES pH8, 85mM KCl, Igepal 10μL mL-1) containing 1X protease 
inhibitor cocktail and 1X PMSF. After incubation on ice for 15 minutes the samples were 
then homogenized using a 2mL dounce homogenizer fitted with pestle ‘B’, using 20 
strokes. The samples were then centrifuged at 430 rcf for 5 minutes at 4oC. The 
supernatant was removed and the pelleted nuclei were lysed with 1mL ice-cold nuclei 
lysis buffer (50mM Tris-HCl pH8.1, 10mM EDTA, 1% SDS) containing protease 
inhibitors (1X protease inhibitor cocktail and 1X PMSF). The nuclei were lysed while 
incubating on ice for 30 minutes. Sonication was performed for 12 minutes using a 
Covaris Focused-ultrasonicator (Covaris S220) with a peak power of 140W, duty factor 
of 10%, and 200 cycles per burst. The sonicated material was then centrifuged at 20,000 
rcf for 15 minutes at 4oC and transferred to a new tube. To quantify the chromatin, 20μL 
of the sonicated chromatin was added to 80μL of ChIP elution buffer (50mM NaHCO3 
and 1%SDS) followed by the addition of 12μL of 5M NaCl. The samples were boiled at 
97oC for 15 minutes and 10μg of RNAseA was added to the tubes once the sample was 
cooled to room temperature. The sample was incubated at 37oC for 10 minutes to allow 
for RNA digestion. The reverse-crosslinked chromatin was then purified using the 
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Purelink Quick PCR purification kit and eluted in 20μL of nuclease free water. After 
quantification via a nanodrop (Thermo Scientific) the total chromatin yield in our 
sonicated material was calculated. To visualize the fragment sizes of the sonicated 
chromatin, we ran 1μg of purified chromatin on a 1.5% agarose gel. If the chromatin 
fragments were concentrated around the 300-500bp range, we continued onto 
immunoprecipitation. If under-sonicated, additional sonication was performed as needed. 
500ng of purified chromatin sample was saved as our input samples, these samples were 
brought to a total volume of 150μL with ChIP elution buffer and stored at -20oC. ChIP 
for each target was carried out using the quantities of chromatin and antibody above-
mentioned. The chromatin for each target was diluted with 5 times the volume of ice-cold 
1X IP dilution buffer (50mM Tris pH7.4, 150mM NaCl, 1% Igepal (v/v), 0.25% 
Deoxycholic acid, 1mM EDTA pH 8.0) containing protease inhibitors. The appropriate 
amount of antibody for each reaction was added and rotated overnight at 4oC. The 
antibody/chromatin complexes were captured by the addition of 150μL of protein A/G 
beads (Pierce #88803), which were first washed twice with 1X IP dilution buffer, for the 
transcription factor ChIPs and 15μL of protein A/G beads for the histone ChIPs. These 
complexes were rotated at 4oC for 2 hours. Following incubation, the beads were 
captured using a magnetic rack and washed twice with IP wash buffer #1 (50mM Tris-
HCl pH 7.4, 150mM NaCl, 1% Igepal (v/v) 0.25% Deoxycholic acid and 1mM EDTA, 
pH8). The beads were resuspended in the wash buffer for each wash and the supernatant 
was removed between each wash. The beads were washed three times with IP wash 
buffer #2 (100mM Tris-Cl pH9, 500mM LiCl, 1% Igepal, and 1% Deoxycholic acid). 
The beads were transferred to a new tube on the third wash. The complexes were then 
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eluted off of the beads by the addition of 75μL of ChIP elution buffer while vortexing at 
room-temperature for 30 minutes. The supernatant was transferred to a new tube and the 
elution step was repeated. The ChIP input samples were thawed and 20μL of 5M NaCl 
was added to the 150μL of final eluted complexes and to the input samples. Crosslinks 
were reversed overnight at 65oC and the ChIPs were purified using the Purelink Quick 
PCR purification kit and the samples were eluted in 35μL of elution buffer. We 
performed qPCR against targets enriched for each of the ChIPs. The ChIPs were diluted 
1:5 and the input samples were diluted to 1ng μL-1. 2μL of DNA was used for each PCR 
and 1ng was used for the input sample. Primers against GAPDH were positive for CTCF 
and H3K4me3; STX16 for CTCF; GREB1 for H3K4me1 and H3K27ac; TFF1 for 
H3K4me1, H3K4me3 and H3K27ac; ZNF180 and ZNF333 for H3K9me3; HOXB2 for 
H3K27me3; and HES3 for H3K27me3. ZNF333 and ZNF180 were negative targets for 
CTCF, ER-α, H3K4me1, H3K4me3, H3K27ac, and H3K27me3. TFF1 and SHISA5 were 
used as negative targets for H3K9me3. 
ChIP-seq libraries were generated using the NEBNext ChIP-seq Library Prep 
Master Mix Set for Illumina (NEB#E6240L) as per manufacturer’s protocol with size 
selection for the insert size of 300bp. Half of adaptor-ligated DNA was saved at 4oC 
before PCR enrichment of adaptor ligated DNA. PCR enrichment was done using 10 
cycles and cleaned with AMPure XP beads at 0.9X as outlined in the protocol. The final 
library was eluted off of the beads using 30μL of 0.1X TE and the quality was analyzed 
with a bioanalyzer (Agilent Technologies). 
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Chromosome conformation capture coupled with qPCR (3C-qPCR) 
Experiments using 3C-qPCR experiment were conducted as Hagège et al. 
described60. Ten million cells (MCF7 or TamR) were harvested and then fixed with 1% 
formaldehyde for 10 min at room temperature followed by 0.2M glycine to quench the 
reaction. Cells were lysed with 0.2% Igepal CA630 for 1hr on ice, then the pelleted 
nuclei were solubilized with 0.3% sodium dodecyl sulfate (SDS) for 1hr at 37oC and 
diluted with 2% Triton X-100 for 1 h at 37oC. The genomic DNA was digested with 400 
U HindIII overnight at 37 oC and the digestion was stopped with 1.6% SDS for 20 min at 
65oC. The digested nuclei were diluted with 1:1 volume of ligation buffer and then 
ligated with 100U T4 DNA ligase. The ligated DNA was de-crosslinked with 300µg 
proteinase K overnight at 65oC and purified by phenol–chloroform extraction. The 3C 
template was dissolved in 10mM Tris-HCl and analyzed with the quantitative PCR. 
 
Parental and TamR RNA sequencing (RNA-seq) sample preparation and processing  
Total RNA were extracted using the ZYMO Research Quick-RNA MiniPrep kit. 
Ten million MCF7 or MCF7-TamR cells were lysed in RNA Lysis Buffer followed by 
removing the majority of gDNA with a Spin-Away Filter. The mixture of RNA and 
ethanol were then loaded onto Zymo-Spin IIICG Column. Trace DNA was removed by 
DNase I on the column followed by washing twice with RNA Wash Buffer. The total 
RNA was eluted with 50 μl DNase/RNase-Free Water. RNA-seq libraries were prepared 
with Illumina TruSeq stranded mRNA kit. 4µg of total RNA of either parental MCF7 or 
MCF7-TamR cells was incubated with RNA purification beads and then washed with 
bead washing buffer. The mRNA was eluted with elution buffer and then reverse 
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transcribed with Superscript III reverse transcriptase. The first strand cDNA was 
synthesized with first strand synthesis act D mix and the second strand cDNA was 
synthesized with second strand marking master mix. After cDNA was synthesized, a 
single adenylate was added to the 3’ end with A-tailing mix and adapters were ligated 
with ligation mix. DNA fragments were enriched with PCR master mix and then purified 
to build the DNA library. The library was sequenced with Illumina HiSeq 2000. The 
differentially expressed genes were identified with CuffDiff61. The 50bp single end 
sequencing reads were aligned with the Tophat module, and then transcripts were 
assembled with Cufflinks. The transcript assemblies were compared to annotation using 
the Cuffcompare and two or more transcript assemblies were merged with Cuffmerge. 
Lastly, the differentially expressed genes and transcripts were found with Cuffdiff. 
 
Identification of compartment patterns and types 
All TCC data were analyzed with HiCLib python package10 to identify chromatin 
compartment A or B. Paired-end reads of TCC data were iteratively aligned to the human 
reference genome (hg19) by bowtie262 with the minimal sequencing length of 20bp and 
the length step of 5bp in the module of HiCLib mapping. The following reads were 
removed from the dataset in the HiCLib HiCdataset object: beginning with the 5bp range 
from the restriction enzyme cut site; the duplicate molecules; the fragment pairs separated 
by less than 2 restriction sites within the same chromosome; extremely large restriction 
fragments (more than 10,000bp) and extremely small restriction fragments (smaller than 
100 bp); both ends of the pairs starting at exactly the same positions; the top 0.5% most 
frequently identified restriction fragments. At this stage the self-circles, dangling ends 
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and PCR duplicate reads were removed and a maximum molecule length of 500bp was 
specified at the initiation of the object. The correlation of two replicates was computed as 
the following: the counts of mapped reads pairs were accumulated at the 1Mb bin, and 
then the correlation of these counts for each chromosome were calculated separately. 
After filtering the reads, the frequency contact matrices were constructed at a bin size of 
100kb with the HiCLib fragmentHiC module. The contacts between loci located within 
the same bin were then removed from the raw heatmap. The bins with less than half of a 
bin sequenced and the 1% of regions with low coverage were also removed. The top 
0.05% of interchromosomal counts as the possible PCR blowouts were truncated 
followed by iterative correction to get the ICE heatmap using the HiCLib binnedData 
module. All bins of the ICE heatmap on a diagonal were removed with the HiCLib 
binnedData module. The bins with less than half of a bin sequenced were also removed. 
All cis contacts were set to zero to obtain only the trans contacts. The cis contacts were 
forged in an interative way. After removing the bins with zero counts the eigenvector 
expansion was performed with the HiCLib binnedData module to get the first 
eigenvectors of compartments. The continuous genomic regions of positive first 
eigenvectors were defined as compartment A (active chromatin), and the continuous 
genomic regions of negative first eigenvectors were defined as compartment B (inactive 
chromatin) individually at the 100kb scale. The compartments of five time points (T0, 
T1, T4, T16, T24) were compared to identify the dynamic patterns (Appendix D-1). 
First, two kinds of compartments: T0 vs. T1 Common and T0 vs. T1 Transit were 
identified by comparing compartments of T0/T1. The Common compartments are the 
overlapping compartments and the Transit compartments are differential compartments, 
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which will be used in the following steps as well. Next, T0 vs. T1 Common and T0 vs. 
T1 transit were compared with T4, T16, T24 independently to generate the (a) T0 vs. T1 
Common vs. T4/T16/T24 Common, (b) T0 vs. T1 Common vs T4/T16/T24 Transit, (c) 
T0 vs. T1 transit vs T4/T16/T24 Common, (d) T0 vs. T1 transit vs T4/T16/T24 Transit. 
Thirdly the pattern 1-15 were produced by comparing the various time points (T4, T16 
and T24) of last step subsets a, b, c, and d, which are vs. T4, vs. T16, vs. T24. The rest 
subsets were divided into pattern 16-24 according to the numbers of converted bins. 
Finally, 24 patterns were identified from the intersection and difference among subsets a, 
b, c, and d. According to their biological meanings, these patterns were able to categorize 
into six types of dynamic changed compartments (DCCs): HCC (patterns 1-4), ETC 
(patterns 5-8), LTC (patterns 9-12), LDC (patterns 13-16), MDC (patterns 17-20), HDC 
(patterns 21-24). 
 
Computation of differential compartments 
The variance of first eigenvector values of compartments identified in T0, T1, T4, 
T16, T24 was computed at the 100kb scale. The difference of HCC/ETC/LTC/LDC with 
MDC/HDC was determined by two-sided Wilcoxon rank-sum test for their averaged 
variance of first eigenvector values. The estimate of False Discover Rate (FDR) of the 
differential compartment between any two compartments was conducted by a 
permutation-based test. In brief, the difference in Means of Eigenvector Values of each of 
two compartments: Compartment 1 and Compartment 2, was first calculated as the 
Observed Value. The Eigenvector Values of two compartments were then pooled 
together and randomly selected one half as randomized Compartment 1 and the other half 
 140 
as randomized Compartment 2. This was done for a total of 1,000 rounds of permutation. 
In each round, the difference in means of Eigenvector Values of each of two randomized 
compartments was calculated as a Permutated Value. All permutated values were 
combined into a null distribution. The FDR is estimated based on how many permutated 
values are above the observed value and the permutated null. 
 
Epigenetic states 
ChIP-seq of H3K4me3, H3K27ac, H3K4me1, H3K27me3, and H3K9me3 data 
sets from five time points of E2-induced MCF7 cells and TamR cells were aligned to the 
human reference genome hg19. We then utilized the Java program ChromHMM v1.1745 
to characterize chromatin epigenetic states by integrating the histone modification ChIP-
seq datasets to identify de novo major re-occuring combinatorial and spatial patterns 
based on a multivariate Hidden Markov Model. The results of the model were then used 
to systematically annotate genome-wide maps of chromatin states. After the ChIP-seq 
data were mapped to the human genome, the BinarizeBam module was used to binarize 
uniquely mapped reads into 1kb bins for model learning. The binarized data were then 
trained with LearnModel and ten epigenetic states were finally identified with a minimum 
p-value after averaging five training rounds. The emission and transition matrices were 
visualized using R. The ten ChromHMM states were classified into three kinds of 
epigenetic states according to the combination of histone marks with the p-value cutoff of 
0.3 for emission matrices. The active states were defined by H3K4me3, H3K27ac and 
H3K4me1, repressive states defined by H3K27me3, H3K9me3 and bivalent states 
including both active and repressive states. 
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Identification of ERα and CTCF binding sites 
ChIP-seq data for ERα and CTCF were aligned to the human reference genome, 
hg19. We then determined binding sites by peaks calling with MACS v1.4.246. The 
identified peaks were coordinated to the various compartments and boundary regions to 
obtain the coincident sites. The peak summits generated by MACS were defined as 
binding sites for the subsequent analyses. 
 
Differential binding analysis of ERα 
We identified ERα differential peaks (DPs) with the R Bioconductor package 
DiffBind v2.6.663,64 using TamR vs. T0/T1/T4/T16/T24 as the contrast. Within the 
anlaysis, peaks were first enriched for genomic loci from ChIP-seq data and then read by 
DiffBind. Next, overlaps of peaks were examined to determine how well similar samples 
cluster together with the function dba.count. Then, overlapped reads in each interval for 
each unique sample were counted with the function dba.contrast. Lastly, a contrast was 
established and then the core analysis of DiffBind was executed by default using 
DESeq265 with the function dba.analyze. Finally, the results were reported and plotted 
with the function dba.report. 
 
Time-series RNA-seq data analysis 
Time-series RNA-seq data of E2-treated MCF7 cells47 were acquired from 
GSE62789. Five time points close to this study (T0 = 0 min, T1 = 40 min, T4 = 160 min, 
T16 = 640 min, T24 = 1280 min) were selected and mapped to the human genome using 
Tophat and gene expression was analyzed with Cuffdiff61. After gene expression values 
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were normalized with log2 transformation, the variances were calculated between the five 
time points. The normalized gene expression values of genes located at each 
compartment types in five time points were visualized with the R program. 
 
Significant Interaction Loops 
The uniquely mapped paired-end reads were inputted into HOMER v4.749 to 
generate the significant interaction loops. In brief, HOMER was originally developed for 
a de novo motif discovery program and is now able to identify significant loops. The 
HOMER analyzeHiC module was used to make interaction matrices, normalize 
interaction counts and identify the significant interaction loops. The loops were further 
filtered with a LogP cutoff of -6 and distance cutoff 20kb between loci centers. 
Tamoxifen resistant differential loops of MCF7-TamR were obtained via the analyeHiC 
module of HOMER using MCF7 T0 as the contrast with the cutoff of FDR<=0.1 and the 
distance of loci pair center at 40kb to 5Mb. 
 
Enrichment of KEGG pathway 
Differentially expressed genes in various compartments were analyzed using 
Gene Set Enrichment Analysis (GSEA) v3.048. Kyoto Encyclopedia of Genes and 
Genomes (KEGG) were selected as the geneset database. Gene ranking was determined 






Raw and processed TCC, ChIP-seq and RNA-seq data for MCF7 and TamR cells 
is deposited in GEO under the accession number GSE108787, and raw and processed 
TCC data for T47D and TamR cells is deposited in GEO under accession number 
GSE119890. The RNA-seq data of E2-treatment time series MCF7 is available at GEO 


















Figure 4.1: Identification of E2-induced compartments in MCF7 cells at T1 versus T0.  
(A) Pearson correlation of two biological replicates with the bin size of 1Mb, 500kb and 
200kb on individual chromosomes at T0 (Top) and T1 (Bottom). (B) Contact matrices of 
compartment A (Black) and B (Red) at T0 (Top) and T1 (Bottom) respectively. (C,D) 
Histograms of compartments with different sizes at T0 and T1 respectively. (E) 
Distribution of compartments A and B in T0 and T1 respectively. (F) The percentage of 
common and transit compartments at T1 vs T0 with various bin sizes. (G) The number of 






















Figure 4.2: Defining E2-induced temporal dynamic re-compartmentalization (TDRC) in 
MCF7 cells. (A) An instructive tree displaying the comparisons of compartments A (Top) 
and B (Bottom) at E2-induced five time-points. T0: control, T1: 1 hour; T4: 4 hours; T16: 
16 hours; and T24: 24 hours. (B) Number of compartments at each of the 24 individual 
patterns categorized into six types of altered compartments: HCC including patterns 1-4; 
ETC including patterns 5-8; LTC including patterns 9-12; LDC including patterns 13-16; 
MDC including patterns 17-20; HDC including patterns 21-24. (C) The variance of first 
eigenvectors of compartment types in T0, T1, T4, T16, T24. The p value was determined 
by the Wilcoxon rank-sum test. (D,E) Snapshots displaying examples of compartment 
changes, MDC (D) and HDC (E) along five time-points of E2-induction. The 
compartment of interest is indicated between the green dashed lines. The blue dashed 






















Figure 4.3: Identification of altered compartments in TamR cells. (A) The number of 
tamoxifen resistant compartments along chromosomes in MCF7 TamR cells. (B) The 
percentage of tamoxifen resistant altered compartments (TRACs), A (Top panel) and B 
(Bottom panel) in TamR cells. The x axis displays the identified compartments after 
comparison with the 24 states identified in responsive cells. (C) Genomic size of six 
types of TRACs and tamoxifen resistant unaltered compartments (TRUCs). (D-F) UCSC 
genome browser snapshots of TRACs and the enclosed genes within their loci. Dark: 
Compartment A; Gray: Compartment B. (D) contracted compartment. Blue lines 






















Figure 4.4: Epigenetic modifications on E2-induced TDRCs and TRACs. (A) Emission 
probabilities of ten epigenetic states trained by a HMM model on five histones. The 
enrichment of the corresponding mark is indicated by higher values and corresponds with 
a darker pink color. (B) Transition probabilities of ten epigenetic states trained by a HMM 
model on five histones. The enrichment of the corresponding mark is indicated by higher 
values and with a darker pink color. (C) The summary of the corresponding histone marks 
and each of the defined epigenetic states. (D) The percentage of epigenetic states on 
dynamic E2-induced compartment A. (E) The percentage of epigenetic states on altered 
TamR compartment A. (F) The percentage of epigenetic states on dynamic E2-induced 












































Figure 4.5: A distribution of ERα and CTCF peaks in E2-induced TDRCs and TRACs.  
(A) The number of ERα (Left) and CTCF (Right) peaks within altered and unaltered TamR 
compartments. (B) Heatmap showing the percentage of altered TamR compartments A 
(Left) and B (Right) with ERα peaks. (C) The average number of CTCF peaks on altered 
TamR compartment boundary in E2-induced five time-points and TamR MCF7 cell lines. 
(D) The distribution of each of the 24 patterns (circled) of ERα peaks within compartments 























Figure 4.6. Gene expression and looping in E2-induced TDRCs and TRACs. (A) The 
number of dynamic DEGs located in each of six types of TDRCs-A. (B) A plot of gene 
expression values along five time-points in each of the six types of TDRCs-A. Each 
green line represents one gene, and blue line represents the average gene expression 
value. (C) The enrichment of KEGG pathways of 1,396 genes in MDC/HDCs-A. (D) The 
heatmap of DEGs of TamR versus MCF7 in each of six types of TRACs-A. (E) The 
number of loops defined by HOMER.  Putative: putative loops identified by HOMER. 
Promoter: one locus of putative loops within -5kb/+1kb of TSS. Enhancer: one locus of 
putative loops within -5kb/+1kb of TSS and the other with either H3K27ac/H3K4me1 
peaks. ERα: at least one locus of loops with an ERα peak located within a promoter-
enhancer region. Gene: genes associated with ERα-PE loops showing differentially 
expressed genes at TA-MDCs-A and TA-HDCs-A. (F) The enrichment of KEGG 
































Figure 4.7. A proposed model for dynamic 3D chromatin architecture. (A-C). 
Constitutive estrogen stimulation in breast cancer cells enhances stronger ERα activity 
and further recruits its distal regulatory machinery and then mobilizes highly dynamic 
gene looping which essentially expand to render a 3D genome re-compartmentalization 
meanwhile force CTCF eviction resulting in reduced insulation activity at the 
compartment boundary. (D). In acquired resistant breast cancer cells, increased crosstalk 
between ERα and other signal transduction pathways such as EGFR/HER2, IGF-IR, and 
AKT/PTEN or altered expression of some key co-regulators particularly reshuffle these 
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Chapter 5.1: Summary 
Chromatin based-mechanisms involved in the establishment and maintenance of 
cellular phenotypes are mediated by higher-order chromatin organization and post 
translational histone modifications. These regulatory processes coordinate the recruitment 
of protein complexes to specific genomic targets that result in gene expression 
alterations. This dissertation seeks to employ integrative high-throughput methodologies 
to investigate dynamic epigenetic changes in cancer cell models. Presented here are new 
contributions to the field of cancer genomics where I investigate the effects of external 
stimuli on higher-order chromatin structure, post translational histone modifications and 
gene expression. In Chapters 2 and 3 I reveal dynamic epigenetic mechanisms in 
pancreatic cancer cell models in response to epigenetic inhibitors. In Chapter 4, I present 
my work in ER positive breast cancer cells where plasticity was observed during 
temporal estrogen stimulation in cell models sensitive or resistant to tamoxifen. Taken 
together, this dissertation reveals novel insight into dynamic epigenomic alterations that 
occur with external stimuli and provides insight into mechanisms underlying the 
therapeutic responses in cancer cells. 
 
Chapter 5.2: Implications of epigenetic plasticity in pancreatic cancer cell models   
 
5.2.1: Overall outlook and contributions to the field  
 The work presented in Chapters 2 and 3 ultimately present an analysis framework 
for investigating genome-wide histone modification landscapes in relation to 3D-
chromatin topology. Additionally, I provide characterization of broad epigenetic domains 
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corresponding to histological grade and give insight into genome-wide domain targets of 
epigenetic inhibitors.  Lastly, this work provides datasets in pancreatic cancer cell-lines 
that are now available for public use for studies desiring to investigate: (1) chromatin 
contacts and (2) epigenomic (histone modifications and 3D chromatin architecture) and 
transcriptomic alterations in response to ICG001 and C646. In section 5.2.4, I propose 
future directions that can build on the studies presented here.  
 
5.2.2: Defining chromatin contacts and chromatin states in PDAC cells  
The goal underlying the first part of this dissertation seeks to characterize 
genome-wide patterns of chromatin structure in pancreatic cancer cell-lines and to 
investigate the effects of two epigenomic inhibitors on these regions (Appendix A, 
Chapters 2 and 3). This work provides an important basis for future studies regarding 
epigenomic regulation and the effects of epigenomic inhibitors on the cancer genome.  
In Chapter 2 of this dissertation, I present the genome-wide interactions within a 
widely used pancreatic cancer cell-line and functionally characterize these regions by: (1) 
defining genome-wide chromatin contacts; (2) classifying the surrounding domains in 
relation to histone modifications; (3) determining how histone acetyltransferase inhibitors 
impact chromosomal organization; and (4) investigating these interactions in regard to 
chromatin regulation mediated by transcription factor binding. This chapter demonstrates 
a computational analytical approach to investigating higher-order chromatin regulation 
data relating to histone modifications and gene expression to classify chromatin looping 
events. For the first time in the literature, we present a genome-wide view of chromatin 
domains in the extensively studied pancreatic cancer cell-line, PANC1.  After classifying 
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these domains with epigenetic histone modifications, annotating these defined states to 
gene regions and correlating PANC1 gene expression with these classified domains, we 
found that domains coordinating with active epigenetic states contained increased gene 
expression patterns. Repressed epigenetic states corresponded with decreased expression, 
providing confidence in our domain classification pipeline as these epigenetic states are 
correlative of gene expression [1]. Modifications such as H3K4me1 are known to play a 
role in gene repression [2] but when co-marked with H3K27ac this signature typically 
corresponds to active enhancers [3]. While there are general trends between histone 
modifications and chromatin state, it is imperative to further investigate chromatin 
machinery within these mechanisms to gain further insight about underlying regulation.  
In the next part of Chapter 2, I investigated changes in interaction domain loci in 
response to two epigenetic inhibitors and associate these altered regions with gene 
expression. In our initial study (Appendix A), we investigated the effect of two histone 
acetyltransferase (HAT) inhibitors on the pancreatic cancer transcriptome and found 
shared and independent targets of ICG-001 and C646. Recent reports have identified 
C646 to help sensitize pancreatic cancer cell-lines to the canonical therapeutic agent used 
to treat pancreatic cancer [4] and has shown efficacy in other cancers [5, 6]. Additionally, 
the efficacy of ICG-001 has shown similar effect [7, 8] and has furthermore been 
promoted its advancement to clinical trials (NCT01764477; NCT01606579; 
NCT01302405). With the potential in reverting the cancer phenotype, little is known 
about the impact of these inhibitors genome-wide. Our study highlighted in Appendix A 
was the first study to characterize the effects of these inhibitors on the cancer 
transcriptome. Chapter 2 builds on this study by investigating potential chromatin-based 
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mechanisms that may be influencing the transcriptional targets of these inhibitors. While 
changes in 3D chromatin topology has been observed in response to temperature stress 
[9], the impact of epigenetic inhibitors on genome-wide contacts was not known. Our 
characterization identified shifts in domains that were correlated with transcription factor-
mediated regulation using TCF7L2. Ultimately, I suggest a potential mechanism by 
which transcription factor associated chromosome interactions containing an active 
epigenetic signature surrounding these regions are altered by epigenomic inhibition.  
 
5.2.3: HAT inhibitors on broad epigenomic domains in PDAC cells 
 In Chapter 3, I further investigate the active histone modification landscape by 
defining typical and broad H3K4me3 and H3K27ac domains in pancreatic cancer cell 
models corresponding to histological grade. I then determine the impact of histone 
acetyltransferase inhibitors on these histone modification domains in the high-grade 
PDAC cell-line, PANC1, the model in which we explore their impact on the 
transcriptome (Appendix A) and chromatin architecture (Chapter 2). Broad epigenomic 
domains have recently been linked to cancer-related genes programs [10, 11]. Our 
comprehensive analysis of super-enhancers and broad H3K4me3 domains in high- and 
low-grade pancreatic ductal adenocarcinoma cell-lines revealed, for the first time, that 
both of genome wide landscapes of these broad epigenomic domains have the ability to 
correspond to distinct high and low histological grades. When correlating annotated 
genes within the broad domains with gene expression in the given cell-lines, we find that 
gene expression correlates with predicted patient prognosis. We observed global 
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acetylation and methylation changes after histone acetyltransferase inhibitor treatment 
and furthermore, alteration in broad domains.  
 
5.2.4: Future Directions  
Cell-lines are important tools for investigating multiple facets of cellular 
mechanisms. However; performing these analyses in low-grade and additional high-grade 
samples would provide additional insight into the aggressive phenotype of PDAC and 
could also allow us to investigate potential mechanisms underlying the different cellular 
phenotype of the individual cell-lines. Recent reports have characterized the PDAC 
transcriptome, genome and epigenome in primary and metastatic PDAC samples as well 
as patient derived xenografts of PDAC of the classical and basal subtypes [12, 13]. 
Integrating the domain characterizations and gene targets from our studies could narrow 
down specific targets and candidates for further investigations. We examine the role of 
TCF7L2 and for the first time, correlate this transcription factor with chromatin 
architecture. However, its direct involvement in the aggressive phenotype in PDAC is not 
well understood. TCF7L2 is a downstream transcription factor of this pathway, there are 
other TCF/LEF family members that could be of importance. Furthermore, future studies 
could incorporate additional transcription factor regulation to determine other regulatory 
mechanisms and moreover the biology of PDAC. These could functionally be tested 
through perturbation experiments of the given transcription factor or chromatin regulator 
and the described experiments could be repeated and integrated with the current datasets 
to infer direct regulatory roles. Future studies modulating target regions within specific 
chromatin states would provide further insight into the functional significance of our 
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associations. For example, the advancements in CRISPR/Cas9 technologies provides 
tools for which we can edit the genome in order to explore molecular consequences. A 
future study could utilize this technology to create a double strand break at a super-
enhancer or broad H3K4me3 region containing a gene potentially contributing to the 
PDAC phenotype using a high- and low-grade cell model to determine the role these 
epigenetic regions are playing on gene expression of the gene of interest. Additionally, 
chromatin architecture data could be used to determine how the absence of this region 
alters chromatin interactions nearby and further phenotypic studies could be carried out to 
determine if targeting the broad region of interest provides clinical potential in reverting 
the cancer phenotype. Ultimately, exploring the relevance would be best determined by 
using human PDAC samples to interrogate these processes. In the realm of the genome-
wide effects of epigenetic inhibitors on chromatin regulation, additional cell models 
should be used to gain insight into more generalized and cell-type specific effects of these 
inhibitors genome-wide.  
 
Chapter 5.3: Implications of chromatin dynamics in breast cancer cell models 
5.3.1: Overall outlook and contributions to the field 
 The work presented in Chapter 4 of this dissertation provides a report of the 
dynamics of 3D chromatin structure across a time course of estradiol (E2) stimulation in 
human estrogen receptor α (ERα) positive breast cancer cells in tamoxifen sensitive and 
resistant cells. In addition to these new revelations regarding chromatin compartment 
regulated through temporal estradiol stimulation, we proved new high-throughput 
datasets available to the general public for further investigations. These datasets include: 
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(1) genome-wide 3D architecture, (2) ChIP-sequencing and (3) RNA-sequencing 
throughout temporal estradiol stimulation in tamoxifen sensitive and resistant cells.  
 
5.3.2: Dynamics during temporal estradiol stimulation  
 In Chapter 4, we present our study in estrogen receptor positive (ER+) breast 
cancer, where we investigate the dynamics of 3D chromatin reorganization. Our 
integrative genomic analyses using ER-α positive breast cell models provided new insight 
into epigenomic regulation of ER+ breast cancer mediated by ER-α. Also, we investigate 
epigenetic alterations in tamoxifen resistant derivatives. We observed genome-wide 
changes in chromatin compartments (open or closed) in breast cancer cells hormone 
starved followed by temporal stimulation of estradiol, an estrogen derivative. Moreover, 
we characterized the changes over five estradiol induction periods with respect to histone 
modifications and gene expression. Our results revealed coordinated changes in 
chromatin compartments in tamoxifen resistant cells, where frequently changed 
compartments were associated with increased ER-α activity. We identify ERα-bound 
promoter-enhancer loops within altered compartments that are linked to TamR 
differential gene expression. Ultimately, this large 3D-scale chromatin data provides a 
rich resource for studying the basic characteristics of hormone-dependent breast cancers 
and provides further insight into the mechanisms of tamoxifen resistance.  
 
5.3.3: Future Directions  
When identifying genome-wide compartmentalization changes, we used two 
different ER+ breast cancer cell-lines, MCF7 and T47D. Our goal in this Chapter was to 
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characterize these compartments and associate epigenetics and gene expression programs 
with these compartments using the MCF7 cell line; however, since these two breast 
cancer cell-lines are of the same classification and contain the same estrogen, 
progesterone and Her2 expression [14] we utilized T47D to confirm that the 
identification of estradiol-induced compartments were consistent between both cell-lines. 
Future studies using more cell-lines with diverse subtypes will provide additional insight 
into the biology of re-compartmentalization in breast cancer models. Additionally, 
carrying these investigations further into human primary samples with matched clinical 
controls will provide more clinical perspective into these dynamic mechanisms in 
tamoxifen resistance. Future studies incorporating high-throughput proteomics data for 
ER-α with our datasets can isolate specific candidates for additional functional studies 
regarding ER-α mediated chromatin regulation. Additionally, disrupting an ER-α region 
within the highly dynamic compartments will allow us to identify the potential 
implications of ER-α within these regulatory regions that are highly altered in response to 
estradiol and also largely changed in response to tamoxifen.  
 
Chapter 5.4: Concluding remarks 
 Chromatin-based mechanisms including higher-order chromatin organization and 
histone modifications have been identified to alter chromatin accessibility and directly 
influence transcriptional programs and furthermore biological outcomes. This dissertation 
seeks to characterize these domains in cell models for pancreatic and breast cancer and to 
ultimately investigate epigenetic plasticity in response to different conditions. We 
observed dynamic changes in chromatin structure in pancreatic cancer in response to 
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epigenetic inhibitors and in breast cancer in response to estrogen stimulation. Future 
work exploring the molecular consequences of these genome-wide alterations are needed 
and furthermore, studies in primary patient samples will provide direct insight into 
clinical importance and can help narrow down directed targets for phenotypic studies. 
Additionally, 3D-FISH experiments can be designed in these models to confirm our 3D-
chromatin findings. This dissertation ultimately provides insight into dynamic epigenetic 
processes. Importantly, this work contributes large genomic datasets that are publically 
available for the scientific community, which provides opportunities for new research 
projects. These datasets can be combined with other publically available data to 
investigate SNPS, other epigenomic modifications and additional DNA binding factors to 















1. Nebbioso, A., et al., Cancer epigenetics: Moving forward. PLoS Genet, 2018. 
14(6): p. e1007362. 
2. Cheng, J., et al., A role for H3K4 monomethylation in gene repression and 
partitioning of chromatin readers. Mol Cell, 2014. 53(6): p. 979-92. 
3. Andersson, R., et al., An atlas of active enhancers across human cell types and 
tissues. Nature, 2014. 507(7493): p. 455-461. 
4. Ono, H., M.D. Basson, and H. Ito, P300 inhibition enhances gemcitabine-induced 
apoptosis of pancreatic cancer. Oncotarget, 2016. 7(32): p. 51301-51310. 
5. Oike, T., et al., C646, a selective small molecule inhibitor of histone 
acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic 
catastrophe. Radiother Oncol, 2014. 111(2): p. 222-7. 
6. Gao, X.N., et al., A histone acetyltransferase p300 inhibitor C646 induces cell 
cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS 
One, 2013. 8(2): p. e55481. 
7. Liu, Y., et al., ICG-001 suppresses growth of gastric cancer cells and reduces 
chemoresistance of cancer stem cell-like population. J Exp Clin Cancer Res, 
2017. 36(1): p. 125. 
8. Zhang, X., et al., Wnt blockers inhibit the proliferation of lung cancer stem cells. 
Drug Des Devel Ther, 2015. 9: p. 2399-407. 
9. Li, L., et al., Widespread rearrangement of 3D chromatin organization underlies 
polycomb-mediated stress-induced silencing. Mol Cell, 2015. 58(2): p. 216-31. 
 184 
10. Hnisz, D., et al., Super-enhancers in the control of cell identity and disease. Cell, 
2013. 155(4): p. 934-47. 
11. Chen, K., et al., Broad H3K4me3 is associated with increased transcription 
elongation and enhancer activity at tumor-suppressor genes. Nat Genet, 2015. 
47(10): p. 1149-57. 
12. Connor, A.A., et al., Integration of Genomic and Transcriptional Features in 
Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. 
Cancer Cell, 2019. 35(2): p. 267-282 e7. 
13. Lomberk, G., et al., Distinct epigenetic landscapes underlie the pathobiology of 
pancreatic cancer subtypes. Nat Commun, 2018. 9(1): p. 1978. 
14. Neve, R.M., et al., A collection of breast cancer cell lines for the study of 





































1. Boyd J (2018). seqsetvis: Set Based Visualizations for Next-Gen Sequencing 
Data. R package version 1.2.0. 
2. Stark R and Brown G (2011). DiffBind: differential binding analysis of ChIP-seq 
peak datasets. 
3. Abulwerdi F, Liao C, Liu M, Azmi AS, Aboukameel A, Mady AS, Gulappa T, 
Cierpicki T, Owens S, Zhang T, Sun D, Stuckey JA, Mohammad RM, 
Nikolovska-Coleska Z. A novel small-molecule inhibitor of mcl-1 blocks 
pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2014;13(3):565-
75. doi: 10.1158/1535-7163.MCT-12-0767. PubMed PMID: 24019208; PMCID: 
PMC4174574. 
4. Adam RC, Yang H, Rockowitz S, Larsen SB, Nikolova M, Oristian DS, Polak L, 
Kadaja M, Asare A, Zheng D, Fuchs E. Pioneer factors govern super-enhancer 
dynamics in stem cell plasticity and lineage choice. Nature. 2015;521(7552):366-
70. doi: 10.1038/nature14289. PubMed PMID: 25799994; PMCID: 
PMC4482136. 
5. Aguilar-Setien A, Loza-Rubio E, Salas-Rojas M, Brisseau N, Cliquet F, Pastoret 
PP, Rojas-Dotor S, Tesoro E, Kretschmer R. Salivary excretion of rabies virus by 
healthy vampire bats. Epidemiol Infect. 2005;133(3):517-22. PubMed PMID: 
15966107; PMCID: 2870282. 
6. Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, Martinez-Torteya A, 
Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Pena JG, Trevino V. 
SurvExpress: an online biomarker validation tool and database for cancer gene 
expression data using survival analysis. PLoS One. 2013;8(9):e74250. doi: 
10.1371/journal.pone.0074250. PubMed PMID: 24066126; PMCID: 
PMC3774754. 
7. Akdemir KC, Chin L. HiCPlotter integrates genomic data with interaction 
matrices. Genome Biol. 2015;16:198. doi: 10.1186/s13059-015-0767-1. PubMed 
PMID: 26392354; PMCID: PMC4576377. 
8. al. KTKe. Histone Acetylation And Methylation. Chromatin and Disease 
Subcellular Biochemistry. 2007;41. 
9. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and Methylation of Histones 
and Their Possible Role in the Regulation of Rna Synthesis. Proc Natl Acad Sci U 
S A. 1964;51:786-94. PubMed PMID: 14172992; PMCID: PMC300163. 
10. Allison DB, Cui X, Page GP, Sabripour M. Microarray data analysis: from 
disarray to consolidation and consensus. Nat Rev Genet. 2006;7(1):55-65. doi: 
10.1038/nrg1749. PubMed PMID: 16369572. 
11. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-
throughput sequencing data. Bioinformatics. 2015;31(2):166-9. doi: 
10.1093/bioinformatics/btu638. PubMed PMID: 25260700; PMCID: 
PMC4287950. 
12. Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, Chen 
Y, Zhao X, Schmidl C, Suzuki T, Ntini E, Arner E, Valen E, Li K, 
Schwarzfischer L, Glatz D, Raithel J, Lilje B, Rapin N, Bagger FO, Jorgensen M, 
Andersen PR, Bertin N, Rackham O, Burroughs AM, Baillie JK, Ishizu Y, 
Shimizu Y, Furuhata E, Maeda S, Negishi Y, Mungall CJ, Meehan TF, Lassmann 
 187 
T, Itoh M, Kawaji H, Kondo N, Kawai J, Lennartsson A, Daub CO, Heutink P, 
Hume DA, Jensen TH, Suzuki H, Hayashizaki Y, Muller F, Forrest ARR, 
Carninci P, Rehli M, Sandelin A. An atlas of active enhancers across human cell 
types and tissues. Nature. 2014;507(7493):455-61. doi: 10.1038/nature12787. 
PubMed PMID: 24670763; PMCID: PMC5215096. 
13. Andoniou CE, Andrews DM, Degli-Esposti MA. Natural killer cells in viral 
infection: more than just killers. Immunol Rev. 2006;214:239-50. doi: 
10.1111/j.1600-065X.2006.00465.x. PubMed PMID: 17100889. 
14. Aparicio O, Geisberg JV, Struhl K. Chromatin immunoprecipitation for 
determining the association of proteins with specific genomic sequences in vivo. 
Curr Protoc Cell Biol. 2004;Chapter 17:Unit 17 7. doi: 
10.1002/0471143030.cb1707s23. PubMed PMID: 18228445. 
15. Arensman MD, Telesca D, Lay AR, Kershaw KM, Wu N, Donahue TR, Dawson 
DW. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer 
growth. Mol Cancer Ther. 2014;13(10):2303-14. doi: 10.1158/1535-7163.MCT-
13-1005. PubMed PMID: 25082960; PMCID: PMC4188417. 
16. Arents G, Burlingame RW, Wang BC, Love WE, Moudrianakis EN. The 
nucleosomal core histone octamer at 3.1 A resolution: a tripartite protein 
assembly and a left-handed superhelix. Proc Natl Acad Sci U S A. 
1991;88(22):10148-52. PubMed PMID: 1946434; PMCID: PMC52885. 
17. Atkinson SR, Marguerat S, Bahler J. Exploring long non-coding RNAs through 
sequencing. Semin Cell Dev Biol. 2012;23(2):200-5. doi: 
10.1016/j.semcdb.2011.12.003. PubMed PMID: 22202731. 
18. Au WC, Yeow WS, Pitha PM. Analysis of functional domains of interferon 
regulatory factor 7 and its association with IRF-3. Virology. 2001;280(2):273-82. 
doi: 10.1006/viro.2000.0782. PubMed PMID: 11162841. 
19. Audia JE, Campbell RM. Histone Modifications and Cancer. Cold Spring Harb 
Perspect Biol. 2016;8(4):a019521. doi: 10.1101/cshperspect.a019521. PubMed 
PMID: 27037415; PMCID: PMC4817802. 
20. Ay F, Bailey TL, Noble WS. Statistical confidence estimation for Hi-C data 
reveals regulatory chromatin contacts. Genome Res. 2014;24(6):999-1011. doi: 
10.1101/gr.160374.113. PubMed PMID: 24501021; PMCID: PMC4032863. 
21. Ay F, Noble WS. Analysis methods for studying the 3D architecture of the 
genome. Genome Biol. 2015;16:183. doi: 10.1186/s13059-015-0745-7. PubMed 
PMID: 26328929; PMCID: PMC4556012. 
22. Ballestar E, Wolffe AP. Methyl-CpG-binding proteins. Targeting specific gene 
repression. Eur J Biochem. 2001;268(1):1-6. PubMed PMID: 11121095. 
23. Bannister AJ, Miska EA, Gorlich D, Kouzarides T. Acetylation of importin-alpha 
nuclear import factors by CBP/p300. Curr Biol. 2000;10(8):467-70. PubMed 
PMID: 10801418. 
24. Bannister AJ, Schneider R, Kouzarides T. Histone methylation: dynamic or 
static? Cell. 2002;109(7):801-6. PubMed PMID: 12110177. 
25. Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and 
risk of intrinsic tumor subtypes. Biochim Biophys Acta. 2015;1856(1):73-85. doi: 
10.1016/j.bbcan.2015.06.002. PubMed PMID: 26071880. 
 188 
26. Barutcu AR, Lajoie BR, Fritz AJ, McCord RP, Nickerson JA, van Wijnen AJ, 
Lian JB, Stein JL, Dekker J, Stein GS, Imbalzano AN. SMARCA4 regulates gene 
expression and higher-order chromatin structure in proliferating mammary 
epithelial cells. Genome Res. 2016;26(9):1188-201. doi: 10.1101/gr.201624.115. 
PubMed PMID: 27435934; PMCID: PMC5052043. 
27. Bau D, Sanyal A, Lajoie BR, Capriotti E, Byron M, Lawrence JB, Dekker J, 
Marti-Renom MA. The three-dimensional folding of the alpha-globin gene 
domain reveals formation of chromatin globules. Nat Struct Mol Biol. 
2011;18(1):107-14. doi: 10.1038/nsmb.1936. PubMed PMID: 21131981; PMCID: 
PMC3056208. 
28. Benayoun BA, Pollina EA, Ucar D, Mahmoudi S, Karra K, Wong ED, Devarajan 
K, Daugherty AC, Kundaje AB, Mancini E, Hitz BC, Gupta R, Rando TA, Baker 
JC, Snyder MP, Cherry JM, Brunet A. H3K4me3 breadth is linked to cell identity 
and transcriptional consistency. Cell. 2014;158(3):673-88. doi: 
10.1016/j.cell.2014.06.027. PubMed PMID: 25083876; PMCID: PMC4137894. 
29. Bird AP, Wolffe AP. Methylation-induced repression--belts, braces, and 
chromatin. Cell. 1999;99(5):451-4. PubMed PMID: 10589672. 
30. Blahnik KR, Dou L, O'Geen H, McPhillips T, Xu X, Cao AR, Iyengar S, Nicolet 
CM, Ludascher B, Korf I, Farnham PJ. Sole-Search: an integrated analysis 
program for peak detection and functional annotation using ChIP-seq data. 
Nucleic Acids Res. 2010;38(3):e13. doi: 10.1093/nar/gkp1012. PubMed PMID: 
19906703; PMCID: PMC2817454. 
31. Blehert DS, Hicks AC, Behr M, Meteyer CU, Berlowski-Zier BM, Buckles EL, 
Coleman JT, Darling SR, Gargas A, Niver R, Okoniewski JC, Rudd RJ, Stone 
WB. Bat white-nose syndrome: an emerging fungal pathogen? Science. 
2009;323(5911):227. Epub 2008/11/01. doi: 1163874 [pii] 
10.1126/science.1163874. PubMed PMID: 18974316. 
32. Bonev B, Cavalli G. Organization and function of the 3D genome. Nat Rev 
Genet. 2016;17(11):661-78. doi: 10.1038/nrg.2016.112. PubMed PMID: 
27739532. 
33. Bonneville R, Jin VX. A hidden Markov model to identify combinatorial 
epigenetic regulation patterns for estrogen receptor alpha target genes. 
Bioinformatics. 2013;29(1):22-8. doi: 10.1093/bioinformatics/bts639. PubMed 
PMID: 23104890. 
34. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human 
microRNAs. Nat Struct Mol Biol. 2006;13(12):1097-101. doi: 
10.1038/nsmb1167. PubMed PMID: 17099701. 
35. Bowen MD, Peters CJ, Nichol ST. The phylogeny of New World (Tacaribe 
complex) arenaviruses. Virology. 1996;219(1):285-90. PubMed PMID: 8623541. 
36. Bowen MD, Peters CJ, Nichol ST. Phylogenetic analysis of the Arenaviridae: 
patterns of virus evolution and evidence for cospeciation between arenaviruses 
and their rodent hosts. Mol Phylogenet Evol. 1997;8(3):301-16. doi: 
10.1006/mpev.1997.0436. PubMed PMID: 9417890. 
37. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA, Crump NT, 
Hazzalin CA, Liszczak G, Yuan H, Larocca C, Saldanha SA, Abagyan R, Sun Y, 
 189 
Meyers DJ, Marmorstein R, Mahadevan LC, Alani RM, Cole PA. Virtual ligand 
screening of the p300/CBP histone acetyltransferase: identification of a selective 
small molecule inhibitor. Chem Biol. 2010;17(5):471-82. doi: 
10.1016/j.chembiol.2010.03.006. PubMed PMID: 20534345; PMCID: 
PMC2884008. 
38. Brand JM, Frohn C, Cziupka K, Brockmann C, Kirchner H, Luhm J. Prolactin 
triggers pro-inflammatory immune responses in peripheral immune cells. Eur 
Cytokine Netw. 2004;15(2):99-104. PubMed PMID: 15319167. 
39. Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, Chiang H, 
Sodre AL, Olson P, Weber JS, Christensen JG. The class I/IV HDAC inhibitor 
mocetinostat increases tumor antigen presentation, decreases immune suppressive 
cell types and augments checkpoint inhibitor therapy. Cancer Immunol 
Immunother. 2018;67(3):381-92. doi: 10.1007/s00262-017-2091-y. PubMed 
PMID: 29124315. 
40. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol 
metabolism by proteolysis of a membrane-bound transcription factor. Cell. 
1997;89(3):331-40. PubMed PMID: 9150132. 
41. Browne BC, Hochgrafe F, Wu J, Millar EK, Barraclough J, Stone A, McCloy RA, 
Lee CS, Roberts C, Ali NA, Boulghourjian A, Schmich F, Linding R, Farrow L, 
Gee JM, Nicholson RI, O'Toole SA, Sutherland RL, Musgrove EA, Butt AJ, Daly 
RJ. Global characterization of signalling networks associated with tamoxifen 
resistance in breast cancer. FEBS J. 2013;280(21):5237-57. doi: 
10.1111/febs.12441. PubMed PMID: 23876235. 
42. Buck MJ, Lieb JD. ChIP-chip: considerations for the design, analysis, and 
application of genome-wide chromatin immunoprecipitation experiments. 
Genomics. 2004;83(3):349-60. PubMed PMID: 14986705. 
43. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription 
polymerase chain reaction assays. J Mol Endocrinol. 2000;25(2):169-93. PubMed 
PMID: 11013345. 
44. Cairns BR. Emerging roles for chromatin remodeling in cancer biology. Trends 
Cell Biol. 2001;11(11):S15-21. PubMed PMID: 11684437. 
45. Calisher CH, Childs JE, Field HE, Holmes KV, Schountz T. Bats: important 
reservoir hosts of emerging viruses. Clin Microbiol Rev. 2006;19(3):531-45. 
PubMed PMID: 16847084. 
46. Calo E, Wysocka J. Modification of enhancer chromatin: what, how, and why? 
Mol Cell. 2013;49(5):825-37. doi: 10.1016/j.molcel.2013.01.038. PubMed PMID: 
23473601; PMCID: PMC3857148. 
47. Campbell CAR. Bats, mosquitoes, and dollars. Boston, Mass.: The Stratford Co. 
1. ; 1925. 
48. Cancer Genome Atlas Research Network. Electronic address aadhe, Cancer 
Genome Atlas Research N. Integrated Genomic Characterization of Pancreatic 
Ductal Adenocarcinoma. Cancer Cell. 2017;32(2):185-203 e13. doi: 
10.1016/j.ccell.2017.07.007. PubMed PMID: 28810144; PMCID: PMC5964983. 
49. Cao F, Fang Y, Tan HK, Goh Y, Choy JYH, Koh BTH, Hao Tan J, Bertin N, 
Ramadass A, Hunter E, Green J, Salter M, Akoulitchev A, Wang W, Chng WJ, 
 190 
Tenen DG, Fullwood MJ. Super-Enhancers and Broad H3K4me3 Domains Form 
Complex Gene Regulatory Circuits Involving Chromatin Interactions. Sci Rep. 
2017;7(1):2186. doi: 10.1038/s41598-017-02257-3. PubMed PMID: 28526829; 
PMCID: PMC5438348. 
50. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, 
Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox 
EA, Silver PA, Gingeras TR, Liu XS, Brown M. Genome-wide analysis of 
estrogen receptor binding sites. Nat Genet. 2006;38(11):1289-97. doi: 
10.1038/ng1901. PubMed PMID: 17013392. 
51. Cauchi S, Froguel P. TCF7L2 genetic defect and type 2 diabetes. Curr Diab Rep. 
2008;8(2):149-55. PubMed PMID: 18445358. 
52. Cawston TE, Young DA. Proteinases involved in matrix turnover during cartilage 
and bone breakdown. Cell Tissue Res. 2010;339(1):221-35. doi: 10.1007/s00441-
009-0887-6. PubMed PMID: 19915869. 
53. Cedar H, Bergman Y. Linking DNA methylation and histone modification: 
patterns and paradigms. Nat Rev Genet. 2009;10(5):295-304. doi: 
10.1038/nrg2540. PubMed PMID: 19308066. 
54. Chargaff E. Chemical specificity of nucleic acids and mechanism of their 
enzymatic degradation. Experientia. 1950;6(6):201-9. PubMed PMID: 15421335. 
55. Chen D, Niu M, Jiao X, Zhang K, Liang J, Zhang D. Inhibition of AKT2 
enhances sensitivity to gemcitabine via regulating PUMA and NF-kappaB 
signaling pathway in human pancreatic ductal adenocarcinoma. Int J Mol Sci. 
2012;13(1):1186-208. doi: 10.3390/ijms13011186. PubMed PMID: 22312312; 
PMCID: PMC3269746. 
56. Chen K, Chen Z, Wu D, Zhang L, Lin X, Su J, Rodriguez B, Xi Y, Xia Z, Chen 
X, Shi X, Wang Q, Li W. Broad H3K4me3 is associated with increased 
transcription elongation and enhancer activity at tumor-suppressor genes. Nat 
Genet. 2015;47(10):1149-57. doi: 10.1038/ng.3385. PubMed PMID: 26301496; 
PMCID: PMC4780747. 
57. Cheng J, Blum R, Bowman C, Hu D, Shilatifard A, Shen S, Dynlacht BD. A role 
for H3K4 monomethylation in gene repression and partitioning of chromatin 
readers. Mol Cell. 2014;53(6):979-92. doi: 10.1016/j.molcel.2014.02.032. 
PubMed PMID: 24656132; PMCID: PMC4031464. 
58. Cheung AC, Cramer P. Structural basis of RNA polymerase II backtracking, 
arrest and reactivation. Nature. 2011;471(7337):249-53. doi: 
10.1038/nature09785. PubMed PMID: 21346759. 
59. Chi P, Allis CD, Wang GG. Covalent histone modifications--miswritten, 
misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 
2010;10(7):457-69. doi: 10.1038/nrc2876. PubMed PMID: 20574448; PMCID: 
PMC3262678. 
60. Choi SH, Gearhart MD, Cui Z, Bosnakovski D, Kim M, Schennum N, Kyba M. 
DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 
acetylation changes. Nucleic Acids Res. 2016;44(11):5161-73. doi: 
10.1093/nar/gkw141. PubMed PMID: 26951377; PMCID: PMC4914088. 
61. Ciabrelli F, Cavalli G. Chromatin-driven behavior of topologically associating 
 191 
domains. J Mol Biol. 2015;427(3):608-25. doi: 10.1016/j.jmb.2014.09.013. 
PubMed PMID: 25280896. 
62. Cicatiello L, Mutarelli M, Grober OM, Paris O, Ferraro L, Ravo M, Tarallo R, 
Luo S, Schroth GP, Seifert M, Zinser C, Chiusano ML, Traini A, De Bortoli M, 
Weisz A. Estrogen receptor alpha controls a gene network in luminal-like breast 
cancer cells comprising multiple transcription factors and microRNAs. Am J 
Pathol. 2010;176(5):2113-30. doi: 10.2353/ajpath.2010.090837. PubMed PMID: 
20348243; PMCID: PMC2861078. 
63. Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, Tassone P, Tagliaferri P. 
Role of gemcitabine-based combination therapy in the management of advanced 
pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer. 
2013;49(3):593-603. doi: 10.1016/j.ejca.2012.08.019. PubMed PMID: 22989511. 
64. Clark DW, Mitra A, Fillmore RA, Jiang WG, Samant RS, Fodstad O, Shevde LA. 
NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast 
epithelial cells from doxorubicin-induced genotoxic stress. Curr Cancer Drug 
Targets. 2008;8(5):421-30. PubMed PMID: 18690848. 
65. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 
2006;127(3):469-80. doi: 10.1016/j.cell.2006.10.018. PubMed PMID: 17081971. 
66. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, 
Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gomez F, Medicherla S, Alfaro 
IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer 
JK. Role of the androgen receptor in breast cancer and preclinical analysis of 
enzalutamide. Breast Cancer Res. 2014;16(1):R7. doi: 10.1186/bcr3599. PubMed 
PMID: 24451109; PMCID: PMC3978822. 
67. Cogswell-Hawkinson A, Bowen R, James S, Gardiner D, Calisher CH, Adams R, 
Schountz T. Tacaribe virus causes fatal infection of an ostensible reservoir host, 
the Jamaican fruit bat. J Virol. 2012;86(10):5791-9. doi: 10.1128/JVI.00201-12. 
PubMed PMID: 22379103; PMCID: 3347293. 
68. Cogswell-Hawkinson AC, Mitchell E. McGlaughlin, Charles H. Calisher, Rick 
Adams, and Tony Schountz. Molecular and Phylogenetic Characterization of 
Cytokine Genes from Seba's Short-tailed Fruit Bat (Carollia perspicillata). Open 
Immunology Journal. 2011;4:31-9. 
69. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, 
Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, 
Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal 
adenocarcinoma and their differing responses to therapy. Nat Med. 
2011;17(4):500-3. doi: 10.1038/nm.2344. PubMed PMID: 21460848; PMCID: 
PMC3755490. 
70. Conesa A, Gotz S. Blast2GO: A comprehensive suite for functional analysis in 
plant genomics. Int J Plant Genomics. 2008;2008:619832. doi: 
10.1155/2008/619832. PubMed PMID: 18483572; PMCID: 2375974. 
71. Connor AA, Denroche RE, Jang GH, Lemire M, Zhang A, Chan-Seng-Yue M, 
Wilson G, Grant RC, Merico D, Lungu I, Bartlett JMS, Chadwick D, Liang SB, 
Eagles J, Mbabaali F, Miller JK, Krzyzanowski P, Armstrong H, Luo X, 
Jorgensen LGT, Romero JM, Bavi P, Fischer SE, Serra S, Hafezi-Bakhtiari S, 
 192 
Caglar D, Roehrl MHA, Cleary S, Hollingsworth MA, Petersen GM, Thayer S, 
Law CHL, Nanji S, Golan T, Smith AL, Borgida A, Dodd A, Hedley D, Wouters 
BG, O'Kane GM, Wilson JM, Zogopoulos G, Notta F, Knox JJ, Gallinger S. 
Integration of Genomic and Transcriptional Features in Pancreatic Cancer 
Reveals Increased Cell Cycle Progression in Metastases. Cancer Cell. 
2019;35(2):267-82 e7. doi: 10.1016/j.ccell.2018.12.010. PubMed PMID: 
30686769. 
72. Consortium EP. An integrated encyclopedia of DNA elements in the human 
genome. Nature. 2012;489(7414):57-74. doi: 10.1038/nature11247. PubMed 
PMID: 22955616; PMCID: PMC3439153. 
73. Cremer M, Kupper K, Wagler B, Wizelman L, von Hase J, Weiland Y, Kreja L, 
Diebold J, Speicher MR, Cremer T. Inheritance of gene density-related higher 
order chromatin arrangements in normal and tumor cell nuclei. J Cell Biol. 
2003;162(5):809-20. doi: 10.1083/jcb.200304096. PubMed PMID: 12952935; 
PMCID: PMC2172812. 
74. Cremer M, von Hase J, Volm T, Brero A, Kreth G, Walter J, Fischer C, Solovei I, 
Cremer C, Cremer T. Non-random radial higher-order chromatin arrangements in 
nuclei of diploid human cells. Chromosome Res. 2001;9(7):541-67. PubMed 
PMID: 11721953. 
75. Cremer T, Cremer C, Baumann H, Luedtke EK, Sperling K, Teuber V, Zorn C. 
Rabl's model of the interphase chromosome arrangement tested in Chinese 
hamster cells by premature chromosome condensation and laser-UV-microbeam 
experiments. Hum Genet. 1982;60(1):46-56. PubMed PMID: 7076247. 
76. Cremer T, Kurz A, Zirbel R, Dietzel S, Rinke B, Schrock E, Speicher MR, 
Mathieu U, Jauch A, Emmerich P, Scherthan H, Ried T, Cremer C, Lichter P. 
Role of chromosome territories in the functional compartmentalization of the cell 
nucleus. Cold Spring Harb Symp Quant Biol. 1993;58:777-92. PubMed PMID: 
7525149. 
77. Crick F. Central dogma of molecular biology. Nature. 1970;227(5258):561-3. 
PubMed PMID: 4913914. 
78. Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, Caudy M, Garapati 
P, Gopinath G, Jassal B, Jupe S, Kalatskaya I, Mahajan S, May B, Ndegwa N, 
Schmidt E, Shamovsky V, Yung C, Birney E, Hermjakob H, D'Eustachio P, Stein 
L. Reactome: a database of reactions, pathways and biological processes. Nucleic 
Acids Res. 2011;39(Database issue):D691-7. doi: 10.1093/nar/gkq1018. PubMed 
PMID: 21067998; PMCID: 3013646. 
79. de Laat W, Duboule D. Topology of mammalian developmental enhancers and 
their regulatory landscapes. Nature. 2013;502(7472):499-506. doi: 
10.1038/nature12753. PubMed PMID: 24153303. 
80. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo 
MA, Mulvihill SJ. Phenotype and genotype of pancreatic cancer cell lines. 
Pancreas. 2010;39(4):425-35. doi: 10.1097/MPA.0b013e3181c15963. PubMed 
PMID: 20418756; PMCID: PMC2860631. 
81. Dekker FJ, Haisma HJ. Histone acetyl transferases as emerging drug targets. Drug 
Discov Today. 2009;14(19-20):942-8. doi: 10.1016/j.drudis.2009.06.008. 
 193 
PubMed PMID: 19577000. 
82. Dekker J, Marti-Renom MA, Mirny LA. Exploring the three-dimensional 
organization of genomes: interpreting chromatin interaction data. Nat Rev Genet. 
2013;14(6):390-403. doi: 10.1038/nrg3454. PubMed PMID: 23657480; PMCID: 
PMC3874835. 
83. Dekker J, Mirny L. The 3D Genome as Moderator of Chromosomal 
Communication. Cell. 2016;164(6):1110-21. doi: 10.1016/j.cell.2016.02.007. 
PubMed PMID: 26967279; PMCID: PMC4788811. 
84. Dekker J, Rippe K, Dekker M, Kleckner N. Capturing chromosome conformation. 
Science. 2002;295(5558):1306-11. doi: 10.1126/science.1067799. PubMed 
PMID: 11847345. 
85. Deng W, Rupon JW, Krivega I, Breda L, Motta I, Jahn KS, Reik A, Gregory PD, 
Rivella S, Dean A, Blobel GA. Reactivation of developmentally silenced globin 
genes by forced chromatin looping. Cell. 2014;158(4):849-60. doi: 
10.1016/j.cell.2014.05.050. PubMed PMID: 25126789; PMCID: PMC4134511. 
86. Deniz O, Flores O, Aldea M, Soler-Lopez M, Orozco M. Nucleosome architecture 
throughout the cell cycle. Sci Rep. 2016;6:19729. doi: 10.1038/srep19729. 
PubMed PMID: 26818620; PMCID: PMC4730144. 
87. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J 
Haematol. 2006;134(5):453-66. doi: 10.1111/j.1365-2141.2006.06215.x. PubMed 
PMID: 16856888. 
88. Dhayat SA, Traeger MM, Rehkaemper J, Stroese AJ, Steinestel K, Wardelmann 
E, Kabar I, Senninger N. Clinical Impact of Epithelial-to-Mesenchymal Transition 
Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 
2018;10(9). doi: 10.3390/cancers10090328. PubMed PMID: 30217058; PMCID: 
PMC6162771. 
89. Di Gangi IM, Mazza T, Fontana A, Copetti M, Fusilli C, Ippolito A, Mattivi F, 
Latiano A, Andriulli A, Vrhovsek U, Pazienza V. Metabolomic profile in 
pancreatic cancer patients: a consensus-based approach to identify highly 
discriminating metabolites. Oncotarget. 2016;7(5):5815-29. doi: 
10.18632/oncotarget.6808. PubMed PMID: 26735340; PMCID: PMC4868723. 
90. Diaferia GR, Balestrieri C, Prosperini E, Nicoli P, Spaggiari P, Zerbi A, Natoli G. 
Dissection of transcriptional and cis-regulatory control of differentiation in human 
pancreatic cancer. EMBO J. 2016;35(6):595-617. doi: 10.15252/embj.201592404. 
PubMed PMID: 26769127; PMCID: PMC4801945. 
91. Dillon SC, Zhang X, Trievel RC, Cheng X. The SET-domain protein superfamily: 
protein lysine methyltransferases. Genome Biol. 2005;6(8):227. doi: 10.1186/gb-
2005-6-8-227. PubMed PMID: 16086857; PMCID: PMC1273623. 
92. Dincer A, Gavin DP, Xu K, Zhang B, Dudley JT, Schadt EE, Akbarian S. 
Deciphering H3K4me3 broad domains associated with gene-regulatory networks 
and conserved epigenomic landscapes in the human brain. Transl Psychiatry. 
2015;5:e679. doi: 10.1038/tp.2015.169. PubMed PMID: 26575220; PMCID: 
PMC5068762. 
93. Ding J, Huang X, Shao N, Zhou H, Lee DF, Faiola F, Fidalgo M, Guallar D, 
Saunders A, Shliaha PV, Wang H, Waghray A, Papatsenko D, Sanchez-Priego C, 
 194 
Li D, Yuan Y, Lemischka IR, Shen L, Kelley K, Deng H, Shen X, Wang J. Tex10 
Coordinates Epigenetic Control of Super-Enhancer Activity in Pluripotency and 
Reprogramming. Cell Stem Cell. 2015;16(6):653-68. doi: 
10.1016/j.stem.2015.04.001. PubMed PMID: 25936917; PMCID: PMC4458159. 
94. DiNorcia J, Lee MK, Moroziewicz DN, Winner M, Suman P, Bao F, Remotti HE, 
Zou YS, Yan SF, Qiu W, Su GH, Schmidt AM, Allendorf JD. RAGE gene 
deletion inhibits the development and progression of ductal neoplasia and 
prolongs survival in a murine model of pancreatic cancer. J Gastrointest Surg. 
2012;16(1):104-12; discussion 12. doi: 10.1007/s11605-011-1754-9. PubMed 
PMID: 22052106; PMCID: PMC4049447. 
95. Dixon JR, Jung I, Selvaraj S, Shen Y, Antosiewicz-Bourget JE, Lee AY, Ye Z, 
Kim A, Rajagopal N, Xie W, Diao Y, Liang J, Zhao H, Lobanenkov VV, Ecker 
JR, Thomson JA, Ren B. Chromatin architecture reorganization during stem cell 
differentiation. Nature. 2015;518(7539):331-6. doi: 10.1038/nature14222. 
PubMed PMID: 25693564; PMCID: PMC4515363. 
96. Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, Hu M, Liu JS, Ren B. 
Topological domains in mammalian genomes identified by analysis of chromatin 
interactions. Nature. 2012;485(7398):376-80. doi: 10.1038/nature11082. PubMed 
PMID: 22495300; PMCID: PMC3356448. 
97. Djavani M, Crasta OR, Zhang Y, Zapata JC, Sobral B, Lechner MG, Bryant J, 
Davis H, Salvato MS. Gene expression in primate liver during viral hemorrhagic 
fever. Virol J. 2009;6:20. doi: 10.1186/1743-422X-6-20. PubMed PMID: 
19216742; PMCID: PMC2657139. 
98. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and 
progression of human cancer. Virchows Arch. 2005;446(5):475-82. doi: 
10.1007/s00428-005-1264-9. PubMed PMID: 15856292. 
99. Dowen JM, Fan ZP, Hnisz D, Ren G, Abraham BJ, Zhang LN, Weintraub AS, 
Schujiers J, Lee TI, Zhao K, Young RA. Control of cell identity genes occurs in 
insulated neighborhoods in mammalian chromosomes. Cell. 2014;159(2):374-87. 
doi: 10.1016/j.cell.2014.09.030. PubMed PMID: 25303531; PMCID: 
PMC4197132. 
100. Downs WG, C.R. Anderson, L. Spence, T.H.G. Aitken, and A.H. Greenhall. 
Tacaribe Virus, a New Agent Isolated from Artibeus Bats and Mosquitos in 
Trinidad, West Indies. American Journal of Tropical Medicine and Hygiene. 
1963;12:640-6. 
101. Doyle S, Vaidya S, O'Connell R, Dadgostar H, Dempsey P, Wu T, Rao G, Sun R, 
Haberland M, Modlin R, Cheng G. IRF3 mediates a TLR3/TLR4-specific 
antiviral gene program. Immunity. 2002;17(3):251-63. PubMed PMID: 
12354379. 
102. Du Z, Zheng H, Huang B, Ma R, Wu J, Zhang X, He J, Xiang Y, Wang Q, Li Y, 
Ma J, Zhang X, Zhang K, Wang Y, Zhang MQ, Gao J, Dixon JR, Wang X, Zeng 
J, Xie W. Allelic reprogramming of 3D chromatin architecture during early 
mammalian development. Nature. 2017;547(7662):232-5. doi: 
10.1038/nature23263. PubMed PMID: 28703188. 
103. Duan Z, Andronescu M, Schutz K, McIlwain S, Kim YJ, Lee C, Shendure J, 
 195 
Fields S, Blau CA, Noble WS. A three-dimensional model of the yeast genome. 
Nature. 2010;465(7296):363-7. doi: 10.1038/nature08973. PubMed PMID: 
20436457; PMCID: PMC2874121. 
104. Durand NC, Shamim MS, Machol I, Rao SS, Huntley MH, Lander ES, Aiden EL. 
Juicer Provides a One-Click System for Analyzing Loop-Resolution Hi-C 
Experiments. Cell Syst. 2016;3(1):95-8. doi: 10.1016/j.cels.2016.07.002. PubMed 
PMID: 27467249; PMCID: PMC5846465. 
105. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high 
throughput. Nucleic Acids Res. 2004;32(5):1792-7. doi: 10.1093/nar/gkh340. 
PubMed PMID: 15034147; PMCID: PMC390337. 
106. Eguchi M, Nguyen C, Lee SC, Kahn M. ICG-001, a novel small molecule 
regulator of TCF/beta-catenin transcription. Med Chem. 2005;1(5):467-72. 
PubMed PMID: 16787331. 
107. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo 
JL, Kim HY, Moon SH, Ha JR, Kahn M. A small molecule inhibitor of beta-
catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S 
A. 2004;101(34):12682-7. doi: 10.1073/pnas.0404875101. PubMed PMID: 
15314234; PMCID: PMC515116. 
108. Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and 
characterization. Nat Methods. 2012;9(3):215-6. doi: 10.1038/nmeth.1906. 
PubMed PMID: 22373907; PMCID: PMC3577932. 
109. Erwin JA, Lee JT. New twists in X-chromosome inactivation. Curr Opin Cell 
Biol. 2008;20(3):349-55. doi: 10.1016/j.ceb.2008.04.007. PubMed PMID: 
18508252; PMCID: PMC2491718. 
110. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng 
AS, Li L, Abbosh PH, Huang TH, Nephew KP. Diverse gene expression and 
DNA methylation profiles correlate with differential adaptation of breast cancer 
cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 
2006;66(24):11954-66. doi: 10.1158/0008-5472.CAN-06-1666. PubMed PMID: 
17178894. 
111. Fang F, He X, Deng H, Chen Q, Lu J, Spraul M, Yu Y. Discrimination of 
metabolic profiles of pancreatic cancer from chronic pancreatitis by high-
resolution magic angle spinning 1H nuclear magnetic resonance and principal 
components analysis. Cancer Sci. 2007;98(11):1678-82. doi: 10.1111/j.1349-
7006.2007.00589.x. PubMed PMID: 17727683. 
112. Farnham PJ. Insights from genomic profiling of transcription factors. Nat Rev 
Genet. 2009;10(9):605-16. doi: 10.1038/nrg2636. PubMed PMID: 19668247; 
PMCID: PMC2846386. 
113. Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and 
mediators in cancer aetiology and progression. Nat Rev Genet. 2016;17(5):284-
99. doi: 10.1038/nrg.2016.13. PubMed PMID: 26972587; PMCID: PMC4888057. 
114. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow 
R, Pavletich NP. Structures of a histone deacetylase homologue bound to the TSA 
and SAHA inhibitors. Nature. 1999;401(6749):188-93. doi: 10.1038/43710. 
PubMed PMID: 10490031. 
 196 
115. Flyamer IM, Gassler J, Imakaev M, Brandao HB, Ulianov SV, Abdennur N, 
Razin SV, Mirny LA, Tachibana-Konwalski K. Single-nucleus Hi-C reveals 
unique chromatin reorganization at oocyte-to-zygote transition. Nature. 
2017;544(7648):110-4. doi: 10.1038/nature21711. PubMed PMID: 28355183; 
PMCID: PMC5639698. 
116. Foley P, Bunyan D, Stratton J, Dillon M, Lynch SA. Further case of Rubinstein-
Taybi syndrome due to a deletion in EP300. Am J Med Genet A. 
2009;149A(5):997-1000. doi: 10.1002/ajmg.a.32771. PubMed PMID: 19353645. 
117. Franke M, Ibrahim DM, Andrey G, Schwarzer W, Heinrich V, Schopflin R, Kraft 
K, Kempfer R, Jerkovic I, Chan WL, Spielmann M, Timmermann B, Wittler L, 
Kurth I, Cambiaso P, Zuffardi O, Houge G, Lambie L, Brancati F, Pombo A, 
Vingron M, Spitz F, Mundlos S. Formation of new chromatin domains determines 
pathogenicity of genomic duplications. Nature. 2016;538(7624):265-9. doi: 
10.1038/nature19800. PubMed PMID: 27706140. 
118. Franklin RE, Gosling RG. Molecular configuration in sodium thymonucleate. 
Nature. 1953;171(4356):740-1. PubMed PMID: 13054694. 
119. Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, 
Bergh J, Katzenellenbogen BS. Gene expression preferentially regulated by 
tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer 
Res. 2006;66(14):7334-40. doi: 10.1158/0008-5472.CAN-05-4269. PubMed 
PMID: 16849584. 
120. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. 
Profiling of estrogen up- and down-regulated gene expression in human breast 
cancer cells: insights into gene networks and pathways underlying estrogenic 
control of proliferation and cell phenotype. Endocrinology. 2003;144(10):4562-
74. doi: 10.1210/en.2003-0567. PubMed PMID: 12959972. 
121. Frick WF, Pollock JF, Hicks AC, Langwig KE, Reynolds DS, Turner GG, 
Butchkoski CM, Kunz TH. An emerging disease causes regional population 
collapse of a common North American bat species. Science. 2010;329(5992):679-
82. Epub 2010/08/07. doi: 329/5992/679 [pii] 
2. 10.1126/science.1188594. PubMed PMID: 20689016. 
122. Fridman WH. Fc receptors and immunoglobulin binding factors. FASEB J. 
1991;5(12):2684-90. PubMed PMID: 1916092. 
123. Frietze S, Wang R, Yao L, Tak YG, Ye Z, Gaddis M, Witt H, Farnham PJ, Jin 
VX. Cell type-specific binding patterns reveal that TCF7L2 can be tethered to the 
genome by association with GATA3. Genome Biol. 2012;13(9):R52. doi: 
10.1186/gb-2012-13-9-r52. PubMed PMID: 22951069; PMCID: PMC3491396. 
124. Fritsche P, Seidler B, Schuler S, Schnieke A, Gottlicher M, Schmid RM, Saur D, 
Schneider G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells 
via the BH3-only protein NOXA. Gut. 2009;58(10):1399-409. doi: 
10.1136/gut.2009.180711. PubMed PMID: 19528037. 
125. Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, 
Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman 
PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, 
Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne 
 197 
CK, Schiff R. FOXA1 overexpression mediates endocrine resistance by altering 
the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl 
Acad Sci U S A. 2016;113(43):E6600-E9. doi: 10.1073/pnas.1612835113. 
PubMed PMID: 27791031; PMCID: PMC5087040. 
126. Fulhorst CF, Bowen MD, Salas RA, Duno G, Utrera A, Ksiazek TG, De 
Manzione NM, De Miller E, Vasquez C, Peters CJ, Tesh RB. Natural rodent host 
associations of Guanarito and pirital viruses (Family Arenaviridae) in central 
Venezuela. Am J Trop Med Hyg. 1999;61(2):325-30. Epub 1999/08/27. PubMed 
PMID: 10463688. 
127. Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S, 
Ho A, Mei PH, Chew EG, Huang PY, Welboren WJ, Han Y, Ooi HS, Ariyaratne 
PN, Vega VB, Luo Y, Tan PY, Choy PY, Wansa KD, Zhao B, Lim KS, Leow SC, 
Yow JS, Joseph R, Li H, Desai KV, Thomsen JS, Lee YK, Karuturi RK, Herve T, 
Bourque G, Stunnenberg HG, Ruan X, Cacheux-Rataboul V, Sung WK, Liu ET, 
Wei CL, Cheung E, Ruan Y. An oestrogen-receptor-alpha-bound human 
chromatin interactome. Nature. 2009;462(7269):58-64. doi: 10.1038/nature08497. 
PubMed PMID: 19890323; PMCID: PMC2774924. 
128. Gabitova L, Gorin A, Astsaturov I. Molecular pathways: sterols and receptor 
signaling in cancer. Clin Cancer Res. 2014;20(1):28-34. doi: 10.1158/1078-
0432.CCR-13-0122. PubMed PMID: 24158702; PMCID: PMC3859141. 
129. Gaddis M, Gerrard D, Frietze S, Farnham PJ. Altering cancer transcriptomes 
using epigenomic inhibitors. Epigenetics Chromatin. 2015;8:9. doi: 
10.1186/1756-8935-8-9. PubMed PMID: 26191083; PMCID: PMC4506402. 
130. Gall JG. Kinetics of deoxyribonuclease action on chromosomes. Nature. 
1963;198:36-8. PubMed PMID: 14010299. 
131. Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH, Li YH, Wang LL, Yu L. A 
histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and 
apoptosis selectively in AML1-ETO-positive AML cells. PLoS One. 
2013;8(2):e55481. doi: 10.1371/journal.pone.0055481. PubMed PMID: 
23390536; PMCID: PMC3563640. 
132. Gargas A, M.T. Trest, M. Christensen, T.J. Volk, D. S. Blehert. Geomyces 
destructans sp. nov. associated with bat white-nose syndrome. Mycotaxon. 
2009;108:147-54. 
133. Gerrard DL, Wang Y, Gaddis M, Zhou Y, Wang J, Witt H, Lin S, Farnham PJ, Jin 
VX, Frietze SE. Three-dimensional analysis reveals altered chromatin interaction 
by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature. J Cell 
Biochem. 2019;120(3):3056-70. doi: 10.1002/jcb.27449. PubMed PMID: 
30548288. 
134. Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan KK, Cheng C, Mu XJ, 
Khurana E, Rozowsky J, Alexander R, Min R, Alves P, Abyzov A, Addleman N, 
Bhardwaj N, Boyle AP, Cayting P, Charos A, Chen DZ, Cheng Y, Clarke D, 
Eastman C, Euskirchen G, Frietze S, Fu Y, Gertz J, Grubert F, Harmanci A, Jain 
P, Kasowski M, Lacroute P, Leng JJ, Lian J, Monahan H, O'Geen H, Ouyang Z, 
Partridge EC, Patacsil D, Pauli F, Raha D, Ramirez L, Reddy TE, Reed B, Shi M, 
Slifer T, Wang J, Wu L, Yang X, Yip KY, Zilberman-Schapira G, Batzoglou S, 
 198 
Sidow A, Farnham PJ, Myers RM, Weissman SM, Snyder M. Architecture of the 
human regulatory network derived from ENCODE data. Nature. 
2012;489(7414):91-100. doi: 10.1038/nature11245. PubMed PMID: 22955619; 
PMCID: PMC4154057. 
135. Geutjes EJ, Bajpe PK, Bernards R. Targeting the epigenome for treatment of 
cancer. Oncogene. 2012;31(34):3827-44. doi: 10.1038/onc.2011.552. PubMed 
PMID: 22139071. 
136. GF Gunnell NS. Fossil evidence and the Origin of Bats. Journal of Mammalian 
Evolution. 2005;12:209-46. 
137. Giles RH, Peters DJ, Breuning MH. Conjunction dysfunction: CBP/p300 in 
human disease. Trends Genet. 1998;14(5):178-83. PubMed PMID: 9613201. 
138. Giroux V, Malicet C, Barthet M, Gironella M, Archange C, Dagorn JC, Vasseur 
S, Iovanna JL. p8 is a new target of gemcitabine in pancreatic cancer cells. Clin 
Cancer Res. 2006;12(1):235-41. doi: 10.1158/1078-0432.CCR-05-1700. PubMed 
PMID: 16397047. 
139. Gondor A, Ohlsson R. Chromosome crosstalk in three dimensions. Nature. 
2009;461(7261):212-7. doi: 10.1038/nature08453. PubMed PMID: 19741702. 
140. Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated 
proteins with a high content of acidic and basic amino acids. Eur J Biochem. 
1973;38(1):14-9. PubMed PMID: 4774120. 
141. Gorin A, Gabitova L, Astsaturov I. Regulation of cholesterol biosynthesis and 
cancer signaling. Curr Opin Pharmacol. 2012;12(6):710-6. doi: 
10.1016/j.coph.2012.06.011. PubMed PMID: 22824431; PMCID: PMC3504641. 
142. Gotz S, Garcia-Gomez JM, Terol J, Williams TD, Nagaraj SH, Nueda MJ, Robles 
M, Talon M, Dopazo J, Conesa A. High-throughput functional annotation and 
data mining with the Blast2GO suite. Nucleic Acids Res. 2008;36(10):3420-35. 
doi: 10.1093/nar/gkn176. PubMed PMID: 18445632; PMCID: 2425479. 
143. Goubau D, Deddouche S, Reis e Sousa C. Cytosolic sensing of viruses. Immunity. 
2013;38(5):855-69. doi: 10.1016/j.immuni.2013.05.007. PubMed PMID: 
23706667. 
144. Gower WR, Jr., Risch RM, Godellas CV, Fabri PJ. HPAC, a new human 
glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In Vitro Cell 
Dev Biol Anim. 1994;30A(3):151-61. PubMed PMID: 25939163. 
145. Grabherr MG, Haas BJ, Yassour M, Levin JZ, Thompson DA, Amit I, Adiconis 
X, Fan L, Raychowdhury R, Zeng Q, Chen Z, Mauceli E, Hacohen N, Gnirke A, 
Rhind N, di Palma F, Birren BW, Nusbaum C, Lindblad-Toh K, Friedman N, 
Regev A. Full-length transcriptome assembly from RNA-Seq data without a 
reference genome. Nat Biotechnol. 2011;29(7):644-52. doi: 10.1038/nbt.1883. 
PubMed PMID: 21572440; PMCID: 3571712. 
146. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 
1997;389(6649):349-52. doi: 10.1038/38664. PubMed PMID: 9311776. 
147. Gu F, Hsu HK, Hsu PY, Wu J, Ma Y, Parvin J, Huang TH, Jin VX. Inference of 
hierarchical regulatory network of estrogen-dependent breast cancer through 
ChIP-based data. BMC Syst Biol. 2010;4:170. doi: 10.1186/1752-0509-4-170. 
PubMed PMID: 21167036; PMCID: PMC3012048. 
 199 
148. Guelen L, Pagie L, Brasset E, Meuleman W, Faza MB, Talhout W, Eussen BH, 
de Klein A, Wessels L, de Laat W, van Steensel B. Domain organization of 
human chromosomes revealed by mapping of nuclear lamina interactions. Nature. 
2008;453(7197):948-51. doi: 10.1038/nature06947. PubMed PMID: 18463634. 
149. Haas BJ, Papanicolaou A, Yassour M, Grabherr M, Blood PD, Bowden J, Couger 
MB, Eccles D, Li B, Lieber M, Macmanes MD, Ott M, Orvis J, Pochet N, Strozzi 
F, Weeks N, Westerman R, William T, Dewey CN, Henschel R, Leduc RD, 
Friedman N, Regev A. De novo transcript sequence reconstruction from RNA-seq 
using the Trinity platform for reference generation and analysis. Nat Protoc. 
2013;8(8):1494-512. doi: 10.1038/nprot.2013.084. PubMed PMID: 23845962; 
PMCID: 3875132. 
150. Hagege H, Klous P, Braem C, Splinter E, Dekker J, Cathala G, de Laat W, Forne 
T. Quantitative analysis of chromosome conformation capture assays (3C-qPCR). 
Nat Protoc. 2007;2(7):1722-33. doi: 10.1038/nprot.2007.243. PubMed PMID: 
17641637. 
151. Hagstrom KA, Meyer BJ. Condensin and cohesin: more than chromosome 
compactor and glue. Nat Rev Genet. 2003;4(7):520-34. doi: 10.1038/nrg1110. 
PubMed PMID: 12838344. 
152. Hamidi T, Algul H, Cano CE, Sandi MJ, Molejon MI, Riemann M, Calvo EL, 
Lomberk G, Dagorn JC, Weih F, Urrutia R, Schmid RM, Iovanna JL. Nuclear 
protein 1 promotes pancreatic cancer development and protects cells from stress 
by inhibiting apoptosis. J Clin Invest. 2012;122(6):2092-103. doi: 
10.1172/JCI60144. PubMed PMID: 22565310; PMCID: PMC3366404. 
153. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. 
Cytokine Growth Factor Rev. 2002;13(4-5):413-21. PubMed PMID: 12220554. 
154. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 
2011;144(5):646-74. doi: 10.1016/j.cell.2011.02.013. PubMed PMID: 21376230. 
155. Hatzis P, Talianidis I. Dynamics of enhancer-promoter communication during 
differentiation-induced gene activation. Mol Cell. 2002;10(6):1467-77. PubMed 
PMID: 12504020. 
156. Heidari N, Phanstiel DH, He C, Grubert F, Jahanbani F, Kasowski M, Zhang MQ, 
Snyder MP. Genome-wide map of regulatory interactions in the human genome. 
Genome Res. 2014;24(12):1905-17. doi: 10.1101/gr.176586.114. PubMed PMID: 
25228660; PMCID: PMC4248309. 
157. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, Barrera LO, 
Van Calcar S, Qu C, Ching KA, Wang W, Weng Z, Green RD, Crawford GE, 
Ren B. Distinct and predictive chromatin signatures of transcriptional promoters 
and enhancers in the human genome. Nat Genet. 2007;39(3):311-8. doi: 
10.1038/ng1966. PubMed PMID: 17277777. 
158. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, 
Singh H, Glass CK. Simple combinations of lineage-determining transcription 
factors prime cis-regulatory elements required for macrophage and B cell 
identities. Mol Cell. 2010;38(4):576-89. doi: 10.1016/j.molcel.2010.05.004. 
PubMed PMID: 20513432; PMCID: PMC2898526. 
159. Heinz S, Romanoski CE, Benner C, Glass CK. The selection and function of cell 
 200 
type-specific enhancers. Nat Rev Mol Cell Biol. 2015;16(3):144-54. doi: 
10.1038/nrm3949. PubMed PMID: 25650801; PMCID: PMC4517609. 
160. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, 
Strom A, Treuter E, Warner M, Gustafsson JA. Estrogen receptors: how do they 
signal and what are their targets. Physiol Rev. 2007;87(3):905-31. doi: 
10.1152/physrev.00026.2006. PubMed PMID: 17615392. 
161. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. 
Nature. 2013;502(7472):480-8. doi: 10.1038/nature12751. PubMed PMID: 
24153301. 
162. Henikoff S, Smith MM. Histone variants and epigenetics. Cold Spring Harb 
Perspect Biol. 2015;7(1):a019364. doi: 10.1101/cshperspect.a019364. PubMed 
PMID: 25561719; PMCID: PMC4292162. 
163. Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, 
Cleverly AL, Desaiah D, Guba SC, Benhadji KA, Slapak CA, Lahn MM. Clinical 
development of galunisertib (LY2157299 monohydrate), a small molecule 
inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel 
Ther. 2015;9:4479-99. doi: 10.2147/DDDT.S86621. PubMed PMID: 26309397; 
PMCID: PMC4539082. 
164. Hessmann E, Schneider G, Ellenrieder V, Siveke JT. MYC in pancreatic cancer: 
novel mechanistic insights and their translation into therapeutic strategies. 
Oncogene. 2016;35(13):1609-18. doi: 10.1038/onc.2015.216. PubMed PMID: 
26119937. 
165. Hiller M, Agarwal S, Notwell JH, Parikh R, Guturu H, Wenger AM, Bejerano G. 
Computational methods to detect conserved non-genic elements in 
phylogenetically isolated genomes: application to zebrafish. Nucleic Acids Res. 
2013;41(15):e151. doi: 10.1093/nar/gkt557. PubMed PMID: 23814184; PMCID: 
PMC3753653. 
166. Hirota K, Miyoshi T, Kugou K, Hoffman CS, Shibata T, Ohta K. Stepwise 
chromatin remodelling by a cascade of transcription initiation of non-coding 
RNAs. Nature. 2008;456(7218):130-4. doi: 10.1038/nature07348. PubMed 
PMID: 18820678. 
167. Hirsch RL. The complement system: its importance in the host response to viral 
infection. Microbiol Rev. 1982;46(1):71-85. PubMed PMID: 7045625; PMCID: 
PMC373211. 
168. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, Hoke HA, 
Young RA. Super-enhancers in the control of cell identity and disease. Cell. 
2013;155(4):934-47. doi: 10.1016/j.cell.2013.09.053. PubMed PMID: 24119843; 
PMCID: PMC3841062. 
169. Hoffman EA, Frey BL, Smith LM, Auble DT. Formaldehyde crosslinking: a tool 
for the study of chromatin complexes. J Biol Chem. 2015;290(44):26404-11. doi: 
10.1074/jbc.R115.651679. PubMed PMID: 26354429; PMCID: PMC4646298. 
170. Honkela A, Peltonen J, Topa H, Charapitsa I, Matarese F, Grote K, Stunnenberg 
HG, Reid G, Lawrence ND, Rattray M. Genome-wide modeling of transcription 
kinetics reveals patterns of RNA production delays. Proc Natl Acad Sci U S A. 
2015;112(42):13115-20. doi: 10.1073/pnas.1420404112. PubMed PMID: 
 201 
26438844; PMCID: PMC4620908. 
171. Hou C, Li L, Qin ZS, Corces VG. Gene density, transcription, and insulators 
contribute to the partition of the Drosophila genome into physical domains. Mol 
Cell. 2012;48(3):471-84. doi: 10.1016/j.molcel.2012.08.031. PubMed PMID: 
23041285; PMCID: PMC3496039. 
172. Hsu PY, Hsu HK, Hsiao TH, Ye Z, Wang E, Profit AL, Jatoi I, Chen Y, Kirma 
NB, Jin VX, Sharp ZD, Huang TH. Spatiotemporal control of estrogen-responsive 
transcription in ERalpha-positive breast cancer cells. Oncogene. 
2016;35(18):2379-89. doi: 10.1038/onc.2015.298. PubMed PMID: 26300005; 
PMCID: PMC4865474. 
173. Hsu PY, Hsu HK, Lan X, Juan L, Yan PS, Labanowska J, Heerema N, Hsiao TH, 
Chiu YC, Chen Y, Liu Y, Li L, Li R, Thompson IM, Nephew KP, Sharp ZD, 
Kirma NB, Jin VX, Huang TH. Amplification of distant estrogen response 
elements deregulates target genes associated with tamoxifen resistance in breast 
cancer. Cancer Cell. 2013;24(2):197-212. doi: 10.1016/j.ccr.2013.07.007. 
PubMed PMID: 23948299; PMCID: PMC3890247. 
174. Huang J, Li K, Cai W, Liu X, Zhang Y, Orkin SH, Xu J, Yuan GC. Dissecting 
super-enhancer hierarchy based on chromatin interactions. Nat Commun. 
2018;9(1):943. doi: 10.1038/s41467-018-03279-9. PubMed PMID: 29507293; 
PMCID: PMC5838163. 
175. Huberman JA. Structure of chromosome fibers and chromosomes. Annu Rev 
Biochem. 1973;42:355-78. doi: 10.1146/annurev.bi.42.070173.002035. PubMed 
PMID: 4581228. 
176. Hubner MR, Eckersley-Maslin MA, Spector DL. Chromatin organization and 
transcriptional regulation. Curr Opin Genet Dev. 2013;23(2):89-95. doi: 
10.1016/j.gde.2012.11.006. PubMed PMID: 23270812; PMCID: PMC3612554. 
177. Huelsenbeck JP, Ronquist F. MRBAYES: Bayesian inference of phylogenetic 
trees. Bioinformatics. 2001;17(8):754-5. PubMed PMID: 11524383. 
178. Hung HL, Kim AY, Hong W, Rakowski C, Blobel GA. Stimulation of NF-E2 
DNA binding by CREB-binding protein (CBP)-mediated acetylation. J Biol 
Chem. 2001;276(14):10715-21. doi: 10.1074/jbc.M007846200. PubMed PMID: 
11154691. 
179. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, 
Jiang J, Howat WJ, Ali S, Carroll JS. Regulation of ERBB2 by oestrogen 
receptor-PAX2 determines response to tamoxifen. Nature. 2008;456(7222):663-6. 
doi: 10.1038/nature07483. PubMed PMID: 19005469; PMCID: PMC2920208. 
180. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key 
determinant of estrogen receptor function and endocrine response. Nat Genet. 
2011;43(1):27-33. doi: 10.1038/ng.730. PubMed PMID: 21151129; PMCID: 
PMC3024537. 
181. Imakaev M, Fudenberg G, McCord RP, Naumova N, Goloborodko A, Lajoie BR, 
Dekker J, Mirny LA. Iterative correction of Hi-C data reveals hallmarks of 
chromosome organization. Nat Methods. 2012;9(10):999-1003. doi: 
10.1038/nmeth.2148. PubMed PMID: 22941365; PMCID: PMC3816492. 
182. IUCN. IUCN Red List Version 2015.1, Table 3a- Status Category summary by 
 202 
major taxonomic group (animals): Conservation International, Arizona State 
University, Texas A&M University, University of Rome, University of Virginia, 
Zoological Society London. ; 2015 [cited 2015 June 11, 2015]. Available from: 
www.iucnredlist.org/mammals. 
183. IUCN. IUCN Red List Version 2015.1, Table 4a- Number of species in each 
IUCN Red List Category in each major animal taxonomic group (class, order): 
Conservation International, Arizona State University, Texas A&M University, 
University of Rome, University of Virginia, Zoological Society London. ; 2015 
[cited 2015 June 11, 2015]. Available from: www.iucnredlist.org/mammals. 
184. Jayme SI, Field HE, de Jong C, Olival KJ, Marsh G, Tagtag AM, Hughes T, 
Bucad AC, Barr J, Azul RR, Retes LM, Foord A, Yu M, Cruz MS, Santos IJ, Lim 
TM, Benigno CC, Epstein JH, Wang LF, Daszak P, Newman SH. Molecular 
evidence of Ebola Reston virus infection in Philippine bats. Virol J. 2015;12:107. 
doi: 10.1186/s12985-015-0331-3. PubMed PMID: 26184657; PMCID: 4504098. 
185. Jenuwein T, Allis CD. Translating the histone code. Science. 
2001;293(5532):1074-80. doi: 10.1126/science.1063127. PubMed PMID: 
11498575. 
186. Ji X, Dadon DB, Powell BE, Fan ZP, Borges-Rivera D, Shachar S, Weintraub AS, 
Hnisz D, Pegoraro G, Lee TI, Misteli T, Jaenisch R, Young RA. 3D Chromosome 
Regulatory Landscape of Human Pluripotent Cells. Cell Stem Cell. 
2016;18(2):262-75. doi: 10.1016/j.stem.2015.11.007. PubMed PMID: 26686465; 
PMCID: PMC4848748. 
187. Jia J, Parikh H, Xiao W, Hoskins JW, Pflicke H, Liu X, Collins I, Zhou W, Wang 
Z, Powell J, Thorgeirsson SS, Rudloff U, Petersen GM, Amundadottir LT. An 
integrated transcriptome and epigenome analysis identifies a novel candidate gene 
for pancreatic cancer. BMC Med Genomics. 2013;6:33. doi: 10.1186/1755-8794-
6-33. PubMed PMID: 24053169; PMCID: PMC3849454. 
188. Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, 
Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo 
DG. Targeting focal adhesion kinase renders pancreatic cancers responsive to 
checkpoint immunotherapy. Nat Med. 2016;22(8):851-60. doi: 10.1038/nm.4123. 
PubMed PMID: 27376576; PMCID: PMC4935930. 
189. Jin F, Li Y, Dixon JR, Selvaraj S, Ye Z, Lee AY, Yen CA, Schmitt AD, Espinoza 
CA, Ren B. A high-resolution map of the three-dimensional chromatin 
interactome in human cells. Nature. 2013;503(7475):290-4. doi: 
10.1038/nature12644. PubMed PMID: 24141950; PMCID: PMC3838900. 
190. Johns EW, Forrester S. Studies on nuclear proteins. The binding of extra acidic 
proteins to deoxyribonucleoprotein during the preparation of nuclear proteins. Eur 
J Biochem. 1969;8(4):547-51. PubMed PMID: 5796141. 
191. Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev 
Genet. 2016;17(10):630-41. doi: 10.1038/nrg.2016.93. PubMed PMID: 
27629931. 
192. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, 
Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, 
Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, 
 203 
Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-
Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, 
Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling 
pathways in human pancreatic cancers revealed by global genomic analyses. 
Science. 2008;321(5897):1801-6. doi: 10.1126/science.1164368. PubMed PMID: 
18772397; PMCID: PMC2848990. 
193. Jordan VC. A century of deciphering the control mechanisms of sex steroid action 
in breast and prostate cancer: the origins of targeted therapy and 
chemoprevention. Cancer Res. 2009;69(4):1243-54. doi: 10.1158/0008-
5472.CAN-09-0029. PubMed PMID: 19208829. 
194. Kalhor R, Tjong H, Jayathilaka N, Alber F, Chen L. Genome architectures 
revealed by tethered chromosome conformation capture and population-based 
modeling. Nat Biotechnol. 2011;30(1):90-8. doi: 10.1038/nbt.2057. PubMed 
PMID: 22198700; PMCID: PMC3782096. 
195. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem Pharmacol. 
2004;68(6):1145-55. doi: 10.1016/j.bcp.2004.03.045. PubMed PMID: 15313412. 
196. Kang R, Tang D, Schapiro NE, Loux T, Livesey KM, Billiar TR, Wang H, Van 
Houten B, Lotze MT, Zeh HJ. The HMGB1/RAGE inflammatory pathway 
promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. 
Oncogene. 2014;33(5):567-77. doi: 10.1038/onc.2012.631. PubMed PMID: 
23318458; PMCID: PMC3795800. 
197. Kaniskan HU, Konze KD, Jin J. Selective inhibitors of protein methyltransferases. 
J Med Chem. 2015;58(4):1596-629. doi: 10.1021/jm501234a. PubMed PMID: 
25406853; PMCID: PMC4345896. 
198. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, Hoshino K, Akira 
S. Lipopolysaccharide stimulates the MyD88-independent pathway and results in 
activation of IFN-regulatory factor 3 and the expression of a subset of 
lipopolysaccharide-inducible genes. J Immunol. 2001;167(10):5887-94. PubMed 
PMID: 11698465. 
199. Ke Y, Xu Y, Chen X, Feng S, Liu Z, Sun Y, Yao X, Li F, Zhu W, Gao L, Chen H, 
Du Z, Xie W, Xu X, Huang X, Liu J. 3D Chromatin Structures of Mature 
Gametes and Structural Reprogramming during Mammalian Embryogenesis. Cell. 
2017;170(2):367-81 e20. doi: 10.1016/j.cell.2017.06.029. PubMed PMID: 
28709003. 
200. Kent WJ, Zweig AS, Barber G, Hinrichs AS, Karolchik D. BigWig and BigBed: 
enabling browsing of large distributed datasets. Bioinformatics. 
2010;26(17):2204-7. doi: 10.1093/bioinformatics/btq351. PubMed PMID: 
20639541; PMCID: PMC2922891. 
201. Keshet I, Lieman-Hurwitz J, Cedar H. DNA methylation affects the formation of 
active chromatin. Cell. 1986;44(4):535-43. PubMed PMID: 3456276. 
202. Ketscher L, Hannss R, Morales DJ, Basters A, Guerra S, Goldmann T, Hausmann 
A, Prinz M, Naumann R, Pekosz A, Utermohlen O, Lenschow DJ, Knobeloch KP. 
Selective inactivation of USP18 isopeptidase activity in vivo enhances ISG15 
conjugation and viral resistance. Proc Natl Acad Sci U S A. 2015;112(5):1577-82. 
doi: 10.1073/pnas.1412881112. PubMed PMID: 25605921; PMCID: 4321242. 
 204 
203. Khan A, Mathelier A, Zhang X. Super-enhancers are transcriptionally more active 
and cell type-specific than stretch enhancers. Epigenetics. 2018;13(9):910-22. doi: 
10.1080/15592294.2018.1514231. PubMed PMID: 30169995; PMCID: 
PMC6284781. 
204. Khan SA, Reddy D, Gupta S. Global histone post-translational modifications and 
cancer: Biomarkers for diagnosis, prognosis and treatment? World J Biol Chem. 
2015;6(4):333-45. doi: 10.4331/wjbc.v6.i4.333. PubMed PMID: 26629316; 
PMCID: PMC4657128. 
205. Khorasanizadeh S. The nucleosome: from genomic organization to genomic 
regulation. Cell. 2004;116(2):259-72. PubMed PMID: 14744436. 
206. Kimmins S, Sassone-Corsi P. Chromatin remodelling and epigenetic features of 
germ cells. Nature. 2005;434(7033):583-9. doi: 10.1038/nature03368. PubMed 
PMID: 15800613. 
207. Koenig A, Linhart T, Schlengemann K, Reutlinger K, Wegele J, Adler G, Singh 
G, Hofmann L, Kunsch S, Buch T, Schafer E, Gress TM, Fernandez-Zapico ME, 
Ellenrieder V. NFAT-induced histone acetylation relay switch promotes c-Myc-
dependent growth in pancreatic cancer cells. Gastroenterology. 
2010;138(3):1189-99 e1-2. doi: 10.1053/j.gastro.2009.10.045. PubMed PMID: 
19900447; PMCID: PMC2895621. 
208. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, 
Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, 
Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, 
Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, 
Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, 
Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Cancer Genome 
Atlas Research N, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis 
Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the 
TGF-beta Superfamily. Cell Syst. 2018;7(4):422-37 e7. doi: 
10.1016/j.cels.2018.08.010. PubMed PMID: 30268436. 
209. Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, 
Suurmeijer AJ, Bischoff R, Gietema JA, de Jong S. Cytoplasmic p21 expression 
levels determine cisplatin resistance in human testicular cancer. J Clin Invest. 
2010;120(10):3594-605. doi: 10.1172/JCI41939. PubMed PMID: 20811155; 
PMCID: PMC2947220. 
210. Kouzarides T. Chromatin modifications and their function. Cell. 
2007;128(4):693-705. doi: 10.1016/j.cell.2007.02.005. PubMed PMID: 
17320507. 
211. Kreth G, Finsterle J, von Hase J, Cremer M, Cremer C. Radial arrangement of 
chromosome territories in human cell nuclei: a computer model approach based 
on gene density indicates a probabilistic global positioning code. Biophys J. 
2004;86(5):2803-12. doi: 10.1016/S0006-3495(04)74333-7. PubMed PMID: 
15111398; PMCID: PMC1304150. 
212. Krumlauf R. Hox genes in vertebrate development. Cell. 1994;78(2):191-201. 
PubMed PMID: 7913880. 
213. Kumar R, Li DQ, Muller S, Knapp S. Epigenomic regulation of oncogenesis by 
 205 
chromatin remodeling. Oncogene. 2016;35(34):4423-36. doi: 
10.1038/onc.2015.513. PubMed PMID: 26804164. 
214. Kuno G. Persistence of arboviruses and antiviral antibodies in vertebrate hosts: its 
occurrence and impacts. Rev Med Virol. 2001;11(3):165-90. PubMed PMID: 
11376480. 
215. Kunz TH, and Linda F. Lumsden. Bat Ecology. Kunz TH, and M. Brock Fenton, 
editor. Chicago: The University of Chicago Press; 2003. 3-89 p. 
216. Kyriazis AA, Kyriazis AP, Sternberg CN, Sloane NH, Loveless JD. 
Morphological, biological, biochemical, and karyotypic characteristics of human 
pancreatic ductal adenocarcinoma Capan-2 in tissue culture and the nude mouse. 
Cancer Res. 1986;46(11):5810-5. PubMed PMID: 3019537. 
217. Kyriazis AP, Kyriazis AA, Scarpelli DG, Fogh J, Rao MS, Lepera R. Human 
pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: 
morphologic, biologic, and biochemical characteristics. Am J Pathol. 
1982;106(2):250-60. PubMed PMID: 6278935; PMCID: PMC1916189. 
218. Lai F, Orom UA, Cesaroni M, Beringer M, Taatjes DJ, Blobel GA, Shiekhattar R. 
Activating RNAs associate with Mediator to enhance chromatin architecture and 
transcription. Nature. 2013;494(7438):497-501. doi: 10.1038/nature11884. 
PubMed PMID: 23417068; PMCID: PMC4109059. 
219. Lam QL, Lu L. Role of leptin in immunity. Cell Mol Immunol. 2007;4(1):1-13. 
PubMed PMID: 17349207. 
220. Lamond AI, Earnshaw WC. Structure and function in the nucleus. Science. 
1998;280(5363):547-53. PubMed PMID: 9554838. 
221. Lan X, Farnham PJ, Jin VX. Uncovering transcription factor modules using one- 
and three-dimensional analyses. J Biol Chem. 2012;287(37):30914-21. doi: 
10.1074/jbc.R111.309229. PubMed PMID: 22952238; PMCID: PMC3438924. 
222. Lan X, Witt H, Katsumura K, Ye Z, Wang Q, Bresnick EH, Farnham PJ, Jin VX. 
Integration of Hi-C and ChIP-seq data reveals distinct types of chromatin 
linkages. Nucleic Acids Res. 2012;40(16):7690-704. doi: 10.1093/nar/gks501. 
PubMed PMID: 22675074; PMCID: PMC3439894. 
223. Lanczky A, Nagy A, Bottai G, Munkacsy G, Szabo A, Santarpia L, Gyorffy B. 
miRpower: a web-tool to validate survival-associated miRNAs utilizing 
expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 
2016;160(3):439-46. doi: 10.1007/s10549-016-4013-7. PubMed PMID: 
27744485. 
224. Lanfear R, Calcott B, Ho SY, Guindon S. Partitionfinder: combined selection of 
partitioning schemes and substitution models for phylogenetic analyses. Mol Biol 
Evol. 2012;29(6):1695-701. doi: 10.1093/molbev/mss020. PubMed PMID: 
22319168. 
225. Langevin C, van der Aa LM, Houel A, Torhy C, Briolat V, Lunazzi A, Harmache 
A, Bremont M, Levraud JP, Boudinot P. Zebrafish ISG15 exerts a strong antiviral 
activity against RNA and DNA viruses and regulates the interferon response. J 
Virol. 2013;87(18):10025-36. doi: 10.1128/JVI.01294-12. PubMed PMID: 
23824820; PMCID: 3753986. 
226. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat 
 206 
Methods. 2012;9(4):357-9. doi: 10.1038/nmeth.1923. PubMed PMID: 22388286; 
PMCID: PMC3322381. 
227. Lanier LL. DAP10- and DAP12-associated receptors in innate immunity. 
Immunol Rev. 2009;227(1):150-60. doi: 10.1111/j.1600-065X.2008.00720.x. 
PubMed PMID: 19120482; PMCID: 2794881. 
228. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, 
Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, 
McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, 
Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortes ML, Auclair D, Saksena 
G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, 
Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, 
Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, 
Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts 
CWM, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, 
Gordenin DA, Sunyaev S, Lander ES, Getz G. Mutational heterogeneity in cancer 
and the search for new cancer-associated genes. Nature. 2013;499(7457):214-8. 
doi: 10.1038/nature12213. PubMed PMID: 23770567; PMCID: PMC3919509. 
229. Le Dily F, Bau D, Pohl A, Vicent GP, Serra F, Soronellas D, Castellano G, 
Wright RH, Ballare C, Filion G, Marti-Renom MA, Beato M. Distinct structural 
transitions of chromatin topological domains correlate with coordinated hormone-
induced gene regulation. Genes Dev. 2014;28(19):2151-62. doi: 
10.1101/gad.241422.114. PubMed PMID: 25274727; PMCID: PMC4180976. 
230. Le Y, Zhou Y, Iribarren P, Wang J. Chemokines and chemokine receptors: their 
manifold roles in homeostasis and disease. Cell Mol Immunol. 2004;1(2):95-104. 
PubMed PMID: 16212895. 
231. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell 
costimulation. Annu Rev Immunol. 1996;14:233-58. doi: 
10.1146/annurev.immunol.14.1.233. PubMed PMID: 8717514. 
232. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell. 
2007;128(4):707-19. doi: 10.1016/j.cell.2007.01.015. PubMed PMID: 17320508. 
233. Li G, Ruan X, Auerbach RK, Sandhu KS, Zheng M, Wang P, Poh HM, Goh Y, 
Lim J, Zhang J, Sim HS, Peh SQ, Mulawadi FH, Ong CT, Orlov YL, Hong S, 
Zhang Z, Landt S, Raha D, Euskirchen G, Wei CL, Ge W, Wang H, Davis C, 
Fisher-Aylor KI, Mortazavi A, Gerstein M, Gingeras T, Wold B, Sun Y, 
Fullwood MJ, Cheung E, Liu E, Sung WK, Snyder M, Ruan Y. Extensive 
promoter-centered chromatin interactions provide a topological basis for 
transcription regulation. Cell. 2012;148(1-2):84-98. doi: 
10.1016/j.cell.2011.12.014. PubMed PMID: 22265404; PMCID: PMC3339270. 
234. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics. 2009;25(14):1754-60. doi: 
10.1093/bioinformatics/btp324. PubMed PMID: 19451168; PMCID: 
PMC2705234. 
235. Li L, Lyu X, Hou C, Takenaka N, Nguyen HQ, Ong CT, Cubenas-Potts C, Hu M, 
Lei EP, Bosco G, Qin ZS, Corces VG. Widespread rearrangement of 3D 
chromatin organization underlies polycomb-mediated stress-induced silencing. 
 207 
Mol Cell. 2015;58(2):216-31. doi: 10.1016/j.molcel.2015.02.023. PubMed PMID: 
25818644; PMCID: PMC4402144. 
236. Li W, Gong K, Li Q, Alber F, Zhou XJ. Hi-Corrector: a fast, scalable and 
memory-efficient package for normalizing large-scale Hi-C data. Bioinformatics. 
2015;31(6):960-2. doi: 10.1093/bioinformatics/btu747. PubMed PMID: 
25391400; PMCID: PMC4380031. 
237. Libbrecht MW, Ay F, Hoffman MM, Gilbert DM, Bilmes JA, Noble WS. Joint 
annotation of chromatin state and chromatin conformation reveals relationships 
among domain types and identifies domains of cell-type-specific expression. 
Genome Res. 2015;25(4):544-57. doi: 10.1101/gr.184341.114. PubMed PMID: 
25677182; PMCID: PMC4381526. 
238. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a 
continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine 
pancreas. Int J Cancer. 1975;15(5):741-7. PubMed PMID: 1140870. 
239. Lieberman-Aiden E, van Berkum NL, Williams L, Imakaev M, Ragoczy T, 
Telling A, Amit I, Lajoie BR, Sabo PJ, Dorschner MO, Sandstrom R, Bernstein 
B, Bender MA, Groudine M, Gnirke A, Stamatoyannopoulos J, Mirny LA, 
Lander ES, Dekker J. Comprehensive mapping of long-range interactions reveals 
folding principles of the human genome. Science. 2009;326(5950):289-93. doi: 
10.1126/science.1181369. PubMed PMID: 19815776; PMCID: PMC2858594. 
240. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich 
L, Barnett DH, Stossi F, Yeo A, George J, Kuznetsov VA, Lee YK, Charn TH, 
Palanisamy N, Miller LD, Cheung E, Katzenellenbogen BS, Ruan Y, Bourque G, 
Wei CL, Liu ET. Whole-genome cartography of estrogen receptor alpha binding 
sites. PLoS Genet. 2007;3(6):e87. doi: 10.1371/journal.pgen.0030087. PubMed 
PMID: 17542648; PMCID: PMC1885282. 
241. Lin JY, Hu GB, Liu DH, Li S, Liu QM, Zhang SC. Molecular cloning and 
expression analysis of interferon stimulated gene 15 (ISG15) in turbot, 
Scophthalmus maximus. Fish Shellfish Immunol. 2015;45(2):895-900. doi: 
10.1016/j.fsi.2015.05.050. PubMed PMID: 26095010. 
242. Litt M, Qiu Y, Huang S. Histone arginine methylations: their roles in chromatin 
dynamics and transcriptional regulation. Biosci Rep. 2009;29(2):131-41. doi: 
10.1042/BSR20080176. PubMed PMID: 19220199; PMCID: PMC5433800. 
243. Litzenburger UM, Buenrostro JD, Wu B, Shen Y, Sheffield NC, Kathiria A, 
Greenleaf WJ, Chang HY. Single-cell epigenomic variability reveals functional 
cancer heterogeneity. Genome Biol. 2017;18(1):15. doi: 10.1186/s13059-016-
1133-7. PubMed PMID: 28118844; PMCID: PMC5259890. 
244. Liu Y, Chen H, Zheng P, Zheng Y, Luo Q, Xie G, Ma Y, Shen L. ICG-001 
suppresses growth of gastric cancer cells and reduces chemoresistance of cancer 
stem cell-like population. J Exp Clin Cancer Res. 2017;36(1):125. doi: 
10.1186/s13046-017-0595-0. PubMed PMID: 28893318; PMCID: PMC5594604. 
245. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands 
in cancer. Curr Mol Med. 2007;7(8):777-89. PubMed PMID: 18331236. 
246. Lomberk G, Blum Y, Nicolle R, Nair A, Gaonkar KS, Marisa L, Mathison A, Sun 
Z, Yan H, Elarouci N, Armenoult L, Ayadi M, Ordog T, Lee JH, Oliver G, Klee 
 208 
E, Moutardier V, Gayet O, Bian B, Duconseil P, Gilabert M, Bigonnet M, Garcia 
S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Secq V, De 
Reynies A, Dusetti N, Iovanna J, Urrutia R. Distinct epigenetic landscapes 
underlie the pathobiology of pancreatic cancer subtypes. Nat Commun. 
2018;9(1):1978. doi: 10.1038/s41467-018-04383-6. PubMed PMID: 29773832; 
PMCID: PMC5958058. 
247. Love MI, Huber W, Anders S. Moderated estimation of fold change and 
dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 
10.1186/s13059-014-0550-8. PubMed PMID: 25516281; PMCID: PMC4302049. 
248. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, 
Young RA. Selective inhibition of tumor oncogenes by disruption of super-
enhancers. Cell. 2013;153(2):320-34. doi: 10.1016/j.cell.2013.03.036. PubMed 
PMID: 23582323; PMCID: PMC3760967. 
249. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and 
remodeling in development and disease. Cold Spring Harb Perspect Biol. 
2011;3(12). doi: 10.1101/cshperspect.a005058. PubMed PMID: 21917992; 
PMCID: 3225943. 
250. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure 
of the nucleosome core particle at 2.8 A resolution. Nature. 1997;389(6648):251-
60. doi: 10.1038/38444. PubMed PMID: 9305837. 
251. Luis AD, Hayman DT, O'Shea TJ, Cryan PM, Gilbert AT, Pulliam JR, Mills JN, 
Timonin ME, Willis CK, Cunningham AA, Fooks AR, Rupprecht CE, Wood JL, 
Webb CT. A comparison of bats and rodents as reservoirs of zoonotic viruses: are 
bats special? Proc Biol Sci. 2013;280(1756):20122753. doi: 
10.1098/rspb.2012.2753. PubMed PMID: 23378666; PMCID: 3574368. 
252. Lupianez DG, Kraft K, Heinrich V, Krawitz P, Brancati F, Klopocki E, Horn D, 
Kayserili H, Opitz JM, Laxova R, Santos-Simarro F, Gilbert-Dussardier B, 
Wittler L, Borschiwer M, Haas SA, Osterwalder M, Franke M, Timmermann B, 
Hecht J, Spielmann M, Visel A, Mundlos S. Disruptions of topological chromatin 
domains cause pathogenic rewiring of gene-enhancer interactions. Cell. 
2015;161(5):1012-25. doi: 10.1016/j.cell.2015.04.004. PubMed PMID: 
25959774; PMCID: PMC4791538. 
253. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, Park JK, Wang H, 
Peng Y, Jiang W, He TC. Wnt/beta-catenin signaling pathway as a novel cancer 
drug target. Curr Cancer Drug Targets. 2004;4(8):653-71. PubMed PMID: 
15578921. 
254. Ma H, Nguyen C, Lee KS, Kahn M. Differential roles for the coactivators CBP 
and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene. 
2005;24(22):3619-31. doi: 10.1038/sj.onc.1208433. PubMed PMID: 15782138. 
255. Mack SC, Pajtler KW, Chavez L, Okonechnikov K, Bertrand KC, Wang X, Erkek 
S, Federation A, Song A, Lee C, Wang X, McDonald L, Morrow JJ, Saiakhova A, 
Sin-Chan P, Wu Q, Michaelraj KA, Miller TE, Hubert CG, Ryzhova M, Garzia L, 
Donovan L, Dombrowski S, Factor DC, Luu B, Valentim CLL, Gimple RC, 
Morton A, Kim L, Prager BC, Lee JJY, Wu X, Zuccaro J, Thompson Y, Holgado 
BL, Reimand J, Ke SQ, Tropper A, Lai S, Vijayarajah S, Doan S, Mahadev V, 
 209 
Minan AF, Grobner SN, Lienhard M, Zapatka M, Huang Z, Aldape KD, 
Carcaboso AM, Houghton PJ, Keir ST, Milde T, Witt H, Li Y, Li CJ, Bian XW, 
Jones DTW, Scott I, Singh SK, Huang A, Dirks PB, Bouffet E, Bradner JE, 
Ramaswamy V, Jabado N, Rutka JT, Northcott PA, Lupien M, Lichter P, 
Korshunov A, Scacheri PC, Pfister SM, Kool M, Taylor MD, Rich JN. 
Therapeutic targeting of ependymoma as informed by oncogenic enhancer 
profiling. Nature. 2018;553(7686):101-5. doi: 10.1038/nature25169. PubMed 
PMID: 29258295; PMCID: PMC5993422. 
256. Magnani L, Stoeck A, Zhang X, Lanczky A, Mirabella AC, Wang TL, Gyorffy B, 
Lupien M. Genome-wide reprogramming of the chromatin landscape underlies 
endocrine therapy resistance in breast cancer. Proc Natl Acad Sci U S A. 
2013;110(16):E1490-9. doi: 10.1073/pnas.1219992110. PubMed PMID: 
23576735; PMCID: PMC3631697. 
257. Marella NV, Bhattacharya S, Mukherjee L, Xu J, Berezney R. Cell type specific 
chromosome territory organization in the interphase nucleus of normal and cancer 
cells. J Cell Physiol. 2009;221(1):130-8. doi: 10.1002/jcp.21836. PubMed PMID: 
19496171. 
258. Marmorstein R. Structure of histone acetyltransferases. J Mol Biol. 
2001;311(3):433-44. doi: 10.1006/jmbi.2001.4859. PubMed PMID: 11492997. 
259. Marsman J, Horsfield JA. Long distance relationships: enhancer-promoter 
communication and dynamic gene transcription. Biochim Biophys Acta. 
2012;1819(11-12):1217-27. doi: 10.1016/j.bbagrm.2012.10.008. PubMed PMID: 
23124110. 
260. Martinez-Sobrido L, Giannakas P, Cubitt B, Garcia-Sastre A, de la Torre JC. 
Differential inhibition of type I interferon induction by arenavirus nucleoproteins. 
J Virol. 2007;81(22):12696-703. doi: 10.1128/JVI.00882-07. PubMed PMID: 
17804508; PMCID: PMC2168988. 
261. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, Fan G, Sun YE. DNA 
methylation-related chromatin remodeling in activity-dependent BDNF gene 
regulation. Science. 2003;302(5646):890-3. doi: 10.1126/science.1090842. 
PubMed PMID: 14593184. 
262. Marwick JA, Kirkham PA, Stevenson CS, Danahay H, Giddings J, Butler K, 
Donaldson K, Macnee W, Rahman I. Cigarette smoke alters chromatin 
remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell 
Mol Biol. 2004;31(6):633-42. doi: 10.1165/rcmb.2004-0006OC. PubMed PMID: 
15333327. 
263. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss 
H, Rimawi M, Schiff R. Tamoxifen resistance in breast tumors is driven by 
growth factor receptor signaling with repression of classic estrogen receptor 
genomic function. Cancer Res. 2008;68(3):826-33. doi: 10.1158/0008-
5472.CAN-07-2707. PubMed PMID: 18245484. 
264. Matsui T, Segall J, Weil PA, Roeder RG. Multiple factors required for accurate 
initiation of transcription by purified RNA polymerase II. J Biol Chem. 
1980;255(24):11992-6. PubMed PMID: 7440580. 
265. Maurano MT, Wang H, John S, Shafer A, Canfield T, Lee K, 
 210 
Stamatoyannopoulos JA. Role of DNA Methylation in Modulating Transcription 
Factor Occupancy. Cell Rep. 2015;12(7):1184-95. doi: 
10.1016/j.celrep.2015.07.024. PubMed PMID: 26257180. 
266. McCullough CE, Marmorstein R. Molecular Basis for Histone Acetyltransferase 
Regulation by Binding Partners, Associated Domains, and Autoacetylation. ACS 
Chem Biol. 2016;11(3):632-42. doi: 10.1021/acschembio.5b00841. PubMed 
PMID: 26555232; PMCID: PMC5067162. 
267. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, 
Bejerano G. GREAT improves functional interpretation of cis-regulatory regions. 
Nat Biotechnol. 2010;28(5):495-501. doi: 10.1038/nbt.1630. PubMed PMID: 
20436461; PMCID: PMC4840234. 
268. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. 
Nature. 2013;501(7467):328-37. doi: 10.1038/nature12624. PubMed PMID: 
24048065; PMCID: PMC4521623. 
269. Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in 
epigenetic regulation. Nat Struct Mol Biol. 2013;20(3):300-7. doi: 
10.1038/nsmb.2480. PubMed PMID: 23463315. 
270. Miki T, Yasuda SY, Kahn M. Wnt/beta-catenin signaling in embryonic stem cell 
self-renewal and somatic cell reprogramming. Stem Cell Rev. 2011;7(4):836-46. 
doi: 10.1007/s12015-011-9275-1. PubMed PMID: 21603945. 
271. Milazzo ML, Barragan-Gomez A, Hanson JD, Estrada-Franco JG, Arellano E, 
Gonzalez-Cozatl FX, Fernandez-Salas I, Ramirez-Aguilar F, Rogers DS, Bradley 
RD, Fulhorst CF. Antibodies to Tacaribe serocomplex viruses (family 
Arenaviridae, genus Arenavirus) in cricetid rodents from new Mexico, Texas, and 
Mexico. Vector Borne Zoonotic Dis. 2010;10(6):629-37. Epub 2010/08/28. doi: 
10.1089/vbz.2009.0206. PubMed PMID: 20795917. 
272. Misteli T, Soutoglou E. The emerging role of nuclear architecture in DNA repair 
and genome maintenance. Nat Rev Mol Cell Biol. 2009;10(4):243-54. doi: 
10.1038/nrm2651. PubMed PMID: 19277046; PMCID: PMC3478884. 
273. Miyamoto MM. A congruence study of molecular and morphological data for 
Eutherian mammals. Mol Phylogenet Evol. 1996;6(3):373-90. doi: DOI 
10.1006/mpev.1996.0087. PubMed PMID: WOS:A1996WB05700005. 
274. Moisan S, Levon S, Cornec-Le Gall E, Le Meur Y, Audrezet MP, Dostie J, Ferec 
C. Novel long-range regulatory mechanisms controlling PKD2 gene expression. 
BMC Genomics. 2018;19(1):515. doi: 10.1186/s12864-018-4892-6. PubMed 
PMID: 29986647; PMCID: PMC6038307. 
275. Morera L, Lubbert M, Jung M. Targeting histone methyltransferases and 
demethylases in clinical trials for cancer therapy. Clin Epigenetics. 2016;8:57. 
doi: 10.1186/s13148-016-0223-4. PubMed PMID: 27222667; PMCID: 
PMC4877953. 
276. Morris JPt, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted 
developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 
2010;10(10):683-95. doi: 10.1038/nrc2899. PubMed PMID: 20814421; PMCID: 
PMC4085546. 
277. Mostoslavsky R, Bardeesy N. Reprogramming Enhancers to Drive Metastasis. 
 211 
Cell. 2017;170(5):823-5. doi: 10.1016/j.cell.2017.08.010. PubMed PMID: 
28841414. 
278. Mourad R, Hsu PY, Juan L, Shen C, Koneru P, Lin H, Liu Y, Nephew K, Huang 
TH, Li L. Estrogen induces global reorganization of chromatin structure in human 
breast cancer cells. PLoS One. 2014;9(12):e113354. doi: 
10.1371/journal.pone.0113354. PubMed PMID: 25470140; PMCID: 
PMC4255042. 
279. Mu GG, Zhang LL, Li HY, Liao Y, Yu HG. Thymoquinone Pretreatment 
Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine 
Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways 
in Pancreatic Cancer. Dig Dis Sci. 2015;60(4):1067-80. doi: 10.1007/s10620-014-
3394-x. PubMed PMID: 25344906. 
280. Murphy WJ, Eizirik E, Johnson WE, Zhang YP, Ryder OA, O'Brien SJ. 
Molecular phylogenetics and the origins of placental mammals. Nature. 
2001;409(6820):614-8. doi: 10.1038/35054550. PubMed PMID: 11214319. 
281. Murthy D, Attri KS, Singh PK. Phosphoinositide 3-Kinase Signaling Pathway in 
Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. 
Front Physiol. 2018;9:335. doi: 10.3389/fphys.2018.00335. PubMed PMID: 
29670543; PMCID: PMC5893816. 
282. Murugesapillai D, McCauley MJ, Maher LJ, 3rd, Williams MC. Single-molecule 
studies of high-mobility group B architectural DNA bending proteins. Biophys 
Rev. 2017;9(1):17-40. doi: 10.1007/s12551-016-0236-4. PubMed PMID: 
28303166; PMCID: PMC5331113. 
283. Muscat GE, Eriksson NA, Byth K, Loi S, Graham D, Jindal S, Davis MJ, Clyne 
C, Funder JW, Simpson ER, Ragan MA, Kuczek E, Fuller PJ, Tilley WD, 
Leedman PJ, Clarke CL. Research resource: nuclear receptors as transcriptome: 
discriminant and prognostic value in breast cancer. Mol Endocrinol. 
2013;27(2):350-65. doi: 10.1210/me.2012-1265. PubMed PMID: 23292282; 
PMCID: PMC5417325. 
284. Nakamoto M, Matsuyama A, Shiba E, Shibuya R, Kasai T, Yamaguchi K, 
Hisaoka M. Prognostic significance of WNT signaling in pancreatic ductal 
adenocarcinoma. Virchows Arch. 2014;465(4):401-8. doi: 10.1007/s00428-014-
1642-2. PubMed PMID: 25146168. 
285. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. 
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a 
histone deacetylase complex. Nature. 1998;393(6683):386-9. doi: 10.1038/30764. 
PubMed PMID: 9620804. 
286. Naumova N, Dekker J. Integrating one-dimensional and three-dimensional maps 
of genomes. J Cell Sci. 2010;123(Pt 12):1979-88. doi: 10.1242/jcs.051631. 
PubMed PMID: 20519580; PMCID: PMC2880011. 
287. Navarro L, David M. p38-dependent activation of interferon regulatory factor 3 
by lipopolysaccharide. J Biol Chem. 1999;274(50):35535-8. PubMed PMID: 
10585427. 
288. Nebbioso A, Tambaro FP, Dell'Aversana C, Altucci L. Cancer epigenetics: 
Moving forward. PLoS Genet. 2018;14(6):e1007362. doi: 
 212 
10.1371/journal.pgen.1007362. PubMed PMID: 29879107; PMCID: 
PMC5991666. 
289. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of 
MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 
2011;11(12):823-36. doi: 10.1038/nri3084. PubMed PMID: 22076556. 
290. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, 
Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo 
WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson 
RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of 
breast cancer cell lines for the study of functionally distinct cancer subtypes. 
Cancer Cell. 2006;10(6):515-27. doi: 10.1016/j.ccr.2006.10.008. PubMed PMID: 
17157791; PMCID: PMC2730521. 
291. Ng HH, Bird A. DNA methylation and chromatin modification. Curr Opin Genet 
Dev. 1999;9(2):158-63. PubMed PMID: 10322130. 
292. Nora EP, Goloborodko A, Valton AL, Gibcus JH, Uebersohn A, Abdennur N, 
Dekker J, Mirny LA, Bruneau BG. Targeted Degradation of CTCF Decouples 
Local Insulation of Chromosome Domains from Genomic Compartmentalization. 
Cell. 2017;169(5):930-44 e22. doi: 10.1016/j.cell.2017.05.004. PubMed PMID: 
28525758; PMCID: PMC5538188. 
293. Nora EP, Lajoie BR, Schulz EG, Giorgetti L, Okamoto I, Servant N, Piolot T, van 
Berkum NL, Meisig J, Sedat J, Gribnau J, Barillot E, Bluthgen N, Dekker J, 
Heard E. Spatial partitioning of the regulatory landscape of the X-inactivation 
centre. Nature. 2012;485(7398):381-5. doi: 10.1038/nature11049. PubMed PMID: 
22495304; PMCID: PMC3555144. 
294. O'Geen H, Frietze S, Farnham PJ. Using ChIP-seq technology to identify targets 
of zinc finger transcription factors. Methods Mol Biol. 2010;649:437-55. doi: 
10.1007/978-1-60761-753-2_27. PubMed PMID: 20680851; PMCID: 
PMC4151297. 
295. O'Malley M, King AN, Conte M, Ellingrod VL, Ramnath N. Effects of cigarette 
smoking on metabolism and effectiveness of systemic therapy for lung cancer. J 
Thorac Oncol. 2014;9(7):917-26. doi: 10.1097/JTO.0000000000000191. PubMed 
PMID: 24926542. 
296. O'Shea TJ, Cryan PM, Cunningham AA, Fooks AR, Hayman DT, Luis AD, Peel 
AJ, Plowright RK, Wood JL. Bat flight and zoonotic viruses. Emerg Infect Dis. 
2014;20(5):741-5. doi: 10.3201/eid2005.130539. PubMed PMID: 24750692; 
PMCID: 4012789. 
297. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The 
transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 
1996;87(5):953-9. PubMed PMID: 8945521. 
298. Oike T, Komachi M, Ogiwara H, Amornwichet N, Saitoh Y, Torikai K, Kubo N, 
Nakano T, Kohno T. C646, a selective small molecule inhibitor of histone 
acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic 
catastrophe. Radiother Oncol. 2014;111(2):222-7. doi: 
10.1016/j.radonc.2014.03.015. PubMed PMID: 24746574. 
299. Oliner JD, Andresen JM, Hansen SK, Zhou S, Tjian R. SREBP transcriptional 
 213 
activity is mediated through an interaction with the CREB-binding protein. Genes 
Dev. 1996;10(22):2903-11. PubMed PMID: 8918891. 
300. Omatsu T, Watanabe S, Akashi H, Yoshikawa Y. Biological characters of bats in 
relation to natural reservoir of emerging viruses. Comp Immunol Microbiol Infect 
Dis. 2007;30(5-6):357-74. Epub 2007/08/21. doi: S0147-9571(07)00048-3 [pii] 
3. 10.1016/j.cimid.2007.05.006. PubMed PMID: 17706776. 
301. Ono H, Basson MD, Ito H. P300 inhibition enhances gemcitabine-induced 
apoptosis of pancreatic cancer. Oncotarget. 2016;7(32):51301-10. doi: 
10.18632/oncotarget.10117. PubMed PMID: 27322077; PMCID: PMC5239476. 
302. Ono K, Demchak B, Ideker T. Cytoscape tools for the web age: D3.js and 
Cytoscape.js exporters. F1000Res. 2014;3:143. doi: 
10.12688/f1000research.4510.2. PubMed PMID: 25520778. 
303. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on 
growth of human breast cancer cells in athymic nude mice. Cancer Res. 
1985;45(2):584-90. PubMed PMID: 3967234. 
304. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling 
AE. The importance of tamoxifen metabolism in tamoxifen-stimulated breast 
tumor growth. Cancer Chemother Pharmacol. 1994;34(2):89-95. PubMed PMID: 
8194171. 
305. Osborne CS, Chakalova L, Brown KE, Carter D, Horton A, Debrand E, 
Goyenechea B, Mitchell JA, Lopes S, Reik W, Fraser P. Active genes 
dynamically colocalize to shared sites of ongoing transcription. Nat Genet. 
2004;36(10):1065-71. doi: 10.1038/ng1423. PubMed PMID: 15361872. 
306. Ouaissi M, Sielezneff I, Silvestre R, Sastre B, Bernard JP, Lafontaine JS, Payan 
MJ, Dahan L, Pirro N, Seitz JF, Mas E, Lombardo D, Ouaissi A. High histone 
deacetylase 7 (HDAC7) expression is significantly associated with 
adenocarcinomas of the pancreas. Ann Surg Oncol. 2008;15(8):2318-28. doi: 
10.1245/s10434-008-9940-z. PubMed PMID: 18506539. 
307. Oudet P, Gross-Bellard M, Chambon P. Electron microscopic and biochemical 
evidence that chromatin structure is a repeating unit. Cell. 1975;4(4):281-300. 
PubMed PMID: 1122558. 
308. Pal B, Bouras T, Shi W, Vaillant F, Sheridan JM, Fu N, Breslin K, Jiang K, 
Ritchie ME, Young M, Lindeman GJ, Smyth GK, Visvader JE. Global changes in 
the mammary epigenome are induced by hormonal cues and coordinated by Ezh2. 
Cell Rep. 2013;3(2):411-26. doi: 10.1016/j.celrep.2012.12.020. PubMed PMID: 
23375371. 
309. Papenfuss AT, Baker ML, Feng ZP, Tachedjian M, Crameri G, Cowled C, Ng J, 
Janardhana V, Field HE, Wang LF. The immune gene repertoire of an important 
viral reservoir, the Australian black flying fox. BMC Genomics. 2012;13:261. 
doi: 10.1186/1471-2164-13-261. PubMed PMID: 22716473; PMCID: 3436859. 
310. Parada LA, McQueen PG, Misteli T. Tissue-specific spatial organization of 
genomes. Genome Biol. 2004;5(7):R44. doi: 10.1186/gb-2004-5-7-r44. PubMed 
PMID: 15239829; PMCID: PMC463291. 
311. Parada LA, McQueen PG, Munson PJ, Misteli T. Conservation of relative 
chromosome positioning in normal and cancer cells. Curr Biol. 
 214 
2002;12(19):1692-7. PubMed PMID: 12361574. 
312. Parker SC, Stitzel ML, Taylor DL, Orozco JM, Erdos MR, Akiyama JA, van 
Bueren KL, Chines PS, Narisu N, Program NCS, Black BL, Visel A, Pennacchio 
LA, Collins FS, National Institutes of Health Intramural Sequencing Center 
Comparative Sequencing Program A, Authors NCSP. Chromatin stretch enhancer 
states drive cell-specific gene regulation and harbor human disease risk variants. 
Proc Natl Acad Sci U S A. 2013;110(44):17921-6. doi: 
10.1073/pnas.1317023110. PubMed PMID: 24127591; PMCID: PMC3816444. 
313. Pawan JL. Rabies in the vampire bat of Trinidad, with special reference to the 
clinical course and the latency of infection. Caribb Med J. 1959;21:137-56. 
PubMed PMID: 14431118. 
314. Perri F, Longo F, Giuliano M, Sabbatino F, Favia G, Ionna F, Addeo R, Della 
Vittoria Scarpati G, Di Lorenzo G, Pisconti S. Epigenetic control of gene 
expression: Potential implications for cancer treatment. Crit Rev Oncol Hematol. 
2017;111:166-72. doi: 10.1016/j.critrevonc.2017.01.020. PubMed PMID: 
28259291. 
315. Pettigrew JD, Jamieson BGM, Robson SK, Hall LS, Mcanally KI, Cooper HM. 
Phylogenetic Relations between Microbats, Megabats and Primates (Mammalia, 
Chiroptera and Primates). Philos T Roy Soc B. 1989;325(1229):489-559. doi: 
DOI 10.1098/rstb.1989.0102. PubMed PMID: WOS:A1989CD42900001. 
316. Phillips DM. The presence of acetyl groups of histones. Biochem J. 1963;87:258-
63. PubMed PMID: 13943142; PMCID: PMC1201885. 
317. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4(5). 
doi: 10.1101/cshperspect.a008052. PubMed PMID: 22438566; PMCID: 
PMC3331705. 
318. Portela A, Esteller M. Epigenetic modifications and human disease. Nat 
Biotechnol. 2010;28(10):1057-68. doi: 10.1038/nbt.1685. PubMed PMID: 
20944598. 
319. Principe DR, DeCant B, Mascarinas E, Wayne EA, Diaz AM, Akagi N, Hwang R, 
Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, Grippo PJ. 
TGFbeta Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis 
and Immune Evasion to Facilitate Tumorigenesis. Cancer Res. 2016;76(9):2525-
39. doi: 10.1158/0008-5472.CAN-15-1293. PubMed PMID: 26980767; PMCID: 
PMC4873388. 
320. Pythoud C, Rodrigo WW, Pasqual G, Rothenberger S, Martinez-Sobrido L, de la 
Torre JC, Kunz S. Arenavirus nucleoprotein targets interferon regulatory factor-
activating kinase IKKepsilon. J Virol. 2012;86(15):7728-38. doi: 
10.1128/JVI.00187-12. PubMed PMID: 22532683; PMCID: PMC3421673. 
321. Raghavan M, Bjorkman PJ. Fc receptors and their interactions with 
immunoglobulins. Annu Rev Cell Dev Biol. 1996;12:181-220. doi: 
10.1146/annurev.cellbio.12.1.181. PubMed PMID: 8970726. 
322. Ramani V, Shendure J, Duan Z. Understanding Spatial Genome Organization: 
Methods and Insights. Genomics Proteomics Bioinformatics. 2016;14(1):7-20. 
doi: 10.1016/j.gpb.2016.01.002. PubMed PMID: 26876719; PMCID: 
PMC4792841. 
 215 
323. Ramirez F, Ryan DP, Gruning B, Bhardwaj V, Kilpert F, Richter AS, Heyne S, 
Dundar F, Manke T. deepTools2: a next generation web server for deep-
sequencing data analysis. Nucleic Acids Res. 2016;44(W1):W160-5. doi: 
10.1093/nar/gkw257. PubMed PMID: 27079975; PMCID: PMC4987876. 
324. Ramos YF, Hestand MS, Verlaan M, Krabbendam E, Ariyurek Y, van Galen M, 
van Dam H, van Ommen GJ, den Dunnen JT, Zantema A, t Hoen PA. Genome-
wide assessment of differential roles for p300 and CBP in transcription regulation. 
Nucleic Acids Res. 2010;38(16):5396-408. doi: 10.1093/nar/gkq184. PubMed 
PMID: 20435671; PMCID: PMC2938195. 
325. Rao SS, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, 
Sanborn AL, Machol I, Omer AD, Lander ES, Aiden EL. A 3D map of the human 
genome at kilobase resolution reveals principles of chromatin looping. Cell. 
2014;159(7):1665-80. doi: 10.1016/j.cell.2014.11.021. PubMed PMID: 
25497547; PMCID: PMC5635824. 
326. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, Livingston DM. Distinct 
roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. 
Proc Natl Acad Sci U S A. 2002;99(23):14789-94. doi: 10.1073/pnas.232568499. 
PubMed PMID: 12397173; PMCID: PMC137497. 
327. Reines D, Conaway JW, Conaway RC. The RNA polymerase II general 
elongation factors. Trends Biochem Sci. 1996;21(9):351-5. PubMed PMID: 
8870500; PMCID: PMC3374595. 
328. Reiter F, Wienerroither S, Stark A. Combinatorial function of transcription factors 
and cofactors. Curr Opin Genet Dev. 2017;43:73-81. doi: 
10.1016/j.gde.2016.12.007. PubMed PMID: 28110180. 
329. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S. Frequency of Smad gene 
mutations in human cancers. Cancer Res. 1997;57(13):2578-80. PubMed PMID: 
9205057. 
330. Ris H, Kubai DF. Chromosome structure. Annu Rev Genet. 1970;4:263-94. doi: 
10.1146/annurev.ge.04.120170.001403. PubMed PMID: 4950239. 
331. Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, Zeng T, Euskirchen G, 
Bernier B, Varhol R, Delaney A, Thiessen N, Griffith OL, He A, Marra M, 
Snyder M, Jones S. Genome-wide profiles of STAT1 DNA association using 
chromatin immunoprecipitation and massively parallel sequencing. Nat Methods. 
2007;4(8):651-7. doi: 10.1038/nmeth1068. PubMed PMID: 17558387. 
332. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, Jones 
PA. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate 
mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids 
Res. 1999;27(11):2291-8. PubMed PMID: 10325416; PMCID: PMC148793. 
333. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, 
Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-6. doi: 
10.1038/nbt.1754. PubMed PMID: 21221095; PMCID: PMC3346182. 
334. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for 
differential expression analysis of digital gene expression data. Bioinformatics. 
2010;26(1):139-40. doi: 10.1093/bioinformatics/btp616. PubMed PMID: 
19910308; PMCID: PMC2796818. 
 216 
335. Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino 
L, Tiriac H, Young CM, Miyabayashi K, Filippini D, Creighton B, Burkhart RA, 
Buscaglia JM, Kim EJ, Grem JL, Lazenby AJ, Grunkemeyer JA, Hollingsworth 
MA, Grandgenett PM, Egeblad M, Park Y, Tuveson DA, Vakoc CR. Enhancer 
Reprogramming Promotes Pancreatic Cancer Metastasis. Cell. 2017;170(5):875-
88 e20. doi: 10.1016/j.cell.2017.07.007. PubMed PMID: 28757253; PMCID: 
PMC5726277. 
336. Roeder RG, Rutter WJ. Multiple forms of DNA-dependent RNA polymerase in 
eukaryotic organisms. Nature. 1969;224(5216):234-7. PubMed PMID: 5344598. 
337. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, 
Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, 
Carroll JS. Differential oestrogen receptor binding is associated with clinical 
outcome in breast cancer. Nature. 2012;481(7381):389-93. doi: 
10.1038/nature10730. PubMed PMID: 22217937; PMCID: PMC3272464. 
338. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-
repressor, DMAP1, to form a complex at replication foci. Nat Genet. 
2000;25(3):269-77. doi: 10.1038/77023. PubMed PMID: 10888872. 
339. Rozengurt E, Sinnett-Smith J, Eibl G. Yes-associated protein (YAP) in pancreatic 
cancer: at the epicenter of a targetable signaling network associated with patient 
survival. Signal Transduct Target Ther. 2018;3:11. doi: 10.1038/s41392-017-
0005-2. PubMed PMID: 29682330; PMCID: PMC5908807. 
340. Russell J, Zomerdijk JC. RNA-polymerase-I-directed rDNA transcription, life and 
works. Trends Biochem Sci. 2005;30(2):87-96. doi: 10.1016/j.tibs.2004.12.008. 
PubMed PMID: 15691654; PMCID: PMC3858833. 
341. Ryu D, Joung JG, Kim NK, Kim KT, Park WY. Deciphering intratumor 
heterogeneity using cancer genome analysis. Hum Genet. 2016;135(6):635-42. 
doi: 10.1007/s00439-016-1670-x. PubMed PMID: 27126234. 
342. Sandi MJ, Hamidi T, Malicet C, Cano C, Loncle C, Pierres A, Dagorn JC, 
Iovanna JL. p8 expression controls pancreatic cancer cell migration, invasion, 
adhesion, and tumorigenesis. J Cell Physiol. 2011;226(12):3442-51. doi: 
10.1002/jcp.22702. PubMed PMID: 21344397. 
343. Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range interaction landscape of 
gene promoters. Nature. 2012;489(7414):109-13. doi: 10.1038/nature11279. 
PubMed PMID: 22955621; PMCID: PMC3555147. 
344. Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, Nakao K, Nakaya T, 
Katsuki M, Noguchi S, Tanaka N, Taniguchi T. Distinct and essential roles of 
transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta 
gene induction. Immunity. 2000;13(4):539-48. PubMed PMID: 11070172. 
345. Sayler KA, Barbet AF, Chamberlain C, Clapp WL, Alleman R, Loeb JC, 
Lednicky JA. Isolation of Tacaribe virus, a Caribbean arenavirus, from host-
seeking Amblyomma americanum ticks in Florida. PLoS One. 
2014;9(12):e115769. doi: 10.1371/journal.pone.0115769. PubMed PMID: 
25536075; PMCID: 4275251. 
346. Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao 
W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman 
 217 
RN, Bernard B, Grandori C, Cancer Genome Atlas N. Pan-cancer Alterations of 
the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. 
Cell Syst. 2018;6(3):282-300 e2. doi: 10.1016/j.cels.2018.03.003. PubMed PMID: 
29596783; PMCID: PMC5892207. 
347. Schneider G, Kramer OH, Schmid RM, Saur D. Acetylation as a transcriptional 
control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma. J 
Gastrointest Cancer. 2011;42(2):85-92. doi: 10.1007/s12029-011-9257-1. 
PubMed PMID: 21271301. 
348. Schoenfelder S, Sexton T, Chakalova L, Cope NF, Horton A, Andrews S, 
Kurukuti S, Mitchell JA, Umlauf D, Dimitrova DS, Eskiw CH, Luo Y, Wei CL, 
Ruan Y, Bieker JJ, Fraser P. Preferential associations between co-regulated genes 
reveal a transcriptional interactome in erythroid cells. Nat Genet. 2010;42(1):53-
61. doi: 10.1038/ng.496. PubMed PMID: 20010836; PMCID: PMC3237402. 
349. Schoumacher RA, Ram J, Iannuzzi MC, Bradbury NA, Wallace RW, Hon CT, 
Kelly DR, Schmid SM, Gelder FB, Rado TA, et al. A cystic fibrosis pancreatic 
adenocarcinoma cell line. Proc Natl Acad Sci U S A. 1990;87(10):4012-6. 
PubMed PMID: 1692630; PMCID: PMC54034. 
350. Schountz T. Immunology of bats and their viruses: challenges and opportunities. 
Viruses. 2014;6(12):4880-901. doi: 10.3390/v6124880. PubMed PMID: 
25494448; PMCID: 4276934. 
351. Schwarzer W, Abdennur N, Goloborodko A, Pekowska A, Fudenberg G, Loe-Mie 
Y, Fonseca NA, Huber W, C HH, Mirny L, Spitz F. Two independent modes of 
chromatin organization revealed by cohesin removal. Nature. 2017;551(7678):51-
6. doi: 10.1038/nature24281. PubMed PMID: 29094699; PMCID: PMC5687303. 
352. Seppola M, Stenvik J, Steiro K, Solstad T, Robertsen B, Jensen I. Sequence and 
expression analysis of an interferon stimulated gene (ISG15) from Atlantic cod 
(Gadus morhua L.). Dev Comp Immunol. 2007;31(2):156-71. doi: 
10.1016/j.dci.2006.05.009. PubMed PMID: 16824598. 
353. Servant N, Varoquaux N, Lajoie BR, Viara E, Chen CJ, Vert JP, Heard E, Dekker 
J, Barillot E. HiC-Pro: an optimized and flexible pipeline for Hi-C data 
processing. Genome Biol. 2015;16:259. doi: 10.1186/s13059-015-0831-x. 
PubMed PMID: 26619908; PMCID: PMC4665391. 
354. Sever R, Glass CK. Signaling by nuclear receptors. Cold Spring Harb Perspect 
Biol. 2013;5(3):a016709. doi: 10.1101/cshperspect.a016709. PubMed PMID: 
23457262; PMCID: PMC3578364. 
355. Sexton T, Yaffe E, Kenigsberg E, Bantignies F, Leblanc B, Hoichman M, 
Parrinello H, Tanay A, Cavalli G. Three-dimensional folding and functional 
organization principles of the Drosophila genome. Cell. 2012;148(3):458-72. doi: 
10.1016/j.cell.2012.01.010. PubMed PMID: 22265598. 
356. Shaw TI, Srivastava A, Chou WC, Liu L, Hawkinson A, Glenn TC, Adams R, 
Schountz T. Transcriptome sequencing and annotation for the Jamaican fruit bat 
(Artibeus jamaicensis). PLoS One. 2012;7(11):e48472. doi: 
10.1371/journal.pone.0048472. PubMed PMID: 23166587; PMCID: 3499531. 
357. Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional 
regulators of lipid synthetic genes. Prog Lipid Res. 2001;40(6):439-52. PubMed 
 218 
PMID: 11591434. 
358. Shin H, Shi Y, Dai C, Tjong H, Gong K, Alber F, Zhou XJ. TopDom: an efficient 
and deterministic method for identifying topological domains in genomes. 
Nucleic Acids Res. 2016;44(7):e70. doi: 10.1093/nar/gkv1505. PubMed PMID: 
26704975; PMCID: PMC4838359. 
359. Shitashige M, Hirohashi S, Yamada T. Wnt signaling inside the nucleus. Cancer 
Sci. 2008;99(4):631-7. doi: 10.1111/j.1349-7006.2007.00716.x. PubMed PMID: 
18177486. 
360. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, Chibbar R. 
Reduced PTEN expression predicts relapse in patients with breast carcinoma 
treated by tamoxifen. Mod Pathol. 2005;18(2):250-9. doi: 
10.1038/modpathol.3800296. PubMed PMID: 15475931. 
361. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 
2017;67(1):7-30. doi: 10.3322/caac.21387. PubMed PMID: 28055103. 
362. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. Nonhistone protein 
acetylation as cancer therapy targets. Expert Rev Anticancer Ther. 
2010;10(6):935-54. doi: 10.1586/era.10.62. PubMed PMID: 20553216; PMCID: 
PMC3273412. 
363. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. A comprehensive 
characterization of pancreatic ductal carcinoma cell lines: towards the 
establishment of an in vitro research platform. Virchows Arch. 2003;442(5):444-
52. doi: 10.1007/s00428-003-0784-4. PubMed PMID: 12692724. 
364. Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J. Distinct 
functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-
tumor activity in primary macrophages. Biochem Pharmacol. 2006;72(11):1469-
76. doi: 10.1016/j.bcp.2006.06.002. PubMed PMID: 16846591. 
365. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen 
MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, 
Botstein D, Lonning PE, Borresen-Dale AL. Gene expression patterns of breast 
carcinomas distinguish tumor subclasses with clinical implications. Proc Natl 
Acad Sci U S A. 2001;98(19):10869-74. doi: 10.1073/pnas.191367098. PubMed 
PMID: 11553815; PMCID: PMC58566. 
366. Sorrentino G, Ruggeri N, Zannini A, Ingallina E, Bertolio R, Marotta C, Neri C, 
Cappuzzello E, Forcato M, Rosato A, Mano M, Bicciato S, Del Sal G. 
Glucocorticoid receptor signalling activates YAP in breast cancer. Nat Commun. 
2017;8:14073. doi: 10.1038/ncomms14073. PubMed PMID: 28102225; PMCID: 
PMC5253666. 
367. Splinter E, de Wit E, Nora EP, Klous P, van de Werken HJ, Zhu Y, Kaaij LJ, van 
Ijcken W, Gribnau J, Heard E, de Laat W. The inactive X chromosome adopts a 
unique three-dimensional conformation that is dependent on Xist RNA. Genes 
Dev. 2011;25(13):1371-83. doi: 10.1101/gad.633311. PubMed PMID: 21690198; 
PMCID: PMC3134081. 
368. St John HC, Bishop KA, Meyer MB, Benkusky NA, Leng N, Kendziorski C, 
Bonewald LF, Pike JW. The osteoblast to osteocyte transition: epigenetic changes 
and response to the vitamin D3 hormone. Mol Endocrinol. 2014;28(7):1150-65. 
 219 
doi: 10.1210/me.2014-1091. PubMed PMID: 24877565; PMCID: PMC5414828. 
369. Stavreva DA, Coulon A, Baek S, Sung MH, John S, Stixova L, Tesikova M, 
Hakim O, Miranda T, Hawkins M, Stamatoyannopoulos JA, Chow CC, Hager 
GL. Dynamics of chromatin accessibility and long-range interactions in response 
to glucocorticoid pulsing. Genome Res. 2015;25(6):845-57. doi: 
10.1101/gr.184168.114. PubMed PMID: 25677181; PMCID: PMC4448681. 
370. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 
2000;403(6765):41-5. doi: 10.1038/47412. PubMed PMID: 10638745. 
371. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, 
Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-wide 
expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50. doi: 
10.1073/pnas.0506580102. PubMed PMID: 16199517; PMCID: PMC1239896. 
372. Sulkin SE, Allen R. Virus infections in bats. Monogr Virol. 1974;8(0):1-103. 
PubMed PMID: 4367453. 
373. Sunami Y, Rebelo A, Kleeff J. Lipid Metabolism and Lipid Droplets in Pancreatic 
Cancer and Stellate Cells. Cancers (Basel). 2017;10(1). doi: 
10.3390/cancers10010003. PubMed PMID: 29295482; PMCID: PMC5789353. 
374. Suzuki S, Suzuki Y, Yamamoto N, Matsumoto Y, Shirai A, Okubo T. Influenza A 
virus infection increases IgE production and airway responsiveness in aerosolized 
antigen-exposed mice. J Allergy Clin Immunol. 1998;102(5):732-40. PubMed 
PMID: 9819289. 
375. Sydow JF, Brueckner F, Cheung AC, Damsma GE, Dengl S, Lehmann E, 
Vassylyev D, Cramer P. Structural basis of transcription: mismatch-specific 
fidelity mechanisms and paused RNA polymerase II with frayed RNA. Mol Cell. 
2009;34(6):710-21. doi: 10.1016/j.molcel.2009.06.002. PubMed PMID: 
19560423. 
376. T B. Zur Frage der Entstehung maligner Tumoren. G Fischer. 1914. 
377. Taberlay PC, Achinger-Kawecka J, Lun AT, Buske FA, Sabir K, Gould CM, 
Zotenko E, Bert SA, Giles KA, Bauer DC, Smyth GK, Stirzaker C, O'Donoghue 
SI, Clark SJ. Three-dimensional disorganization of the cancer genome occurs 
coincident with long-range genetic and epigenetic alterations. Genome Res. 
2016;26(6):719-31. doi: 10.1101/gr.201517.115. PubMed PMID: 27053337; 
PMCID: PMC4889976. 
378. Tagami H, Ray-Gallet D, Almouzni G, Nakatani Y. Histone H3.1 and H3.3 
complexes mediate nucleosome assembly pathways dependent or independent of 
DNA synthesis. Cell. 2004;116(1):51-61. PubMed PMID: 14718166. 
379. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate 
cancer stem cells? Clin Cancer Res. 2010;16(12):3153-62. doi: 10.1158/1078-
0432.CCR-09-2943. PubMed PMID: 20530697. 
380. Tanabe H, Habermann FA, Solovei I, Cremer M, Cremer T. Non-random radial 
arrangements of interphase chromosome territories: evolutionary considerations 
and functional implications. Mutat Res. 2002;504(1-2):37-45. PubMed PMID: 
12106644. 
381. Tang Z, Luo OJ, Li X, Zheng M, Zhu JJ, Szalaj P, Trzaskoma P, Magalska A, 
 220 
Wlodarczyk J, Ruszczycki B, Michalski P, Piecuch E, Wang P, Wang D, Tian SZ, 
Penrad-Mobayed M, Sachs LM, Ruan X, Wei CL, Liu ET, Wilczynski GM, 
Plewczynski D, Li G, Ruan Y. CTCF-Mediated Human 3D Genome Architecture 
Reveals Chromatin Topology for Transcription. Cell. 2015;163(7):1611-27. doi: 
10.1016/j.cell.2015.11.024. PubMed PMID: 26686651; PMCID: PMC4734140. 
382. Teo JL, Kahn M. The Wnt signaling pathway in cellular proliferation and 
differentiation: A tale of two coactivators. Adv Drug Deliv Rev. 
2010;62(12):1149-55. doi: 10.1016/j.addr.2010.09.012. PubMed PMID: 
20920541. 
383. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer 
(IGV): high-performance genomics data visualization and exploration. Brief 
Bioinform. 2013;14(2):178-92. doi: 10.1093/bib/bbs017. PubMed PMID: 
22517427; PMCID: PMC3603213. 
384. Tian W, Han X, Yan M, Xu Y, Duggineni S, Lin N, Luo G, Li YM, Han X, 
Huang Z, An J. Structure-based discovery of a novel inhibitor targeting the beta-
catenin/Tcf4 interaction. Biochemistry. 2012;51(2):724-31. doi: 
10.1021/bi201428h. PubMed PMID: 22224445. 
385. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, 
Salzberg SL, Rinn JL, Pachter L. Differential gene and transcript expression 
analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 
2012;7(3):562-78. doi: 10.1038/nprot.2012.016. PubMed PMID: 22383036; 
PMCID: PMC3334321. 
386. Turmelle AS, Jackson FR, Green D, McCracken GF, Rupprecht CE. Host 
immunity to repeated rabies virus infection in big brown bats. J Gen Virol. 
2010;91(Pt 9):2360-6. Epub 2010/06/04. doi: vir.0.020073-0 [pii] 
4. 10.1099/vir.0.020073-0. PubMed PMID: 20519458. 
387. Ucar D, Bayarsaihan D. Cell-specific gene promoters are marked by broader 
spans of H3K4me3 and are associated with robust gene expression patterns. 
Epigenomics. 2015;7(2):129-31. doi: 10.2217/epi.14.87. PubMed PMID: 
25942528. 
388. Ugai H, Uchida K, Kawasaki H, Yokoyama KK. The coactivators p300 and CBP 
have different functions during the differentiation of F9 cells. J Mol Med (Berl). 
1999;77(6):481-94. PubMed PMID: 10475063. 
389. Unkeless JC, Scigliano E, Freedman VH. Structure and function of human and 
murine receptors for IgG. Annu Rev Immunol. 1988;6:251-81. doi: 
10.1146/annurev.iy.06.040188.001343. PubMed PMID: 2968084. 
390. Van Speybroeck L. From epigenesis to epigenetics: the case of C. H. Waddington. 
Ann N Y Acad Sci. 2002;981:61-81. PubMed PMID: 12547674. 
391. van Steensel B, Dekker J. Genomics tools for unraveling chromosome 
architecture. Nat Biotechnol. 2010;28(10):1089-95. doi: 10.1038/nbt.1680. 
PubMed PMID: 20944601; PMCID: PMC3023824. 
392. Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. A census of 
human transcription factors: function, expression and evolution. Nat Rev Genet. 
2009;10(4):252-63. doi: 10.1038/nrg2538. PubMed PMID: 19274049. 
393. Varet H, Brillet-Gueguen L, Coppee JY, Dillies MA. SARTools: A DESeq2- and 
 221 
EdgeR-Based R Pipeline for Comprehensive Differential Analysis of RNA-Seq 
Data. PLoS One. 2016;11(6):e0157022. doi: 10.1371/journal.pone.0157022. 
PubMed PMID: 27280887; PMCID: PMC4900645. 
394. Vietri Rudan M, Barrington C, Henderson S, Ernst C, Odom DT, Tanay A, 
Hadjur S. Comparative Hi-C reveals that CTCF underlies evolution of 
chromosomal domain architecture. Cell Rep. 2015;10(8):1297-309. doi: 
10.1016/j.celrep.2015.02.004. PubMed PMID: 25732821; PMCID: 
PMC4542312. 
395. Vincent AJ, Ren S, Harris LG, Devine DJ, Samant RS, Fodstad O, Shevde LA. 
Cytoplasmic translocation of p21 mediates NUPR1-induced chemoresistance: 
NUPR1 and p21 in chemoresistance. FEBS Lett. 2012;586(19):3429-34. doi: 
10.1016/j.febslet.2012.07.063. PubMed PMID: 22858377. 
396. von Hansemann D. Ueber asymmetrische Zelltheilung in epithel Krebsen und 
deren biologische Bedeutung. Virchows Arch. Path Anat. 1890:119, 299. 
397. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. Mi-2 complex 
couples DNA methylation to chromatin remodelling and histone deacetylation. 
Nat Genet. 1999;23(1):62-6. doi: 10.1038/12664. PubMed PMID: 10471500. 
398. Wall I, Schmidt-Wolf IG. Effect of Wnt inhibitors in pancreatic cancer. 
Anticancer Res. 2014;34(10):5375-80. PubMed PMID: 25275031. 
399. Wang J, Lan X, Hsu PY, Hsu HK, Huang K, Parvin J, Huang TH, Jin VX. 
Genome-wide analysis uncovers high frequency, strong differential chromosomal 
interactions and their associated epigenetic patterns in E2-mediated gene 
regulation. BMC Genomics. 2013;14:70. doi: 10.1186/1471-2164-14-70. PubMed 
PMID: 23368971; PMCID: PMC3599885. 
400. Wang L, Tang Y, Cole PA, Marmorstein R. Structure and chemistry of the 
p300/CBP and Rtt109 histone acetyltransferases: implications for histone 
acetyltransferase evolution and function. Curr Opin Struct Biol. 2008;18(6):741-
7. doi: 10.1016/j.sbi.2008.09.004. PubMed PMID: 18845255; PMCID: 
PMC2643075. 
401. Wang L-F. Bats and Viruses:  a Breif Review. Virologica Sinica. 2009;24(2):93-
9. 
402. Wang LF, Walker PJ, Poon LL. Mass extinctions, biodiversity and mitochondrial 
function: are bats 'special' as reservoirs for emerging viruses? Curr Opin Virol. 
2011;1(6):649-57. doi: 10.1016/j.coviro.2011.10.013. PubMed PMID: 22440923. 
403. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear 
factor-kappa B RelA transcription factor is constitutively activated in human 
pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5(1):119-27. PubMed 
PMID: 9918209. 
404. Wapenaar H, Dekker FJ. Histone acetyltransferases: challenges in targeting bi-
substrate enzymes. Clin Epigenetics. 2016;8:59. doi: 10.1186/s13148-016-0225-2. 
PubMed PMID: 27231488; PMCID: PMC4881052. 
405. Weinmann R, Roeder RG. Role of DNA-dependent RNA polymerase 3 in the 
transcription of the tRNA and 5S RNA genes. Proc Natl Acad Sci U S A. 
1974;71(5):1790-4. PubMed PMID: 4525293; PMCID: PMC388326. 
406. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. 
 222 
Cancer Cell. 2003;4(6):425-9. PubMed PMID: 14706334. 
407. Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, 
Span PN, Stunnenberg HG. ChIP-Seq of ERalpha and RNA polymerase II defines 
genes differentially responding to ligands. EMBO J. 2009;28(10):1418-28. doi: 
10.1038/emboj.2009.88. PubMed PMID: 19339991; PMCID: PMC2688537. 
408. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer 
treatment. J Clin Invest. 2014;124(1):30-9. doi: 10.1172/JCI69738. PubMed 
PMID: 24382387; PMCID: PMC3871231. 
409. Whalen S, Truty RM, Pollard KS. Enhancer-promoter interactions are encoded by 
complex genomic signatures on looping chromatin. Nat Genet. 2016;48(5):488-
96. doi: 10.1038/ng.3539. PubMed PMID: 27064255; PMCID: PMC4910881. 
410. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, 
Lee TI, Young RA. Master transcription factors and mediator establish super-
enhancers at key cell identity genes. Cell. 2013;153(2):307-19. doi: 
10.1016/j.cell.2013.03.035. PubMed PMID: 23582322; PMCID: PMC3653129. 
411. Wibbelt G, Moore MS, Schountz T, Voigt CC. Emerging diseases in Chiroptera: 
why bats? Biol Lett. 2010;6(4):438-40. Epub 2010/04/30. doi: rsbl.2010.0267 
[pii] 
5. 10.1098/rsbl.2010.0267. PubMed PMID: 20427329. 
412. Workman JL, Kingston RE. Alteration of nucleosome structure as a mechanism 
of transcriptional regulation. Annu Rev Biochem. 1998;67:545-79. doi: 
10.1146/annurev.biochem.67.1.545. PubMed PMID: 9759497. 
413. Wright JB, Brown SJ, Cole MD. Upregulation of c-MYC in cis through a large 
chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism 
in colorectal cancer cells. Mol Cell Biol. 2010;30(6):1411-20. doi: 
10.1128/MCB.01384-09. PubMed PMID: 20065031; PMCID: PMC2832500. 
414. Wu AH, Huang YL, Zhang LZ, Tian G, Liao QZ, Chen SL. MiR-572 prompted 
cell proliferation of human ovarian cancer cells by suppressing PPP2R2C 
expression. Biomed Pharmacother. 2016;77:92-7. doi: 
10.1016/j.biopha.2015.12.005. PubMed PMID: 26796271. 
415. Xiao J, Jin R, Wagner D. Developmental transitions: integrating environmental 
cues with hormonal signaling in the chromatin landscape in plants. Genome Biol. 
2017;18(1):88. doi: 10.1186/s13059-017-1228-9. PubMed PMID: 28490341; 
PMCID: PMC5425979. 
416. Xiao X, Song BL. SREBP: a novel therapeutic target. Acta Biochim Biophys Sin 
(Shanghai). 2013;45(1):2-10. doi: 10.1093/abbs/gms112. PubMed PMID: 
23257291. 
417. Xu W, Wang Z, Zhang W, Qian K, Li H, Kong D, Li Y, Tang Y. Mutated K-ras 
activates CDK8 to stimulate the epithelial-to-mesenchymal transition in 
pancreatic cancer in part via the Wnt/beta-catenin signaling pathway. Cancer Lett. 
2015;356(2 Pt B):613-27. doi: 10.1016/j.canlet.2014.10.008. PubMed PMID: 
25305448. 
418. Xu YM, Du JY, Lau AT. Posttranslational modifications of human histone H3: an 
update. Proteomics. 2014;14(17-18):2047-60. doi: 10.1002/pmic.201300435. 
PubMed PMID: 25044606. 
 223 
419. Yang SR, Chida AS, Bauter MR, Shafiq N, Seweryniak K, Maggirwar SB, Kilty 
I, Rahman I. Cigarette smoke induces proinflammatory cytokine release by 
activation of NF-kappaB and posttranslational modifications of histone 
deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol. 
2006;291(1):L46-57. doi: 10.1152/ajplung.00241.2005. PubMed PMID: 
16473865. 
420. Yang Z. PAML 4: phylogenetic analysis by maximum likelihood. Mol Biol Evol. 
2007;24(8):1586-91. doi: 10.1093/molbev/msm088. PubMed PMID: 17483113. 
421. Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. 
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 
2016;30(4):355-85. doi: 10.1101/gad.275776.115. PubMed PMID: 26883357; 
PMCID: PMC4762423. 
422. Yu W, He B, Tan K. Identifying topologically associating domains and 
subdomains by Gaussian Mixture model And Proportion test. Nat Commun. 
2017;8(1):535. doi: 10.1038/s41467-017-00478-8. PubMed PMID: 28912419; 
PMCID: PMC5599511. 
423. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) 
in continuous culture: sensitivity to asparaginase. Int J Cancer. 1977;19(1):128-
35. PubMed PMID: 832918. 
424. Zavoral M, Minarikova P, Zavada F, Salek C, Minarik M. Molecular biology of 
pancreatic cancer. World J Gastroenterol. 2011;17(24):2897-908. doi: 
10.3748/wjg.v17.i24.2897. PubMed PMID: 21734801; PMCID: PMC3129504. 
425. Zhang G, Cowled C, Shi Z, Huang Z, Bishop-Lilly KA, Fang X, Wynne JW, 
Xiong Z, Baker ML, Zhao W, Tachedjian M, Zhu Y, Zhou P, Jiang X, Ng J, Yang 
L, Wu L, Xiao J, Feng Y, Chen Y, Sun X, Zhang Y, Marsh GA, Crameri G, 
Broder CC, Frey KG, Wang LF, Wang J. Comparative analysis of bat genomes 
provides insight into the evolution of flight and immunity. Science. 
2013;339(6118):456-60. doi: 10.1126/science.1230835. PubMed PMID: 
23258410. 
426. Zhang X, Lou Y, Zheng X, Wang H, Sun J, Dong Q, Han B. Wnt blockers inhibit 
the proliferation of lung cancer stem cells. Drug Des Devel Ther. 2015;9:2399-
407. doi: 10.2147/DDDT.S76602. PubMed PMID: 25960639; PMCID: 
PMC4423515. 
427. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum 
C, Myers RM, Brown M, Li W, Liu XS. Model-based analysis of ChIP-Seq 
(MACS). Genome Biol. 2008;9(9):R137. doi: 10.1186/gb-2008-9-9-r137. 
PubMed PMID: 18798982; PMCID: PMC2592715. 
428. Zhang Y, Morris JPt, Yan W, Schofield HK, Gurney A, Simeone DM, Millar SE, 
Hoey T, Hebrok M, Pasca di Magliano M. Canonical wnt signaling is required for 
pancreatic carcinogenesis. Cancer Res. 2013;73(15):4909-22. doi: 10.1158/0008-
5472.CAN-12-4384. PubMed PMID: 23761328; PMCID: PMC3763696. 
429. Zhao C, Denison C, Huibregtse JM, Gygi S, Krug RM. Human ISG15 
conjugation targets both IFN-induced and constitutively expressed proteins 
functioning in diverse cellular pathways. Proc Natl Acad Sci U S A. 
2005;102(29):10200-5. doi: 10.1073/pnas.0504754102. PubMed PMID: 
 224 
16009940; PMCID: 1177427. 
430. Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the 
functional organization of mammalian genomes. Nat Rev Genet. 2011;12(1):7-18. 
doi: 10.1038/nrg2905. PubMed PMID: 21116306. 
431. Zhou W, Liang IC, Yee NS. Histone deacetylase 1 is required for exocrine 
pancreatic epithelial proliferation in development and cancer. Cancer Biol Ther. 
2011;11(7):659-70. PubMed PMID: 21301206; PMCID: PMC3084970. 
432. Zink D, Fischer AH, Nickerson JA. Nuclear structure in cancer cells. Nat Rev 
Cancer. 2004;4(9):677-87. doi: 10.1038/nrc1430. PubMed PMID: 15343274. 
433. Zuin J, Dixon JR, van der Reijden MI, Ye Z, Kolovos P, Brouwer RW, van de 
Corput MP, van de Werken HJ, Knoch TA, van IWF, Grosveld FG, Ren B, 
Wendt KS. Cohesin and CTCF differentially affect chromatin architecture and 
gene expression in human cells. Proc Natl Acad Sci U S A. 2014;111(3):996-


















Altering cancer transcriptomes using epigenomic inhibitors 
 
 
Published in the following citation: Gaddis, M., Gerrard, D., Frietze, S., & Farnham, P. 
J. (2015). Altering cancer transcriptomes using epigenomic inhibitors. Epigenetics 



































Background: Due to the hyper-activation of WNT signaling in a variety of cancer types, 
there has been a strong drive to develop pathway-specific inhibitors with the eventual 
goal of providing a chemotherapeutic antagonist of WNT signaling to cancer patients. A 
new category of drugs, called epigenetic inhibitors, are being developed that hold high 
promise for inhibition of the WNT pathway. The canonical WNT signaling pathway 
initiates when WNT ligands bind to receptors, causing the nuclear localization of the co-
activator β-catenin (CTNNB1), which leads to an association of β-catenin with a member 
of the TCF transcription factor family at regulatory regions of WNT-responsive genes. 
The TCF/β-catenin complex then recruits CBP (CREBBP) or p300 (EP300), leading to 
histone acetylation and gene activation. A current model in the field is that CBP-driven 
expression of WNT target genes supports proliferation whereas p300-driven expression 
of WNT target genes supports differentiation. The small molecule inhibitor ICG-001 
binds to CBP, but not to p300, and competitively inhibits the interaction of CBP with β-
catenin. Upon treatment of cancer cells, this should reduce expression of CBP-regulated 
transcription, leading to reduced tumorigenicity and enhanced differentiation. 
Results: We have compared the genome-wide effects on the transcriptome after treatment 
with ICG-001 (the specific CBP inhibitor) versus C646, a compound that competes with 
acetyl-coA for the Lys-coA binding pocket of both CBP and p300. We found that both 
drugs cause large-scale changes in the transcriptome of HCT116 colon cancer cells and 
PANC1 pancreatic cancer cells and reverse some tumor-specific changes in gene 
expression. Interestingly, although the epigenetic inhibitors affect cell cycle pathways in 
both the colon and pancreatic cancer cell lines, the WNT signaling pathway was affected 
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only in the colon cancer cells. Notably, WNT target genes were similarly downregulated 
after treatment of HCT116 with C646 as with ICG-001. 
Conclusion: Our results suggest that treatment with a general HAT inhibitor causes 
similar effects on the transcriptome as does treatment with a CBP-specific inhibitor and 
that epigenetic inhibition affects the WNT pathway in HCT116 cells and the cholesterol 
biosynthesis pathway in PANC1 cells. 
 
Background  
Due to the hyper-activation of WNT signaling in a variety of cancer types (1,2), 
there has been a strong drive to develop antagonists of WNT signaling for cancer 
treatment. Standard inhibitors of the WNT signaling pathway include biologic inhibitors, 
such as small interfering RNAs, antibodies, and recombinant proteins, and chemical 
inhibitors, such as NSAIDs, vitamins, and polyphenols, that have fairly general (or 
unknown) targets (1,3,4). However, a new category of drugs to target the WNT pathway 
is being developed that holds high promise as chemotherapeutics. These drugs, called 
epigenetic inhibitors, function to modify chromatin structure. Chromatin is composed of 
nucleosomes, which are comprised of 146 bp of DNA wrapped around eight core histone 
proteins (two copies each of H2A, H2B, H3, and H4). The N terminal tails of the core 
histones that constitute the nucleosome are subject to various different types of 
modifications that can influence chromatin structure and either enhance or inhibit the 
ability of transcription factors to bind to and regulate their target genes. The pattern of 
histone modifications throughout the genome, in combination with the pattern of DNA 
methylation, is called the epigenome. Recent studies have revealed that different histone 
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modifications are associated with active vs. silenced chromatin, that different cell types 
show different epigenomic patterns of silenced vs. active chromatin, and that changes in 
chromatin structure can have a dramatic effect on cell proliferation, differentiation, and 
survival. One widely studied histone modification is acetylation; histone acetylation is a 
critical regulatory mechanism of gene expression and plays an important role in gene 
expression. In fact, acetylation of histone H3 on lysine 27 is the epigenetic modification 
that most precisely identifies distal regulatory regions that serve as active enhancers (5). 
Because cancer genomes show changes in histone acetylation patterns, there is great 
interest in the use of acetylation inhibitors that inhibit signaling pathways linked to 
human cancers for epigenetic therapy (6).  
Drugs that inhibit acetylation are particularly relevant for inhibition of the WNT 
pathway. The canonical WNT signaling pathway initiates when WNT ligands bind to 
receptors, resulting in the nuclear localization of the co-activator β-catenin (CTNNB1), 
which leads to an association of β-catenin with a member of the TCF/LEF transcription 
factor family at regulatory regions of WNT responsive genes (7,8). The TCF/β-catenin 
complex can interact with co-activators such as CBP (CREBBP) and p300 (EP300) 
which function in part through the acetylation of histone H3 on lysine 27 (5). Thus, it has 
been proposed that the initiation of the WNT signaling pathway ultimately ends with 
histone acetylation and a relaxing of the chromatin structure, a process necessary for gene 
activation. The small molecule inhibitor ICG-001 binds to CBP and competitively 
inhibits the interaction of CBP with β-catenin (9,10), with the expected result of loss of 
active histone at promoters and enhancers regulated by TCF/β-catenin/CBP complexes 
(Appendix A-1A). Importantly, ICG-001 does not bind to the highly related histone 
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acetyltransferase (HAT) p300 and should not affect the activity of promoters or 
enhancers bound by TCF/β-catenin/p300 complexes. Thus, ICG-001 is thought to 
specifically decrease the expression of only the subset of WNT target genes regulated by 
β-catenin/CBP interactions. These proposed effects of ICG-001 are in contrast to those of 
C646 an inhibitor that competes with acetyl-coA for the Lys-coA binding pocket of p300 
(Appendix A-1B). C646 is very selective for p300 versus six other unrelated histone 
acetyltransferases (11). Although no direct comparisons have been performed, due to the 
mode of action of C646 and because the HAT domains of p300 and CBP have greater 
than 90% similarity, it has been proposed that C646 is a general inhibitor for both CBP 
and p300 (11). Of importance for the role of ICG-001 as a chemotherapeutic drug, studies 
suggest that CBP-driven transcription helps to maintain pluripotency whereas p300-
driven transcription pushes cells toward a differentiated state (3,12-15); examples of 
genes thought to be regulated by CBP vs. p300 are shown in Appendix A-1C. However, 
the hypothesis that ICG-001 specifically downregulates only the subset of WNT target 
genes involved in proliferation (such as BIRC5 and CCND1) has not been tested on a 
genome-wide scale. Because a derivative of ICG-001 called PRI-724 is now in clinical 
trials (NCT01302405 and NCT01606579), it is critical to have a thorough understanding 
of the specificity and effectiveness of this drug. Therefore, we have compared the 
genome-wide effects on the transcriptome of ICG-001 versus C646 in two cancer cell 
lines that constitutively express the components of the transcription complex that 
mediates WNT signaling (Appendix A-1D). 
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Results 
ICG-001 and C646 have similar effects on the transcriptome of HCT116 colon cancer 
cells.  
Constitutive activation of WNT target genes via a TCF/β-catenin/CBP complex is 
thought to be a major driver of colorectal cancer. Therefore, it has been proposed that 
treatment of colon cancer cells with ICG-001 should specifically inhibit the WNT 
pathway (by preventing recruitment of the co-activator CBP to TCF/β-catenin target 
genes) and reduce the tumorigenicity of the cells. In support of this hypothesis, Emami et 
al. (10) have shown that ICG-001 reduces growth of colon carcinoma cells in culture and 
reduces the formation of colon and small intestinal polyps in a mouse model system. As 
noted above, CBP is highly related to another HAT called p300 and many studies have 
shown similar functions for p300 and CBP (16). In fact, a ChIP-seq analysis of p300 and 
CBP in T98G glioblastoma cells immediately after release from serum starvation arrest 
showed that almost all of the CBP genomic binding sites were also bound by p300 (17). 
However, under the tested conditions, a small set of genomic sites were preferentially 
bound by either CBP or p300, suggesting that there might be some specificity in their 
action. It is also possible that cell type plays a critical role in specifying CBP vs. p300 
contributions to regulating the transcriptome. For example, approximately 50% of 
Rubinstein-Taybi syndrome patients have mutations in CBP but only 3% of patients have 
mutations in p300 (18). Of course, functional specificity can also occur post-DNA 
binding because the two HATs only share extensive, but not complete, homology. If, for 
example, CBP and p300 recruit different interaction partners they could have opposite 
effects on transcription at a given promoter. In support of this hypothesis, Ma et al. have 
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shown that both CBP and p300 can bind to the BIRC5 promoter but they have opposite 
effects on transcription (19). 
To determine if the effects on the transcriptome after specifically inhibiting CBP 
are different than the effects after inhibiting both CBP and p300, we treated HCT116 
colon cancer cells with 0.05% DMSO, 10 μM ICG-001, or 10 μM C646 for 12 and 96 h. 
Samples were prepared in replicate and Illumina HumanHT-12 v4 expression arrays were 
used to detect changes in gene expression (Appendix A-2). Genes having a detection P 
value less than 0.01 in any of the control or treated cell populations were selected for 
further analysis; this constituted a total of 15,092 genes from HCT116 cells, of which 
3,689 showed differential expression in drug-treated cells (differential expression P value 
less than 0.05). After selecting the significant differentially expressed genes, the 
expression fold change was calculated for each gene and Euclidean distance was used for 
K-means clustering of expression fold change (Appendix A-3). We found that, contrary 
to our initial expectations, a very similar response was observed for both drugs. Genes 
that were downregulated by both drugs were involved in the cell cycle and WNT 
signaling (Appendix A-3). However, some genes did show drug-specific changes in 
HCT116 cells. According to the mechanism of action of each drug, genes with decreased 
levels of expression only after treatment with ICG-001 should be regulated by CBP but 
not by p300, whereas genes with decreased levels of expression only after treatment with 
C646 but not with ICG-001 should be regulated by p300 but not by CBP. A gene 
ontology analysis of the approximately 400 genes affected only by ICG-001 revealed a 
strong enrichment for genes controlling the cell cycle whereas the approximately 500 
genes only affected by C646 were not related to cell proliferation. Thus, in HCT116 cells, 
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both drugs have a broad effect on gene regulation that includes downregulation of genes 
involved in proliferation control. However, treatment of colorectal cancer cells with ICG-
001 alters the expression of a greater number of cell cycle-regulated genes than does 
treatment with C646. 
 
ICG-001 and C646 have similar effects on the transcriptome of PANC1 cells.  
As noted above, the WNT/TCF/β-catenin/CBP path- way has been proposed to be 
a major positive regulator of proliferation of colon cancer cells. Perhaps β-catenin/ CBP 
complexes play a prominent role in WNT-mediated gene expression in HCT116 cells 
(with little contribution by β-catenin/p300 complexes), explaining why the effects of 
ICG-001 were so widespread and why treatment with the two drugs elicited similar 
responses. To determine if ICG-001 has a similar widespread effect on other cancer cells, 
we also examined pancreatic cancer cells. Pancreatic ductal adenocarcinoma, the most 
common form of pancreatic cancer, displays activation of the WNT/β-catenin pathway 
(20-25) and is therefore predicted to respond to treatment with ICG-001. We treated 
PANC1 cells with ICG-001 or C646 and analyzed gene expression. Again, we found that 
ICG-001 and C646 have similar effects on PANC1 cells (Appendix A-4), with genes 
involved in cell cycle regulation being down-regulated by both drugs. However, in this 
case, cell proliferation-related genes were not enriched categories in gene sets 
downregulated specifically by either ICG-001 or C646. Interestingly, in PANC1 cells, the 
cholesterol biosynthesis pathway was highly enriched for genes specifically 
downregulated by ICG-001, suggesting that perhaps genes involved in cholesterol 
biosynthesis are specific CBP, but not p300, target genes. In contrast, p300-specific genes 
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(identified as those responsive only to C646) appear to be involved in various types of 
signaling pathways, including PI3K/AKT signaling which is linked to cell survival. To 
determine if gene responses to the drugs were cell type-specific, we compared the genes 
whose expression was altered by ICG-001 or C646 in both HCT116 and PANC1 cells (a 
total of 6,732 genes). Genes that were significantly detected in HCT116 or in PANC1 
cells (P value <0.01) and which had a differential P value <0.05 and a fold change 
greater than 1.2 (5,182 genes) were compared using hierarchical clustering with 
Euclidean distance and average linkage measures (Appendix A-5). We found that 
although some genes were altered in a cell type-specific manner, most genes were 
similarly affected in both cell types. A gene ontology analysis revealed that the top two 
categories of genes downregulated by ICG-001 or C646 in both HCT116 and PANC1 
cells were oxidative phosphorylation and mitochondrial dysfunction. Genes that were 
commonly upregulated by the drugs in both cell types are involved in pathways such as 
death receptor signaling and INOS signaling. 
 
Effectiveness of the epigenetic inhibitors in reverting a tumor cell phenotype.  
The ultimate goal of epigenetic therapy is to revert the transcriptome from a 
tumor-specific pattern of gene expression back to the expression patterns seen in nor- mal 
cells. To determine the extent to which the epigenetic inhibitors ICG-001 and C646 are 
effective in this goal, we obtained RNA-seq expression data for 41 normal and 274 tumor 
colon cells from the TCGA Consortium. Using this data, we identified 16,416 genes that 
were expressed in either normal or colon samples, using log2 (RSEM + 1) >2. Of these, 
11,824 genes were differentially expressed (adjusted differential P value <0.001) in the 
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tumor samples as compared to the normal tissues. To determine if the drugs were 
effective in reverting the expression of these genes back to normal levels, we compared 
the set of genes deregulated in the tumors with the set of genes responsive to the drug 
treatments, identifying a set of 2,028 common genes. If the drugs   are having an anti-
tumor effect, then genes that are up- regulated in tumors should be downregulated by the 
drugs and genes that are downregulated in tumors should be up- regulated by the drug. 
Using a log2(RSEM + 1) cutoff of 2, we identified 2,029 genes that showed expression 
changes (adjusted P value <0.05) in colon tumor cells, as compared to the normal tissues. 
An analysis of these expression patterns (Appendix A-6) shows that many genes had 
expression changes in the correct direction as a result of treatment with at least one drug 
(that is, a gene that is upregulated in tumors was down- regulated by a drug or a gene that 
is downregulated in tumors was upregulated by a drug). Analysis of four normal and 125 
pancreatic tumor samples revealed a much smaller set of genes showing expression 
changes in tumors. Using a log2(RSEM + 1) cutoff of 2, we identified only 167 genes 
that showed expression changes (adjusted P value <0.05) in pancreatic tumor cells, as 
compared to the normal tissues. It is unclear as to whether the small number of 
differentially expressed genes in the pancreatic tumors as compared to the colon tumors 
is due to real differences in cancer phenotypes, to the small number of normal pancreatic 
samples, or other possibilities such as tumor heterogeneity. To increase the number of 
analyzed genes, we also obtained a list of 596 genes that are differentially expressed in 
normal hTERT-HPNE pancreatic cells as compared to PANC1 cells (26). We examined 
the responses of the 167 genes that are differentially regulated in normal pancreatic tissue 
vs. tumors and the 596 genes that are differentially regulated in normal HPNE cells 
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grown in culture vs. PANC1 cells to drug treatment. We found that many of the genes 
whose expression is deregulated in pancreatic tumors or PANC1 cells showed 
appropriate responses to at least one drug (that is, genes upregulated in tumors or PANC1 
were downregulated by the drugs and genes downregulated in tumors or PANC1 were 
upregulated by the drugs) (Appendix A-6).  Thus, treatment with the epigenetic 
inhibitors is effective in reverting some of the tumor-specific transcriptome to a normal 
pattern. 
 
Direct targeting of a component of the transcription complex that mediates WNT 
signaling.  
As described above, ICG-001 was developed to be a specific inhibitor of the 
WNT pathway. We therefore directly analyzed the WNT pathway using a list of genes 
previously implicated as components of this pathway (http://www. 
stanford.edu/group/nusselab/cgi-bin/wnt/). We found that a subset of these proposed 
WNT target genes were expressed in HCT116 and/or PANC1 cells and were significantly 
affected by treatment with ICG-001 or C646 (Appendix A-7). The overall trend of the 
effects of ICG-001 and C646 on WNT targets was similar in a given cell line. However, 
the WNT pathway-related genes responded quite differently to the epigenetic inhibitors 
in the different cell lines. In general, the response of the genes listed in Appendix A-1C 
was more similar to what was predicted when HCT116 cells were treated with the 
epigenetic inhibitors than when PANC1 cells were treated with the drugs. For example, 
expression of the transcription factor JUN (which is involved in specifying differentiated 
phenotypes) is increased by both drugs in HCT116 but is decreased by both drugs in 
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PANC1. Conversely, the expression of MYC, a transcription factor involved in cell 
proliferation, is reduced by both drugs in HCT116 but is increased by both drugs in 
PANC1 cells. The gene ontology results suggest that ICG-001 and C646 affect the WNT 
pathway in HCT116 cells but not in PANC1 cells. Of course, it is also possible that 
different downstream target genes mediate the WNT pathway in pancreatic cancer cells 
as compared to colon cancer cells. The HATs CBP and p300 are brought to genomic 
regulatory elements by the DNA binding protein TCF7L2 via interaction with the 
bridging protein β-catenin.  If ICG-001 and C646, which block the recruitment or 
function of the HAT activity of the co-activators CBP and p300, are specific inhibitors of 
the WNT signaling pathway in PANC1 cells, then targeting TCF7L2 should result in 
similar effects on the transcriptome as does drug treatment. In contrast, if the epigenetic 
inhibitors are in fact targeting a different pathway in PANC1 cells, then genes affected by 
reduction of TCF7L2 should be different than the set of genes affected by the drugs. To 
identify genes affected by direct targeting of a component of the transcriptional complex 
implicated in WNT regulation, we used siRNAs to knockdown TCF7L2 in PANC1 cells. 
Cells were treated with control siRNAs or siRNAs specific for TCF7L2 and RNA was 
analyzed by RNA-seq. We analyzed the top 1,000 genes that were affected by 
knockdown of TCF7L2 and the top 1,000 genes affected by treatment with ICG-001 
(Appendix A-8). Interestingly, there were very few genes affected by reduction of 
TCF7L2 that were also affected by ICG-001. Specifically, the WNT pathway was 
identified in the set of genes affected upon reduction of TCF7L2 but not by treatment 
with ICG-001 (Appendix A-4). These results suggest that in PANC1 cells co-activators 
other than CBP cooperate with TCF7L2 to regulate gene expression and support the 
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hypothesis that the anti-proliferative effects of ICG-001 in PANC1 cells are not due to 
inhibition of the WNT pathway.  
 
Discussion 
Recent studies have shown large changes in the epigenomic patterns in normal vs. 
cancer cells, suggesting that epigenetic therapy may be commonly applicable to 
treatments of various cancers. Drugs that target epigenetic regulators are being developed 
(27-29), some of which are moving into clinical trials.  However, the specificity of action 
of many of these drugs has not yet been thoroughly examined. In particular, genome-
wide analyses of their effects have not been determined. In our study, we compare the 
effects of treatment with C646, which   is thought to compete with acetyl-coA for the 
Lys-coA binding pocket of both p300 and CBP (11) to the effects of ICG-001, which 
specifically binds to CBP and prevents its interaction with the co-activator β-catenin. 
Theoretically, ICG-001 is expected to be of higher specificity than C646 because it 
should only affect β-catenin/ CBP-driven transcription whereas C646 should affect all 
genes regulated by either CBP or p300, regardless of whether β-catenin is involved. 
However, it is possible that ICG-001 has broader effects than anticipated if the drug 
affects the ability of CBP to interact with other as- of-yet unknown co-activators. In 
addition, we note that CBP and p300 can acetylate non-histone proteins (30); thus, both 
compounds could also have effects on non- chromatin bound proteins. Although we 
initially expected cells to respond differently to C646 and ICG-001, our results suggest 
that generally these two drugs have similar effects on the transcriptome of tumor cells. 
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However, we did identify some cell-specific and drug-specific responses after epigenetic 
inhibition.  
We observed dramatic effects on the transcriptome upon treatment of HCT116 
colon cancer cells with either ICG-001 or C646, with thousands of genes showing 
differential expression. Interestingly, the responses to the two drugs were quite similar 
overall, with both drugs causing a reduction in certain genes involved in the WNT 
pathway. Because ICG-001 affects only CBP-driven transcription and not p300-driven 
transcription, these results suggest that perhaps the majority of the WNT-related active 
regulatory elements in HCT116 cells are bound by β-catenin/CBP complexes. We did 
identify a set of approximately 500 genes whose expression was down- regulated by 
ICG-001 and not by C646 (these are potential CBP-specific target genes) and a set of 
approximately 500 genes whose expression was downregulated by C646 but not by ICG-
001 (these are potential p300-specific target genes). These results are similar to a 
previous study of CBP and p300 in T98G glioblastoma cells that found that the two 
factors bound mainly to the same sites but that some specific binding sites could be 
identified (17). Interestingly, the genes specifically responsive to ICG-001 but not to 
C646 in HCT116 cells showed enrichment for cell proliferation-related gene ontology 
categories. Taken together, these results suggest that thousands of genes are regulated 
both by p300 and CBP (many of which are involved in cell proliferation) and that CBP-
specific genes may also include additional genes that regulate cell proliferation whereas 
p300-specific genes are involved in other processes. In general, our results in HCT116 
cells support the current model implicating WNT-mediated cell signaling as a critical 
regulator of cancer cell proliferation. 
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Although the WNT pathway has been implicated in the development of pancreatic 
cancer, the studies are not as extensive as those related to WNT’s role in colon cancer 
(20-25). We show that, in general, the effects of ICG-001 and C646 on the transcriptome 
of PANC1 cells are similar to those observed upon treatment of HCT116 cells. For 
example, a set of genes involved in cell proliferation show reduced expression upon 
treatment of PANC1 with either ICG-001 or C646. However, we did observe several 
differences in the response of PANC1 cells to the epigenetic inhibitors, as compared to 
HCT116 cells. First, we found that many of the enriched gene categories that responded 
specifically to ICG-001 treatment of PANC1 cells are involved in cholesterol 
biosynthesis. Interestingly, many cancers have a high dependency on accelerated 
biogenesis and uptake of lipids and cholesterol and inhibition of these pathways has been 
proposed to be a therapeutic opportunity for metabolic targeting of cancer growth 
(31,32).  Cholesterol homeostasis in mammalian cells is maintained in part by a basic-
helix-loop-helix family of transcription factors called the sterol regulatory element 
binding proteins (SREBPs) (33,34). The SREBP family members activate a number of 
target genes involved in cholesterol and fatty acid metabolism through binding to sterol 
regulatory elements in the promoters of target genes. In fact, SREBP transcription factors 
have been suggested to be novel therapeutic targets (35). Interestingly, SREBP proteins 
require interaction with CBP to mediate transcriptional activation (36). Thus, the 
treatment of PANC1 cells with ICG-001 likely disrupts a functional interaction between 
CBP and a SREBP family member, causing downregulation of genes involved in the 
cholesterol biosynthetic pathway (Appendix A-9). Second, in PANC1 cells the WNT 
pathway was not enriched in downregulated genes after treatment with either drug and 
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several critical WNT target genes showed unexpected transcriptional responses. Notably, 
expression of JUN (which promotes differentiation) was predicted to be increased upon 
treatment but in PANC1 cells JUN expression was decreased (JUN did show the 
expected response in HCT116 cells). Similarly, expression of MYC (which promotes 
proliferation) was predicted to be de- creased upon treatment but in PANC1 cells MYC 
expression was increased (MYC did show the expected response in HCT116 cells). The 
transcriptional response of the MYC gene was particularly surprising because it is 
considered to be a critical mediator of WNT signaling. Upregulation of MYC in PANC1 
suggests that the drugs do not inhibit the WNT pathway in these cells.  This hypothesis is 
supported by our finding that in PANC1 cells knockdown of TCF7L2, the transcription 
factor that brings β-catenin and CBP to regulatory elements to regulate WNT-responsive 
genes, does not affect expression of the same genes as are affected by treatment with 
ICG-001. While our work was in progress, another group reported treatment of pancreatic 
cancer cells with ICG- 001 (37). They showed that treatment of PANC1 cells with 10uM 
ICG-001 was effective at reducing cell proliferation in culture and reducing colony 
formation in soft agar. Al- though global effects on the PANC1 transcriptome were not 
examined in that study, the noted effects on proliferation are consistent with our finding 
that cell cycle-related genes are downregulated in response to ICG-001 and C646. That 
study did, however, perform microarray expression analysis after treatment of a different 
pancreatic cancer cell line (AsPC-1) with ICG-001 and found that 569 transcripts were 
upregulated and 150 transcripts were downregulated. Because only 117 of the 719 drug- 
responsive genes were altered in β-catenin knockdown cells, they concluded that ICG-
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001 had a broader effect than simply as a disrupter of WNT/β-catenin signaling in AsPC-
1 cells. 
As noted above, epigenetic inhibitors are considered promising new drugs for 
cancer treatment. One current clinical trial employs PRI-724, a derivative of ICG-001, in 
combination with gemcitabine in patients with advanced or metastatic pancreatic 
adenocarcinoma (NCT01764477). Gemcitabine is considered a first-line treatment for 
pancreatic adenocarcinoma but has poor overall efficacy because pancreatic cancer cells 
develop resistance to the drug (38). While investigating the pathways that lead to drug 
resistance, the transcriptional regulator NUPR1 (also known as anti-apoptotic protein p8 
or Candidate of Metastasis-1) was identified as being involved in the acquisition of 
gemcitabine resistance by pancreatic cancer cells (39). NUPR1 normally functions as a 
stress response gene in the pancreas, but it has been shown to contribute to metastasis, 
anti-apoptotic activity and pancreatic cancer development (40,41). Interestingly, our 
genome-wide analyses identified NUPR1 as one of the top upregulated genes after 
treatment of PANC1 cells with ICG-001. The upregulation of NUPR1 by ICG-001 may 
explain why ICG-001 plus gemcitabine did not increase overall lifespan in an in vivo 
pancreatic cancer cell xenograft model (37). Although the mechanism by which NUPR1 
promotes oncogenesis and/or drug resistance in pancreatic cells is not yet known, NUPR1 
has been shown to form a complex with p300 and TP53 to upregulate and promote 
cytoplasmic translocation of CDKN1A (p21) in breast cancer cells (42). Although 
nuclear p21 is a negative regulator of cell cycle progression, studies have associated 
cytoplasmic p21 with drug resistance and oncogenic activity in breast and testicular 
cancer (43-45). Vincent et al. (44) showed that treatment of NUPR1-expressing cells with 
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PI3K-AKT inhibitors could reverse cytoplasmic p21 localization and re-sensitize cells to 
doxorubicin. Importantly, studies have also shown that inhibition of the PI3K-AKT 
pathway in pancreatic cancer helps re-sensitize cells to gemcitabine (46,47). Thus, adding 
a PI3K-AKT inhibitor to the combined usage of ICG-001 plus gemcitabine may be the 
most effective treatment combination. However, it should also be noted that C646 caused 
only a modest increase in NUPR1 in PANC1 cells and that C646, but not ICG- 001, 
specifically inhibited the PI3K-AKT pathway (see Figure 4). Taken together, these 
results suggest that per- haps C646 plus gemcitabine would be more effective than ICG-
001 plus gemcitabine in the treatment of pancreatic cancer.  
 
Conclusions  
We have compared the genome-wide effects on the transcriptome of ICG-001 (a 
specific CBP inhibitor) versus C646 (a compound that competes with acetyl-coA for the 
Lys-coA binding pocket of both CBP and p300). We found that ICG-001 has a similar 
broad specificity as C646 in HCT116 colon cancer, with both drugs decreasing the 
expression of cell cycle-related and WNT pathway genes. In contrast, ICG-001 and C646 
affect cell cycle- related genes but do not result in appropriate responses of critical WNT 
target genes in PANC1 cancer cells. The effects of ICG-001 on PANC1 cells and 
comparison to gene expression patterns in TCF7L2 knockdown cells suggests that ICG-
001 inhibits proliferation of pancreatic cancer cells via a mechanism different than the 
WNT pathway. Gene ontology analyses point toward disruption of SREBP-CBP 
functional interactions as a possible cause of the anti-proliferative function of ICG-001 in 
pancreatic cancer cells. Importantly, both epigenetic inhibitors are effective at reversing 
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Cell growth conditions 
The human cell lines HCT116 (ATCC #CCL-247) and PANC1 (ATCC #CRL-
1469) were obtained from the American Type Culture Collection. HCT116 and PANC1 
cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin. Michael Kahn (University of Southern 
California) provided ICG-001 and C646 was obtained from VWR (catalog # 102516–
240). Cells were treated with 10 μM ICG-001, 10 μM C646, or 0.05% DMSO and 
collected after 12 or 96 h. Cells for the 12-h treatments were grown to 70% confluency 
before addition of the drugs or DMSO. Cells for the 96-h treatments were grown at 40% 
to 50% confluency before addition of the drugs or DMSO and were passaged before they 
could reach 90% confluency. New media and drugs were added every 24 h. After 
treatment, gene expression was analyzed using Illumina BeadChips. 
 
Microarray RNA expression 
Total RNA was collected using Trizol according to the manufacturer’s 
instructions (Life Technologies). To confirm RNA samples were not degraded, RNA 
quality was checked with the Experion StdSens kit (Bio-Rad) prior to amplification and 
labeling. The Illumina TotalPrep RNA Amplification Kit (Life Technologies catalog # 
AMIL1791) was used according to the manufacturer’s instructions to amplify and label 
 244 
RNA samples for Illumina array hybridization. Labeled RNAs were analyzed with 
Illumina HT-12 v4 Expression BeadChips (Catalog #: BD-103-0204) with the Direct 
Hybridization Assay and then scanned on an Illumina HiScan (catalog # BD-103- 0604). 
The data were analyzed and exported from Illumina’s GenomeStudio software using 
quantile normalization with- out background subtraction. Each drug/DMSO treatment 
and time point was performed using two independent bio- logical replicates. The 
correlation between replicates was calculated to ensure that the data were reproducible, 
replicate samples were averaged together and genes with a detection P value <0.01 were 
considered for further analysis. Differential expression analysis was performed using 
Illumina’s custom differential expression error model, which assumes a normal 
distribution of the target signal intensity and takes into account biological variation, non-
specific biological variation, and technical error. For more detail on Illumina’s custom 
error model, see GenomeStudio Gene Expression Module v1.0 User Guide (pages 103 
and 104).  Genes with a differential expression P value <0.05 were considered to be 
significantly differentially expressed. 
 
TCF7L2 knockdown 
TCF7L2 knockdown was performed in triplicate by siRNA transfection. 
Transfections were performed using Lipofectamine RNAiMax (Life Technologies) 
according to manufacturer’s instructions. A final concentration of 40nM siRNAs 
targeting either TCF7L2 (catalog # 4392420, Life Technologies) or a non-specific 
negative control siRNA (catalog # AM4611, Life Technologies) were used using reduced 
serum OptiMEM media (Life Technologies). Media was changed 12 h post transfection 
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and total RNA was collected 48 h post transfection using Trizol according to 
manufacturer’s instructions (Life Technologies). Knockdown efficiency was detected 
using RT-qPCR and then samples were analyzed by RNA-seq. 
 
RNA-Seq 
Total RNA was used for polyA+ RNA selection using oligo-dT beads and 
subjected to library construction by True-Seq library preparation kits (Illumina), followed 
by Illumina HiSeq2000 sequencing. The RNA-seq reads were aligned to the human 
genome hg19 using Bowtie2 with ultrasensitive parameters. The RNA-seq reads were 
counted over gene exons using HTSeq (48). EdgeR was used for statistical analyses of 
siControl and siTCF7L2 samples, and a fold change of 2 was used to call the 
differentially expressed genes (49). 
 
Ingenuity pathway analysis 
Gene network diagrams in Appendix A-9 were created through use of IPA. The 
expression data were analyzed through the use of QIAGEN’s Ingenuity® Pathway Ana- 
lysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity). For each subset of 
genes, a core analysis was run with parameters set to consider only direct relationships 
and relationships between molecules that have been experimentally observed. The 






Expression array analyses for control and treated cells and RNA-seq datasets for 
TCF7L2 knockdown experiments have been deposited in GEO (GSE64039 and 






























Appendix A-1. Targeting the WNT pathway using epigenetic inhibitors. WNT 
signaling culminates when, upon recruitment of β-catenin/CBP or β-catenin/p300 
complexes to the DNA via a TCF/LEF family member, CBP and p300 activate 
transcription by acetylating histone H3.  (A) Treatment with ICG-001 disrupts the 
interaction of CBP with β-catenin, blocking CBP-driven, but not p300-driven 
transcription. (B) In contrast to the effects of ICG-001, C646 competes with acetyl-coA 
for the Lys-coA binding pocket of both CBP and p300, preventing HAT activity of both 
complexes. (C) Examples of predicted gene expression differences mediated by β-
catenin/CBP vs. β-catenin/p300 complexes (15). (D) RNA levels in HCT116 and PANC1 































Appendix A-2. The effects of epigenetic inhibitors on the transcriptome of HCT116 
and PANC1 cells. HCT116 colon cancer cells and PANC1 pancreatic adenocarcinoma 
cells were treated in duplicate with DMSO or 10 μM ICG-001 or C646 for 12 or 96 h (12 
samples per cell line). Cells were harvested and RNA was analyzed using Illumina 
HumanHT-12 v4 expression arrays. Any gene having a detection P value <0.01 in any of 
the samples was selected for differential gene analysis; genes having a differential P 
value <0.05 were further analyzed. The number of upregulated (red) and downregulated 
(green) genes under each condition for each cell line is shown. 
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Appendix A-3. Effects of epigenetic inhibitors on gene expression in HCT116 cells.  
(A) Genes differentially expressed after treatment of HCT116 cells with ICG-001 or 
C646 (see Figure 2) were analyzed using Euclidean distance and K-means clustering of 
expression fold change. (B) Gene ontology analyses are shown for the genes commonly 
up- and downregulated by both drugs and for the genes that are downregulated only by 
one of the drugs in HCT116 cells. Terms related to the cell cycle are shown in red and 
terms related to WNT signaling are shown in blue. The numbers 1 to 6 in the brackets in 














































Appendix A-4. Effects of epigenetic inhibitors on gene expression in PANC1 cells.  
(A) Genes differentially expressed after treatment of PANC1 cells with ICG-001 or C646 
(see Figure 2) were analyzed using Euclidean distance and K-means clustering of 
expression fold change. (B) Gene ontology analyses are shown for the genes commonly 
up- and downregulated by both drugs and for the genes that are downregulated only by 
one of the drugs in PANC1 cells. Terms related to the cell cycle are shown in red. The 
numbers 1 to 6 in the brackets in panel A refer to different clusters that were used in the 


























Appendix A-5. ICG-001 and C646 affect many of the same genes in HCT116 and 
PANC1 cells. (A) Genes that were significantly detected in both HCT116 or in PANC1 
cells (P value <0.01) were analyzed for expression differences caused by drug treatment. 
All genes having a differential P value <0.05 and a fold change greater than 1.2 were 
analyzed using Euclidean distance and hierarchical clustering. (B) Gene ontology 
analyses are shown for the genes commonly up- or downregulated in HCT116 and 


















Appendix A-6. Epigenetic inhibitors can partially restore a normal expression pattern to 
tumor cells  
 
Appendix A-6. Epigenetic inhibitors can partially restore a normal expression pattern to 
tumor cells. Genes that showed tumor-specific changes in expression in TCGA colon 
RNA-seq samples (left), TCGA pancreatic RNA-seq samples (right, top), plus 
differentially expressed genes identified by comparison of normal to tumor pancreatic 
cell lines (right bottom) were analyzed for responses to drug treatments. In the T/N 
columns, green indicates that the gene was downregulated in the tumor cells whereas red 
indicates the gene was upregulated in the tumor cells. The blue brackets indicate genes 
that were downregulated in the tumor cells and upregulated by the drugs (resulting in an 
expression level closer to that in normal cells) whereas the black brackets represent the 
genes that were upregulated in the tumor cells and downregulated by the drugs (resulting 
in an expression level closer to that in normal cells). The color scale indicates the fold 
change of gene expression in HCT116 or PANC1 cells after treatment with ICG-001 
(ICG) or C646. 
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Appendix A-7. Effects of drug treatments on WNT pathway genes. (A) Shown are the 
expression changes in previously identified WNT pathway genes 
(http://www.stanford.edu/group/nusselab/cgi-bin/wnt/) that have a detection P value 
<0.01 and a differential P value <0.05 after 96 h of treatment of HCT116 or PANC1 cells 
with either ICG-001 (ICG) or C646. (B) Shown are the predicted results (based on the 
model shown in Figure 1) and the actual responses to the drugs after treatment of 
HCT116 or PANC1 cells for a set of WNT target genes. In the prediction column, a red 
arrow indicates that the gene should have been upregulated by ICG-001and the green 
arrow indicates that the gene should have been downregulated by ICG-001, according to 
the model. For each cell type, the actual response is shown for both drugs: a red arrow 
indicates that expression was increased as predicted by the model, a green arrow indicates 
expression was decreased as predicted by the model, a gray arrow indicates that the 
expression pattern upon treatment did not correspond to the prediction, and an x indicates 



















Appendix A-8. In PANC1 cells, treatment with ICG-001 does not affect the same genes as 













Appendix A-8. In PANC1 cells, treatment with ICG-001 does not affect the same genes 
as does reduction in levels of TCF7L2. (A) PANC1 cells were treated with siRNAs to 
TCF7L2 and RNA-seq was performed. The top 1,000 differentially expressed genes after 
knockdown of TCF7L2 were compared to the top 1,000 genes identified to be responsive 
to ICG-001 in PANC1 cells. (B) Gene ontology analyses are shown for the genes 
commonly up- and downregulated by knockdown of TCF7L2 and treatment with ICG-
001 and genes that are only affected by knockdown of TCF7L2. Terms related to the cell 























Appendix A-9: ICG-001 negatively regulates the cholesterol biosynthesis network.  
IPA was used to show the rela0onships between SREBF1 and other genes involved in 
cholesterol biosynthesis that are affected by treatment of PANC1 cells with ICG-001 or 
C646. The arrows indicate direction interactions between the SREBF1 transcription 
factor and the other genes. Each of the indicated genes was down-‐regulated (indicated by 
the green color) by ICG-001 but up-regulated or unaffected by C646 (indicated by the red 
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Appendix B-1: Comparison of TCC and HiC TADs and boundaries. A comparison of 
the number of topological associated domains and TAD boundaries between PANC1 TCC 















Appendix B-2: Visualization of Repeated HMM state S1/S7/S9. IGV snapshot of 













Appendix B-3: Length distribution of topological domains in drug treated PANC1 
 
 
Appendix B-3: Length distribution of topological domains in drug-treated PANC1. 










Appendix B-4: Pearson correlation between sub-domain and change of sub-domain 
 
 
Appendix B-4: Pearson correlation between sub-domain and change of sub-domain. 







































































































































































Appendix C-1. Identification of super-enhancers in PANC1 cells. A. Super-enhancers 
were identified using Ranked Ordering of Super-Enhancers (ROSE) [5, 60], where 
H3K27ac signal relative to input is ranked and visualized. The dashed line distinguishes 
between typical-enhancers and super-enhancers. B. We visualized the signal of core 
histone modifications including: H3K27ac, H3K4me1 and H3K4me3 within typical- or 
super-enhancers relative to gene regions (proximal <5 kb and distal >5 kb from the TSS). 
The signal is represented as log2 fold enrichment over input signal. C. Genome snapshots 
of representative gene regions marked by super-enhancers in PANC1. D. Gene ontology 















































Appendix C-2. Identifying Broad H3K4me3 domains in PANC1 cells. A. Broad 
H3K4me3 domains were determined by MACS2 with the –broad flag activated. We then 
ranked the size of the domains and visualized them. The dashed line represents the cutoff 
of the top 5% of H3K4me3, which are defined as broad H3K4me3 domains. B. We then 
investigated the signal of core histone modifications including: H3K27ac, H3K4me1 and 
H3K4me3 within typical- and broad- H3K4me3 regions proximal (<5 kb) or distal (>5 





























Appendix C-3: Pathway analysis of super-enhancers and broad H3K4me3 domains in 






Appendix C-3. Pathway analysis of super-enhancers and broad H3K4me3 domains 


































































Appendix C-4. Gene expression relative to broad domains. Heatmaps showing the 
relative expression levels of genes marked by A. super-enhancers, B. broad H3K4me3, or 
C. both broad domains across 7 human PDAC cell lines. The number of genes belonging 
to each domain type is indicated. HGU corresponds to High-Grade Unique and LGU 




















































































Appendix C-5. The impact of ICG-001 treatment on broad H3K4me3 domains. A. 
Differential analysis of H3K4me3 genome-wide enrichment in PANC1 cells treated with 
ICG-001. Significantly altered regions are indicated by the colored dots (FDR <0.1). B. 
Genome browser snapshots of altered H3K4me3 regions. C. Differential binding analysis 
of broad H3K4me3 regions. D. Venn diagrams showing overlap of super-enhancers and 





















Appendix C-6: Chromatin-interacting domains in PANC1 cells. A. Genome-wide 
interaction matrix of chromosome contacts identified from TCC. B. Distribution of 






















Appendix C-7: Domains with increased ChIP-seq signal after HAT inhibitor treatment 





Appendix C-7: Domains with increased ChIP-seq signal after HAT inhibitor 
treatment are enriched in boundary regions. Feature enrichment analysis of super-



























































Appendix D-1. Identification of 24 patterns of dynamic compartments. The 
continuous genomic regions of positive first eigenvector were defined as compartment A 
(open chromatin) and the coutinuous genomic regions of negative first eigenvector was 
defined as compartment B (close chromatin). The time series compartments (A or B 
individually) were compared as follows: First, two kinds of compartments: T0 vs T1 
Common and T0 vs T1 Transit were identified by comparing compartments T0/T1. The 
“Common” compartments are the overlapping compartments and the “Transit” 
compartments are differential compartments, which were used in the following steps as 
well. Next, the common compartments  identified from T0 vs T1 and Transit 
compartments identified from T0 vs T1 were compared with T4, T16, T24 independently 
to generate the (a) T0 vs T1 Common vs T4/T16/T24 Common, (b) T0 vs T1 Common vs 
T4/T16/T24 Transit, (c) T0 vs T1 Transit vs T4/T16/T24 Common, (d) T0 vs T1 Transit 
vs T4/T16/T24 Transit.Lastly, the patterns denoted as 1-15 were produced by comparing 
the various time points (T4, T16 and T24) of subsets (a, b, c, and d) identified from the 
previous step, which we refer to as “vs T4”, “vs T16”, “vs T24” as shown in the Venn 
diagram. The rest of the subsets (X shown in Venn diagram) were divided into patterns 
16-24 according to the numbers of converted bins (Suppl. Figure S15). Left column: 
compartment A, right column: compartment B. In the Venn diagram, numbers without 








MCF7: MCF7 cell lines 
MCF7Lp: MCF7L parental cells 
MCF7L TamR: MCF7L Tamoxifen resistant cells 
*: p < 0.05; **: p < 0.01, t-test 
 
 
Appendix D-2. Validation of 3C-qPCR for HOMER loops. HOMER interaction loops 
are named as genes located at the interaction loops. Three 3C-qPCRs were performed for 











Appendix D-3. For each 100 kb bin, the p values of first eigenvectors of compartments 
of T0 vs TamR, T1 vs TamR, T4 vs TamR, T16 vs TamR, T24 vs TamR were computed 
by Wilcoxon rank-sum test. Then False Discovery Rate (FDR) was determined by the 






























Tacaribe virus (TCRV) is a mammalian arenavirus that was first isolated from 
artibeus bats in the 1950s. Subsequent experimental infection of Jamaican fruit bats 
(Artibeus jamaicensis) caused a disease similar to that of naturally infected bats. 
Although substantial attention has focused on bats as reservoir hosts of viruses that cause 
human disease, little is known about the interactions between bats and their pathogens. 
We performed a transcriptome-wide study to illuminate the response of Jamaican fruit 
bats experimentally infected with TCRV. Differential gene expression analysis of 
multiple tissues revealed global and organ-specific responses associated with innate 
antiviral responses, including interferon alpha/beta and Toll-like receptor signaling, 
activation of complement cascades, and cytokine signaling, among others. Genes 
encoding proteins involved in adaptive immune responses, such as gamma interferon 
signaling and co-stimulation of T cells by the CD28 family, were also altered in response 
to TCRV infection. Immunoglobulin gene expression was also elevated in the spleens of 
infected bats, including IgG, IgA, and IgE isotypes. These results indicate an active 
innate and adaptive immune response to TCRV infection occurred but did not prevent 
fatal disease. This de novo assembly provides a high-throughput data set of the Jamaican 
fruit bat and its host response to TCRV infection, which remains a valuable tool to 
understand the molecular signatures involved in antiviral responses in bats.  
 
Importance 
As reservoir hosts of viruses associated with human disease, little is known about 
the interactions between bats and viruses. Using Jamaican fruit bats infected with 
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Tacaribe virus (TCRV) as a model, we characterized the gene expression responses to 
infection in different tissues and identified pathways involved with the response to 
infection. This report is the most detailed gene discovery work in the species to date and 




Bats are a phylogenetically and geographically diverse group of mammals, with 
about 1,150 species (1, 2). Certain bat species have been identified as reservoir hosts of 
zoonotic viruses associated with significant human morbidity and mortality, including 
rabies virus and other lyssaviruses, Marburg virus, Nipah virus, and Hendra virus (3). 
They also are suspected reservoirs of other viruses, such as the ebolaviruses, and Middle 
East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) 
coronaviruses (CoVs) (4–6). Each of these viruses can cause severe disease in humans 
but are not known to cause disease in their reservoir hosts (3, 7). Although nearly 200 
viruses have been associated with bats, there are likely many more (8). As non-model 
organisms, virtually nothing is known about bat immune responses. Although bats appear 
to have small genomes relative to other mammals (9), genomic analyses suggest that bats 
share most features of other mammals (8, 10–12).  
Despite serving as reservoir hosts of several zoonotic viruses, some bats are also 
susceptible to infectious diseases. White nose syndrome, which has caused the deaths of 
millions of bats in North America, is a fungal disease threatening some species with 
extinction (13–16). Bats can shed rabies virus and other lyssaviruses for prolonged 
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periods, but the infection is always fatal (3, 17–21). Because bats are important members 
of their ecosystems, a better understanding of the immune responses and subsequent 
pathogenesis to infectious agents is essential. To this end, we developed a laboratory 
model for the study of infection of Jamaican fruit bats (Artibeus jamaicensis) by a natural 
bat pathogen, Tacaribe virus (TCRV) (11, 21, 22).  
TCRV is a mammarenavirus first isolated from two species of diseased artibeus 
bats in the late 1950s near Port-of-Spain, Trinidad, and is most closely related to Junïn 
and Machupo viruses, which cause Argentine and Bolivian hemorrhagic fevers, 
respectively (23–25). Each arenavirus is associated with a specific host species, and the 
distribution of the host therefore dictates the distribution of the virus. All known reservoir 
hosts of mammarenaviruses are rodents; however, the reservoir host of TCRV remains 
unclear. It was suspected that artibeus bats were reservoirs of TCRV given its original 
isolation from multiple artibeus bats and the inability to detect it in other mammals (25–
27). Interestingly, TCRV was isolated from lone star ticks collected in Florida in 2012 
(28). The tick-derived isolate was nearly identical to the TCRV isolate from Trinidad 
(TRVL-11573), with 99.6% nucleotide identity across its genome (28). Recent studies by 
our group found that TCRV causes fatal disease or is cleared without pathology in 
Jamaican fruit bats, features that are inconsistent for a reservoir host (22). In many of 
these bats, substantial neutrophil and lymphocytic infiltration into tissues occurred, which 
suggests a role for these cells in the host response to TCRV (22). 
The present study was designed to characterize the transcriptional responses of 
bats with TCRV disease. Accordingly, we performed RNA sequencing of spleens and 
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liver and kidney samples from experimentally infected bats and generated a broad bat 
transcriptome rich in annotated genes. These target tissues were chosen because they 
represent the organs with the most significant pathology in our previous report (8). This 
report is the most comprehensive gene discovery work in the species to date and the 




High-quality de novo assembly and annotation of the Jamaican fruit bat transcriptome 
We previously reported a high mortality rate in Jamaican fruit bats experimentally 
infected with TCRV, in which high-dose inoculations (106 50% tissue culture infective 
doses [TCID50]) caused significant and fatal disease as early as 10 days post infection 
(22). Histopathologic findings revealed multiple organ involvement in TCRV disease, 
including acute neutrophilic splenitis and white pulp hyperplasia, as well as plasmacytic 
and histiocytic splenitis. To profile the host pathogenic transcriptional response, we 
generated stranded poly(A) Illumina RNA-Seq (transcriptome sequencing) libraries using 
RNA extracted from the organs of experimentally infected bats. For this analysis, we 
harvested the livers, kidneys, and spleens from 2 control bats (Dulbecco’s phosphate-
buffered saline [DPBS] treated) and 2 TCRV-infected bats with fatal disease (Appendix 
E-1). Our previous analysis indicated TCRV RNA was present in each of these tissues at 
time of collection (22). A total of 12 pooled samples were sequenced, generating 
693,106,150 raw 100-bp paired-end reads. After demultiplexing, trimming of poor-
quality reads and adapter sequences, and removing duplicate reads, 691,108,820 
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nonredundant reads per sample were used for the transcriptome assembly. De novo 
assembly of the global transcriptome was performed using Trinity, resulting in 349,855 
assembled transcripts of greater than or equal to 300 bp (mean length of 997 bp) with an 
N50 of 3,419 bases that were clustered into 175,144 nonredundant clustered transcripts 
(unigenes) (Appendix E-2A) (29). Inspection of these unigenes identified from the 
combined transcriptome showed that 35% of the contigs (12,600) are expressed in each 
of the three different tissues (fragments per kilobase per million [FPKM]), whereas the 
expression of many tissue-specific contigs was identified in the spleen, liver, and kidney 
(Appendix E-2B).  
The combined Jamaican fruit bat transcriptome was systematically annotated 
using the Trinotate pipeline, a software suite that automates the functional annotation of 
the assembled contigs (30). The annotation report for the combined assembly from the 
Trinotate pipeline represents the predicted coding sequences of Jamaican fruit bat genes 
and the results of homology searches against the databases listed in Data Set S1. Among 
the 227,656 transcripts containing complete open reading frame (ORF) sequences, 
124,204 non-redundant ORFs (54%) were associated with high-confidence coding 
predictions, BLAST homology and PFAM domain content. We compared this combined 
Jamaican fruit bat transcriptome assembly to those of other mammals through BLASTX 
analysis. The bat Brandt’s myotis (Myotis brandtii) had the highest number of related 
sequences (8,060 similar sequences). Among other mammals were the big brown bat 
(Eptesicus fuscus) and the black flying fox (Pteropus alecto) (with 7,947 and 6,955 
similar sequences, respectively) (Appendix E-2C). 
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Differential gene expression following TCRV infection  
To investigate the molecular response of bats to TCRV infection, differential gene 
expression analysis was performed. We used a pairwise comparison of TCRV-infected 
samples against the corresponding controls and found that the expression levels of 
hundreds of different genes were altered during TCRV infection (Appendix E-3A). The 
spleen had the largest number of differentially expressed genes (DEGs); among these 
1,912 DEGs, 1,187 were upregulated and 725 were downregulated following infection 
(Appendix E-3C; false discovery rate [FDR], =0.01; log2 fold change =2). We also 
determined that the kidney and liver each had a greater number of upregulated genes (251 
and 188, respectively) compared to the number of downregulated genes in these tissues 
following TCRV infection (123 and 72, respectively). A comparison of all TCRV-
infected tissues against all of the uninfected controls revealed 62 upregulated and 16 
downregulated genes (Appendix E-3B and C).  
 
Immune gene expression profile in response to TCRV infection  
To gain specific insight into the immune-related gene expression altered in 
response to TCRV infection, we utilized the ImmPort database to identify those TCRV-
altered genes that relate to immune-system functions (31). Approximately 23% of the 
4,723 genes available in the database corresponded to the differentially expressed genes 
annotated in our analysis. The coordinating transcript expression values of these 
identified immune genes were used to evaluate the relationship between the specific 
uninfected and infected tissues (Appendix E-4A). While all three tissue types studied 
had unique expression profiles in the infected samples, we further analyzed the 
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transcripts contained in cluster 3, which represent sequences with overall shared 
expression patterns and found that these corresponding genes map to pathways identified 
to be affected in response to viral infection (Appendix E-4B). Notably, with the use of 
Ingenuity Pathway Analysis (IPA [Qiagen]), we identified the interferon (IFN) signaling 
pathway to be among the top pathways altered upon TCRV infection. IFNs are a family 
of cytokines secreted by host cells in response to viruses and other pathogens to confer 
antiviral states upon uninfected neighboring cells in an effort to prevent spread of 
infection (32). Given that the IFN response has been explored in bats in regard to 
pathogen-host response (33), we then further examined the relationship between these 
factors within the spleen, kidney, and liver in response to TCRV infection and found that 
while most of the identified IFN pathway-related genes were upregulated, all of the 
factors identified in this pathway had statistically significant differential expression (log2 
fold change =2; FDR=0.01) in the spleen (Appendix E-4C). We validated differential 
expression of select immune genes via reverse transcription-quantitative PCR (RT-qPCR) 
and confirmed upregulation of ISG15 and IRF7 in the spleen and kidney tissues and 
downregulation of HLA-DRA in the kidney.  
In addition to the IFN-signaling pathway, we identified signaling pathways for 
Toll-like receptors (TLRs) and interleukin-6 (IL-6) (among other cytokines), as well as 
pathways for T-helper cell differentiation and the Th1 pathway (Appendix E-4B). 
Further analysis of all DEGs via the Reactome plugin (Cytoscape) identified additional 
key pathways involved in the immune response. Specifically, we identified increased 
transcript levels of several cytokine genes (IL6, IL8, IL1A, IL1B, and IFNG) and 
chemokine genes (CXCL1, CXCL2, CXCL3, CXCL5, and CXCL6). To highlight 
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markers associated with circulating immune cells, we focused on those DEGs that were 
common to two or more tissues, and the data are consistent with increased infiltration of 
neutrophils into the infected tissues. In kidneys, neutrophil infiltration can cause hyper-
inflammation and kidney damage (34). This is further supported by the presence of 
enriched expression levels of neutrophil gelatinase-associated lipocalin (NGALl) in all 
three tissues, which is a biomarker for renal damage in humans (35). 
Transcripts for IgG, IgM, IgA, and IgE were identified in the spleen data, and the 
level of each was significantly elevated in the infected bats. Six transcripts of IgG heavy 
chains were identified, including 5 with complete and distinct V regions. The six IgG 
constant regions were identical, other than one that contained a Thr in place of an Ala, 
which could represent an allele or a sequencing error. The hinge regions, which are 
frequently different between IgG subclasses within a species, were identical in all 6 
transcripts. These two features suggest that Jamaican fruit bats have a single IgG isotype. 
The 5 V regions contain the canonical mammalian Ig sequences, including 4 framework 
regions (FR) and 3 complementarity-determining regions (CDRs) (Appendix E-5). Three 
distinct CDR3 sequences were present in these 5 transcripts. Two had 2 tyrosine residues, 
whereas the three that were identical had 6, substantially more than what has been 
reported in the CDR3s of other bat species (36, 37). Sequences for T-cell receptor alpha 
constant region domains were present in the assembly, although none had complete V 
regions. Expression of TCR-α was identified in all uninfected and infected tissues, TCR-
β in all spleen and liver tissues, TCR-γ in all spleen and liver tissues, and TCR-δ in all 
spleen and uninfected liver tissues.  
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Gene ontology of annotated differentially expressed genes in TCRV-infected tissues 
To characterize the overall transcriptome in response to TCRV infection, we 
performed an unbiased evaluation of the top 10 Reactome pathways (ranked by 
P value) associated with DEGs in various organs. In all three tissues, genes controlling 
cell cycle progression were elevated, including many associated with hypoxia, cell stress, 
senescence, and chromatin organization. 
Spleen differential expression analysis indicated that immune system pathways 
were significantly elevated, including type I and II IFN signaling, antiviral IFN-
stimulated genes (ISGs), interleukin signaling, and T and B cell activation pathways. 
Interestingly, genes involved in the complement cascade were repressed, including the 
genes for phosphatidylinositol 3-kinase and complement receptor 1. SH2B1, a gene 
encoding an important signal transduction adaptor in several pathways, including JAK, 
prolactin, platelet-derived growth factor, and nerve growth factor signaling, was also 
significantly downregulated in the spleen (38). We also identified repression of pro-
apoptotic genes BMP and PMAIP1 as well as repression of genes involved in calcium 
mobilization following TCRV infection (39). 
In the liver, Reactome analysis revealed strong immune activation signatures, 
including T-cell receptor and CD28 costimulatory signaling. No evidence of B-cell or 
NK cell activities was present. TLR and RIG-I/MDA5 signaling for type I IFN responses 
was also elevated, despite no evidence of differentially expressed type I IFN genes. 
Unlike the spleen, complement pathways were also enriched. The IFN-γ signaling 
pathway was also identified, although IFNG itself was not differentially expressed. 
Despite these findings, further indications of apoptotic activation were not differentially 
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expressed in the livers. As in the spleen, many metabolic genes were elevated, whereas 
genes involved in calcium mobilization were repressed. In the kidneys, Reactome 
analysis suggested that platelet calcium-associated degranulation may occur; the genes 
F13A1 and TMSB4X were elevated along with other genes involved in calcium 
mobilization. As in the other tissues, evidence of innate antiviral responses was present, 
including TLR signaling, RIG-I/MDA5 activity, and type I IFN signaling genes. 
Interleukin and IFN-γ signaling were also among the pathways characterized secondary 
to gene upregulation in the kidneys. 
 
Discussion  
Our previous work demonstrated that TCRV is pathogenic to Jamaican fruit bats 
and has allowed us to perform the most complete examination to date of a pathogenic 
virus infection in a bat species (22). Despite their importance to human health as 
reservoirs of emerging viruses, the characterization of infections in bats at the cellular 
and molecular levels has been limited relative to other model organisms, such as 
rodents. Fortunately, the emerging advantage of next-generation sequencing technologies 
has been fundamental to our understanding of disease responses; however, minimal 
reference data sets are available for bats. To this end, our group was among the first to 
perform next-generation sequencing on bats with a small-scale Illumina sequencing of 
kidney and lung tissues in a single library from the Jamaican fruit bat (8,11). 
Furthermore, in the present study we generated a high-quality transcriptomic data 
set for the Jamaican fruit bat and comprehensively profiled the altered immune genes 
in response to TCRV infection.  
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To gain insight into the pathogenic infection of Jamaican fruit bats, we performed 
high-throughput RNA sequencing of TCRV-infected spleen, liver, and kidney tissues and 
corresponding sham-inoculated controls. We produced high-quality non-redundant reads, 
and our Trinity de novo assembly resulted in 349,855 transcripts, which were further 
assembled into 124,204 contigs. The number of non-redundant contigs we identified is 
similar to those from other transcriptome assemblies reported for the black flying fox 
(126,378) (10), Rickett’s big-footed bat (104,987), and the greater short-nosed fruit bat 
(171,394) (40). 
We employed a pairwise comparison of all infected tissues versus sham-
inoculated controls to identify altered gene expression levels upon pathogenic TCRV 
infection. We utilized a log2 fold change cutoff of >2 with an FDR of <0.01. We chose a 
stringent cutoff because of our small sample size (n = 2) for each tissue type under each 
condition. This revealed approximately 25% more genes upregulated than 
downregulated. The spleen is instrumental in systemic and local immune responses and 
has been used to study viral responses in many organisms, including bats (3, 41). We 
observed the greatest number of differentially expressed genes in spleen tissues compared 
to the liver and kidneys. Further analysis revealed that the majority of these differentially 
expressed genes identified in the spleen belonged to immune-related pathways. 
Ingenuity Pathway Analysis identified enrichment of the helper T cell 
differentiation and Th1 pathway (Appendix E-4B) genes IFNG, IFNGR2, IL12RB2, 
IL6ST, SOCS1, and SOCS2, supporting a role for mobilization of a Th1 response. 
Despite this, levels of helper T cell genes, such as CD4 or T-cell receptor (TCR) genes, 
were not statistically different in infected bats. CD4 sequences were not in the assembly, 
 306 
suggesting the CD4 level was below the threshold of depth of RNA-Seq. TCR-α, TCR-β, 
TCR-γ, and TCR-δ sequences were present in the assembly, and they appear to share 
features found in TCRs of other species. There was insufficient sequence data to evaluate 
TCR variable, diversity, or joining segments for T-cell receptors. Further studies using 
next-generation repertoire sequencing will be required to fully examine the TCR loci. 
Unfortunately, without monoclonal antibodies to identify CD4+ or CD8- cells by flow 
cytometry, it is difficult to determine whether T cells are expanding in response to 
infection. Other indicators of T-cell activation include the elevated expression of 
granzyme A and B genes (GZMA, GZMB), IL-12 and CCL5 (RANTES), and the 
activated T-cell chemotactic factor gene CXCL1 in the spleens of infected bats. 
Transcripts for IgG, IgM, IgA, and, interestingly, IgE were significantly higher in 
the infected bats. IgE is not typically associated with viral infections, but has been 
associated with anaphylaxis after influenza vaccinations (42–44). No transcripts for IgD 
were present in the transcriptome, similar to what has been observed for other microbats 
(45). Alignments of the 6 IgG transcripts were identical, except for one transcript that 
had a Thr instead of Ala at position 395, which likely represents an allele or sequencing 
error. Only one IgG transcript has been found in Seba’s fruit bat (Carollia perspicillata) 
(45); thus, it is not unexpected that Jamaican fruit bats may only have a single IgG 
isotype. The Jamaican fruit bat IgG shares 94% identity and 96% similarity with the 
Seba’s fruit bat IgG constant region. The hinge regions of all IgG transcripts were also 
identical and distinct from those of Seba’s fruit bat IgG. Hinge regions are generally 
considered hallmark indicators of IgG subclasses (46). It is possible that Jamaican fruit 
bats have IgG subclasses but without a genome or transcriptome profiling of Ig 
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transcripts this question could be difficult to address. 
The heavy-chain variable regions of the 5 Jamaican fruit bat transcripts showed 
many differences, suggesting they represent distinct segments and multiple V region 
gene families. The limited number of V regions makes it difficult to assign Jamaican fruit 
bat sequences to gene families. We are unable to estimate the number of V, D, or J 
segments with the transcriptome data; however, bats appear to have much larger 
numbers of these segments than most mammals (36, 37). It is noteworthy that the 
three CDR3 regions have more tyrosine residues than are found in most other bat 
species immunoglobulins. The presence of tyrosines is thought to contribute to antibody 
interactions with a spectrum of epitopes (47–49), and the lack of these in bat 
antibodies has been postulated to account for why bats have generally poorer responses 
to infectious agents (50, 51). 
Only a single variable region light-chain sequence was significantly elevated in 
the infected bats, which had most similarity to the IgLV7 variable gene family. Studies of 
big brown bats (Eptisicus fuscus) suggest they express predominantly, if not exclusively, 
λ light chains; thus our findings are similar (52). Considering that a single light chain was 
elevated in infected bats, it may be possible to clone this cDNA and co-express it with 
each of the 5 heavy-chain sequences described herein to determine if the antibodies 
are reactive to TCRV antigens. 
We also detected elevated expression of polymeric immunoglobulin receptor 
(PIGR), which exports IgA antibodies across the epithelium into mucosa (53), in the 
spleens of infected bats. Considering the presence of TCRV in oral and rectal swabs and 
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in the lungs (22), it is likely that virus-specific IgA is present at these sites. The 
development of antibodies to artibeus IgA will be necessary to verify this. 
The principal gene for somatic hypermutation (SHM) that leads to affinity 
maturation is activation-induced cytidine deaminase (AID) (54); however, despite its 
presence in all four bats in this study, its expression was not significantly elevated in the 
spleens. Other genes involved in SHM (54) were elevated, including those coding for 
DNA polymerase θ (POLQ), polymerase (POLN), and replication protein A (RPA). The 
level of APOBEC3, coding for another RNA-editing enzyme with lower SHM activity 
(55), was not elevated. Examination of little brown bat (Myotis lucifugus) antibody 
cDNA sequences suggests bats do not use SHM to a great extent (36), and our findings 
are congruent with this observation. In our previous work with TCRV and MERS 
coronavirus (CoV) infection of Jamaican fruit bats (22, 56), antibody responses were 
poor, suggesting that affinity maturation is limited in bats. 
Global differential expression evaluation of TCRV-infected tissues revealed 
alterations in calcium mobilization, a characteristic mechanism of host response to 
infection by viruses, including arenaviruses (57). Additionally, our analysis revealed few 
indications of NK cell activation and minimal expression of genes that are associated 
with T-cell exhaustion (i.e., Ly6e and Fcgr3). It is noteworthy that bats appear to be 
missing many NK cell-associated genes (10, 58, 59); thus it may be that the functions of 
bat NK cells are substantially different from those of human or mouse NK cells. We 
detected increased IFNG, GZMA, and GZMB expression in the spleen infected tissues, 
and while these proteins are produced by both NK cells and T cells, we believe their 
presence correlates more strongly with a T-cell origin due to the increased number of T-
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cell associated genes upregulated relative to NK cell genes. Moreover, the bats in this 
report were euthanized on days 10 and 11, a time point at which T-cell activation should 
be occurring. Thus, T-cell exhaustion, a feature of some lymphocytic choriomeningitis 
virus (LCMV) isolates, is likely not occurring in bats infected with TCRV (60, 61). 
We identified several genes associated with neutrophil activation. These results 
areconsistent with our previous histopathological findings in this species, where we noted 
neutrophilic infiltration that was likely a result of proliferating lymphocytes (22). 
Additionally, our results are also consistent with a recent Lassa virus isolate from Mali 
that similarly induces neutrophil infiltration in nonhuman primates (62). The abundant 
expression of NGAL may provide a diagnostic tool; its protein, neutrophil gelatinase 
associated lipocalin, is secreted in the urine, which is detectable with commercially 
available diagnostic kits (e.g., Pacific Biomarkers, Seattle, WA). 
A recent study looked at differential gene expression in an embryonic cell line 
from Egyptian fruit bats infected with Marburg virus (63). In contrast to the observed 
host responses in the Egyptian fruit bat cells, we identified the JAK/STAT signaling 
pathway as one of the immune-related pathways upregulated in response to pathogenic 
TCRV infection, suggesting a contributory role for this pathway in pathogenesis. 
Additionally, a study exploring the innate immune response to Newcastle disease virus in 
large flying fox cells, a newly characterized a subset of antiviral factors was found (64). 
Among these factors was the CHAC1 gene, which we identified to be 4-fold upregulated 
in spleen and kidney tissues. Together, this evidence along with our previous 
pathogenicity studies shows that a typical antiviral response occurs to TCRV in Jamaican 
fruit bats. 
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We focused additional analyses on immune genes with similar expression in all 
tissues (cluster 3 [Appendix E-4A]). Among the top pathways identified was the IFN 
signaling pathway. The signaling factors in this pathway exert their antiviral activities 
through the induction of other antiviral proteins (32). The IFN response has been 
explored in bat cells (33), and in all bat species examined, the type I IFN locus has 
undergone substantial contraction, with only three functional IFN-α genes but with 
constitutive IFN-α expression in at least one species (65). Specifically, recent discoveries 
have revealed enhanced IFN signaling in antiviral immunity and have identified its 
involvement in arenavirus response mechanisms. We therefore furthered our analysis 
regarding these pathways (51, 66). We found that most IFN signaling genes identified in 
this subset were upregulated in all tissues; however, 5 of these genes had no significant 
differential expression identified in the kidney and 2 had none in the liver. Notably, of the 
differentially expressed factors, the IFNAR1 gene was downregulated in the spleen and 
BCL2 was downregulated in the kidney. Apoptotic pathways play a critical role as 
defense mechanisms for a host when infected by a viral pathogen; BCL2 encodes an anti-
apoptotic protein that is known to be involved in a typical antiviral response (67), and the 
observed downregulation of BCL2 in the kidneys upon TCRV infection suggests 
promotion of apoptotic pathways stimulated by IFN signaling in response to infection. 
In contrast, BCL2 was determined to be upregulated in spleen and liver tissues. 
Additionally, another anti-apoptotic factor gene, Mcl-1, was also upregulated in these 
tissues. Recent work with mice infected with LCMV, as well as other studies, has 
demonstrated the involvement of these factors in promoting naive T-cell survival and 
memory T cell activation (68, 69). Together, these results support congruency of our 
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annotated transcriptome given what is known about the coordination of immune genes 
altered in response to viral infection as well as the identification of genes specific to the 
antiviral response in bats (61). 
As might be expected during an acute antiviral response, IFN-stimulated gene 15 
(ISG15) was elevated in infected tissues. Reactome pathway analysis identified ISG15 in 
several immune pathways, including the innate immune response, cytokine signaling, 
IFN-α/β signaling, and RIG-I/MDA5-mediated induction of IFN-α/β pathways, which 
has also been previously identified in a bat pathogenic viral response (64). ISG15 is an 
important gene in the innate immune response, particularly the type I IFN antiviral 
response; however, the ISG15-encoded protein has recently been demonstrated to have 
additional functions as a ubiquitin-like modifier that covalently conjugates to other 
cellular proteins to form an “ISGylated” complex (70). Various roles of ISG15 have been 
identified in immune responses; when secreted extracellularly, ISG15 can act to drive 
expression of IFN-γ, which was elevated in the spleen. Alternatively, intracellular 
expression can modulate type I IFN signaling (71). 
Although IFN-α, IFNB, IFNL, and IFNG transcripts were present in all of the 
tissues analyzed, the only differentially expressed transcript was IFNG in the spleen. In 
contrast, indications of downstream signaling initiated by IFN type I and type II were 
present, suggesting either transcript turnover prior to the time of sample collections or the 
potential for alternative routes of pathway activation. Previous work examining in vitro 
infection of the black flying fox with Tioman virus suggests a prominent role for IFN-γ 
(72). To this end, there are potential differences between bat species in terms of their 
responses to viruses that may account for apathogenic infections (e.g., reservoir hosts) or 
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disease. Future work with cell culture from our model system may help to clarify these 
points. Furthermore, the DEGs involved in IFN-α/β signaling suggest that a typical 
antiviral innate immune response occurred in the bats. Within the spleen, expression of 
36% of the genes was upregulated in the IFN-α/β signaling pathway, whereas the 
kidneys and livers had approximately 16% and 34% elevated expression of these same 
genes, respectively. This indicates a more robust type I IFN response in the spleen. 
Together, de novo transcriptome analysis of our high-throughput RNA-Seq data 
from Jamaican fruit bats infected with TCRV provides a high-quality data set and also 
a comprehensive gene expression analysis of immune gene expression responses in 
bats during a pathogenic infection. This data set will provide a strong basis for additional 
analyses. Further investigation of our identified pathways in vitro and in vivo will 
significantly contribute to our understanding of pathogenic viral infections in bats. 
Moreover, the data here will facilitate future experimental studies of artibeus bats and 
their cells, which have been used as models for MERS CoV and Zaire Ebola virus and 




This study provides a comprehensive analysis of the transcriptional landscape of 
Jamaican fruit bats during infection with Tacaribe virus. This natural pathogen of artibeus 
bats causes high-mortality disease with similar clinical manifestations to the South 
American hemorrhagic fevers and Lassa fever. In summary, this analysis identified the 
global response to TCRV infection. Our results suggest diverse immune responses, 
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including alterations in neutrophil activation, interferon signaling, markers for 
lymphocytes, and antibodies. We found substantial signatures of neutrophil activation in 
the spleen, kidney, and liver of bats with fatal disease. The innate and adaptive immune 
response appeared to be functional and typical of the canonical antiviral response. Many 
activation markers of T and B lymphocytes were also found; however, few indications of 
NK cell activity or T-cell exhaustion were apparent. IgG, IgM, IgA, and IgE sequences 
were abundantly expressed in the spleens of infected bats, and five immunoglobulin 
heavy-chain V segments were identified. Despite the clear evidence of antibody synthesis 
during infection, AID expression was not elevated, suggesting somatic hypermutation 
and affinity maturation were absent or minimal. Analysis of immunoglobulin heavy-
chain and TCR V regions suggests that Jamaican fruit bats have canonical 
immunoglobulin and TCR genes found in most mammals. Moreover, the species appears 
to have a single IgG subclass. These results are the most extensive gene discovery work 
completed in Jamaican fruit bats to date and the first to describe differential immune gene 
expression in bats during a pathogenic virus infection. 
 
Materials and Methods 
Experimental TCRV infection in bats, sample collection, and RNA extraction  
Experimental infections of Jamaican fruit bats were previously reported (22). 
Briefly, two Jamaican fruit bats were inoculated with 100 μl of sterile Dulbecco’s 
phosphate-buffered saline (DPBS) as negative controls (bat IDs 688 and 689), and two 
bats were inoculated with 100 μl containing 106 TCID50 TCRV (bat IDs 714 and 729). 
Negative control bats were euthanized at the end of the experimental period (45 days), 
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whereas TCRV-infected bats were euthanized as they became moribund (days 11 and 18, 
respectively). Necropsies were performed directly following euthanasia, and organs were 
harvested and collected in RNAlater stabilization reagent (Qiagen). RNA was extracted 
from flash-frozen tissues by homogenization with a Mini Bead Beater (BioSpec Products, 
Inc.), using QiaShredder columns with the RNeasy kit (Qiagen). 
 
RNA-Seq 
Stranded Illumina libraries for each tissue were prepared from total RNA using 
the NEB Ultra Directional RNA library prep kit with poly(A) selection. Sequencing 
(paired-end 100 bp) was performed on the Illumina HiSeq-2000 platform at the UC 
Denver Genomics core. 
 
Read processing and assembly 
For transcriptome assembly, raw reads were filtered for adapter sequences and 
low-quality reads, and assembly was performed using Trinity (30) with the following 
parameters: —min_contig_length 300 —min_glue 3—min_kmer_cov 2. Resulting 
contigs were processed for read alignment and abundance estimation with Bowtie and 
RSEM (75, 76). Differential expression was performed using the edgeR package within 
the Trinity differential analysis pipeline using default parameters (77). A pairwise 
comparison was made between TCRV-infected samples and control uninfected samples. 
Genes were considered differentially expressed with an FDR of <0.01 and a log2 fold 
change > 2. 
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Gene ontology and pathway analysis 
BLAST alignments and functional annotations were performed using Blast2GO 
Pro or Ingenuity Pathway Analysis (78, 79). Direct pathway analysis for immune-related 
genes was performed using the gene list from the ImmPort database (31). 
 
Immunoglobulin sequence analysis 
Contigs for immunoglobulins were translated using the default translation table of 
MacVector software. MUSCLE alignments were made to identify leader, framework 
regions, and complementarity-determining regions of the V segments using a black flying 
fox sequence as a reference (NCBI GenBank accession no. ADD71702.1) (50). Heavy 
chains and hinge regions were identified by BLAST against other Chiroptera. 
 
RT-qPCR validation of RNA-Seq data 
The experimental primer sequences used in RT-qPCR analysis are listed in Fig. 
S2. cDNA was generated using SuperScript III reverse transcriptase (Thermo Scientific) 
and SYBR Select master mix for CFX (Applied Biosystems). The same two Jamaican 
fruit bats that were used for uninfected samples in RNA-Seq were also used as uninfected 
samples for RT-qPCR. 
 
Accession number(s) 











Appendix E-1: Transcriptomic analysis of Jamaican fruit bats infected with Tacaribe 
virus (TCRV). Jamaican fruit bats were inoculated with either TCRV or DPBS (n=2 for 
each condition). De novo assembly of the Jamaican fruit bat transcriptome was 
performed using RNA-Seq data from kidney, liver, and spleen tissues. Differentially 




Appendix E-2: De novo assembly of the Jamaican fruit bat transcriptome 
 
Appendix E-2: De novo assembly of the Jamaican fruit bat transcriptome. (A) 
Trinity assembly resulted in the construction of the de novo-assembled Jamaican fruit bat 
transcriptome with 644,933,364 assembled bases. (B) Examination of the identified 
contigs from the transcriptome assembly showed that 35% (12,600) are expressed in the 
spleen, kidney, and liver tissues (FRKM, greater than 1). (C) We compared this 
transcriptome assembly to those of other mammals through BLASTX analysis and 
identified transcripts similar to those present in other bat species. 
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Appendix E-3: Differential gene expression analysis following TCRV infection in 
Jamaican fruit bats 
 
Appendix E-3: Differential gene expression analysis following TCRV infection in 
Jamaican fruit bats. We used a pairwise comparison of TCRV-infected samples against 
the corresponding control uninfected samples and found that the expression levels of 
hundreds of genes were altered with TCRV infection in the different tissues. (A) 
Differential expression analysis revealed upregulated genes (green) and downregulated 
genes (orange) defined by edgeR (log2 fold change > 2 and FDR < 0.01). (B) Inspection 
of altered genes in all infected tissues versus control tissues showed fewer changed genes 
common to all tissues. (C) Quantification of differentially expressed genes from panels A 
and B. 
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Appendix E-4: Immune-specific expression analysis of TCRV-infected Artibeus 
jamaicensis bats 
 
Appendix E-4: Immune-specific expression analysis of TCRV-infected Artibeus 
jamaicensis bats. (A) Immport database immune-related genes and their expression 
values (FPKM) were clustered (k-means = 6) to investigate the relationship between 
uninfected and infected tissues. (B) We performed Ingenuity Pathway Analysis to 
characterize the specific immune pathways for those genes identified in cluster 3 (n = 
117) from panel A. (C) Interferon signaling was among the top pathways identified to be 
altered after TCRV infection. We then identified these specific genes involved in 
interferon signaling and explored their alterations in the different tissues in response to 
TCRV infection. Green corresponds to upregulated and orange to downregulated (FDR, 
<0.01; log2 fold change, >2); gray indicates no significant differential expression. 
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Appendix E-5: Amino acid alignment of Jamaican fruit bat IgG V regions  
 
 
Appendix E-5: Amino acid alignment of Jamaican fruit bat IgG V regions. Five V 
region transcripts were identified in the Jamaican fruit bat spleen transcriptomes and 
aligned with a V region of an annotated black flying fox V region (50). Framework 
regions (FR1 to FR4) and complementarity-determining regions (CDR1 to CDR3) were 
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The following tables contain data access information for publically available datasets 
discussed in this dissertation. 
 
Table 1: Data accession corresponding to publically available datasets (abbreviations: 
Ch=Chapter; Rep=Replicate) 









































































































































































































































































































































































































CTCF 1,2 GEO GSM2913254 
2 DNase-
seq 
















































96hr 1,2 GEO GSM1563236 
2 HiC PANC1 parental 
 
1 GEO GSM2827313 
2 HiC PANC1 parental 
 
2 GEO GSM2827314 
2,A RNA-
seq 
PANC1 siTCF7L2 48hr 1 GEO GSM1556985 
2,A RNA-
seq 
PANC1 siTCF7L2 48hr 2 GEO GSM1556986   
2,A RNA-
seq 
PANC1 siTCF7L2 48hr 3 GEO GSM1556987   
2,A RNA-
seq 
PANC1 siControl 48hr 1 GEO GSM1556982 
2,A RNA-
seq 
PANC1 siControl 48hr 2 GEO GSM1556983   
2,A RNA-
seq 









































































































3 GEO GSM2913269 
2,3 TCC PANC1 parental 
 
1,2 GEO GSM1684570   
4 TCC MCF7 parental  0hr 1 GEO GSM2913210 
4 TCC MCF7 100nM 
Estradiol 
1hr 1 GEO GSM2913211 
4 TCC MCF7 100nM 
Estradiol 
4hr 1 GEO GSM2913212 
4 TCC MCF7 100nM 
Estradiol 
16hr 1 GEO GSM2913213 
4 TCC MCF7 100nM 
Estradiol 
24hr 1 GEO GSM2913214 
4 TCC MCF7 TamR 
 
1 GEO GSM2913258 
4 TCC MCF7 TamR Input 1,2 GEO GSM2913259 
4 TCC MCF7 TamR H3K4me3 1,2 GEO GSM2913260 
4 TCC MCF7 TamR H3K27ac 1,2 GEO GSM2913261 
4 TCC MCF7 TamR H3K4me1 1,2 GEO GSM2913262 
4 TCC MCF7 TamR H3K27me3 1,2 GEO GSM2913263 
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4 TCC MCF7 TamR H3K9me3 1,2 GEO GSM2913264 
4 TCC MCF7 TamR ER-alpha 1,2 GEO GSM2913265 
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4 TCC T47D parental 0hr 1,2 GEO GSM3386607 
4 TCC T47D 100nM 
Estradiol 
1hr 1,2 GEO GSM3386608 
4 TCC T47D 100nM 
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4hr 1,2 GEO GSM3386609 
4 TCC T47D 100nM 
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4 TCC T47D 100nM 
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24hr 1,2 GEO GSM3386611 
4 TCC T47D TamR 
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